Pyrido[2,3-D]imidazole derivatives and their use as inhibitors of ITK for the treatment of skin diseases - Patent Application 20070122999
Patent Information
- Application Number
- JP2023535824
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-15
- Filing Date
- 2021-12-13
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for atopic dermatitis and other skin diseases are inadequate in modulating the inflammatory response and pruritus, as they do not effectively target interleukin-2-induced T-cell kinase (ITK) and tropomyosin receptor kinase (TRKA), which play crucial roles in cytokine production and skin inflammation.
Development of imidazopyridine derivatives that act as inhibitors of ITK and TRKA, specifically designed to target these kinases to reduce cytokine production and skin inflammation, thereby addressing the pathophysiology of atopic dermatitis and other dermatological conditions.
The ITK and TRKA inhibitors effectively suppress pathogenic T-cell responses, reducing cytokine production and skin inflammation, providing relief from pruritus and potentially improving the quality of life for patients with atopic dermatitis and other skin diseases.
Smart Images

Figure 2022130175000001 
Figure 2022130175000002 
Figure 2022130175000003
Abstract
Description
[Technical Field]
[0001] The present invention relates to imidazopyridine derivatives, their use in medicine, compositions containing them, processes for their preparation, and intermediates used in such processes. More specifically, the present invention relates to inhibitors of interleukin-2-inducible T-cell kinase (ITK) and their use in the treatment of diseases mediated by ITK, particularly skin diseases such as dermatitis (e.g., atopic dermatitis). [Background technology]
[0002] Atopic dermatitis (AD) is a common chronic inflammatory skin disease with high prevalence in both children and adults. Patients with AD suffer from dry and itchy skin lesions that can significantly affect their quality of life. Genetic and environmental factors may contribute to the disruption of the skin barrier and immune hyperactivation, which are key drivers of AD pathogenesis.
[0003] The pathogenic role of T cell- and Th2 cell-derived cytokines IL-4 and IL-13 in AD was demonstrated by the clinical development of dupilumab, an antibody against the IL-4 receptor that blocks the activity of both IL-4 and IL-13. The important activity of these cytokines is consistent with the early clinical efficacy observed with Janus kinase (JAK) inhibitors, which block the signal transduction of IL-4 and IL-13 as well as other inflammatory cytokines produced in the skin. Therapeutic strategies that can effectively control the production of IL-4 and IL-13 are alternative approaches to modulating this pathway. Furthermore, Th1, Th22, and Th17 cells, and the cytokines they produce, IFNγ, IL-22, and IL-17, respectively, also contribute to the development of AD.
[0004] Effective anti-inflammatory agents for AD would modulate the dominant T cell-driven inflammatory response. Interleukin-2-inducible T cell kinase (ITK) is a member of the Tec family of tyrosine kinases. ITK expression is primarily restricted to immune cells such as T cells, natural killer (NK) cells, natural killer T (NKT) cells, and mast cells. In T cells, ITK amplifies T cell receptor (TCR)-dependent signals to promote T cell activation, cytokine production, and T cell proliferation. Deletion of ITK or inhibition of ITK activity in T cells results in the suppression of TCR-induced IL-4 and IL-13 production, which plays a central role in contributing to the pathophysiology of AD. Because ITK also contributes to the TCR-dependent production of several inflammatory cytokines, such as IL-2, IL-17, IL-22, IL-31, IFNγ, and TNF-α, ITK inhibitors are expected to have additional efficacy compared to IL-4 receptor antagonists. Furthermore, ITK-deficient CD8+ T cells exhibit impaired cytotoxic T lymphocyte expansion, reduced degranulation, and defective cytolytic ability. ITK-deficient mice and / or mice treated with ITK inhibitors exhibit reduced disease in models of type 1 diabetes, lymphoproliferative disorders, allergy / asthma, and airway hyperresponsiveness. Furthermore, ITK-deficient mice or mice treated with ITK inhibitors exhibit reduced skin inflammation in models of dermatitis. Increased ITK levels have been described in peripheral T cells from patients with moderate to severe AD, and ITK expression is elevated in skin lesions from AD patients.
[0005] Furthermore, tropomyosin receptor kinase (TRK) is expressed by cells in the skin, such as keratinocytes, neurons, mast cells, and basophils. Both TRKA and its ligand, nerve growth factor (NGF), are present in the skin, and their expression is enhanced in AD skin lesions. NGF levels in skin lesions from AD patients have been shown to correlate with the severity of itch. The cytokines IL-4 and IL-13, which contribute to AD pathogenesis, have been shown to enhance TRKA expression by keratinocytes. In addition to regulating neuronal development and maintenance, NGF can sensitize nociceptors and promote pruritus in the skin. Pruritus is a major factor contributing to the reduced quality of life of AD patients. Therapies that can suppress pruritus not only provide relief to patients but also disrupt the cycle of itch and scratching that contributes to barrier breakdown, thus reducing the course and chronicity of the disease.
[0006] NGF is also expressed by and has effects on non-neuronal cells. NGF induces keratinocyte proliferation, promotes basophil activation, and stimulates mast cell degranulation, contributing to neurogenic itch and inflammation. Furthermore, TRKA expression has been reported on TCR-stimulated peripheral blood T cells and T cells collected from synovial fluid derived from arthritis patients, and NGF induces T cell proliferation. Therefore, TRKA inhibition in the skin may suppress skin inflammation in addition to reducing pruritus.
[0007] These data suggest that ITK inhibitors suppress pathogenic T cell responses and reduce cytokine production, and thus have therapeutic value in the treatment of various inflammatory and autoimmune diseases, including dermatological conditions such as atopic dermatitis, contact dermatitis, psoriasis, alopecia areata, and vitiligo. Furthermore, inhibitors of both ITK and TRKA activity should be particularly advantageous in the treatment of dermatological conditions such as those mentioned above (e.g., atopic dermatitis).
[0008] References Benecke H et al., Expert Opin. Invest. Drugs. 2013;22:1167-1179; Bissonette R, Papp KA et al., Brit. J. Derm. 2016;175:902-911; Botchkarev VA, Yaar M, Peters EMJ et al., J. Invest. Dermatology. 2006;126:1719-1727; Brunner PM et al., J Allergy Clin Immunol. 2017;139(4S):S65-S76; Kapnick SM, Stinchcombe JC et al., Immunol. 2017;198:2699-2711; Lin TA, McIntyre KW et al., Biochemistry 2004;43:11056-11062; Matsumura S, Terao M et al., J. Derm. Science 2015;78:215-223; Otsuka A, Nomura T et al., Immunological Reviews. 2017;278:246-262; Raychaudhuri SP, Raychaudhuri SK et al., Arthritis & Rheumatism 2011;63:3243-3252; Sabat R, Wolk K et al., Seminars in Immunopathology 2019;41:359-377; Sahu N and August A. Curr. Top. Med. Chem. 2009;9:690-703; Von Bonin A, Rausch A et al., Exp. Derm. 2010;20:41-47; Yamaguchi J, Aihara M et al., J. Dermatol. Science. 2008;53:48-54
Summary of the Invention
[0009] [Means for solving the problem]
[0010] According to a first aspect of the present invention, a compound of formula (I)
[0011] [ka] (In the formula, R 0 is H and R 1 is methyl or R 0 , R 1 and the carbon atoms to which they are attached form an optionally gem-difluorosubstituted cyclopropyl; R 2 is H, (C1-C4)alkyl, hydroxy(C1-C4)alkyl or (C1-C4)alkyl substituted by 1, 2 or 3 F, Each R 3 are independently H, F, or (C1-C4) alkyl; R 3 together with the carbon atoms to which they are attached, (C4-C7)cycloalkyl, (C4-C7)cycloalkyl substituted by 1, 2 or 3 F, 1 or 2 R 6 (C4-C7)cycloalkyl substituted by (C5-C7)bicycloalkyl, (C5-C7)bicycloalkyl substituted by one or two F, C-bonded 6-membered saturated heterocycloalkyl containing one N or one O and optionally substituted by oxo, or C-bonded 6-membered saturated heterobicycloalkyl containing one N or one O and optionally substituted by oxo Forming R4 is H, F, (C1-C6) alkyl optionally substituted by 1, 2 or 3 F, -NR 7 R 8 , (C4-C7)cycloalkyl, C-linked 6-membered saturated heterocycloalkyl containing one N or one O and optionally substituted by oxo, N-linked 6-, 7-, or 8-membered saturated heterocycloalkyl containing one N and optionally one O and optionally substituted by oxo, N-linked 6-, 7-, or 8-membered saturated heterobicycloalkyl containing one N and optionally one O and optionally substituted by oxo, or N-linked 5- or 6-membered heteroaryl containing one or two N; R 5 is H, halogen, (C1-C6)alkyl, (C1-C6)alkoxy, or (C1-C6)alkoxy substituted with (C1-C4)alkoxy; Each R 6 are independently (C1-C3) alkyl; R 7 is (C1-C6) alkyl, R 8 is (C1-C6) alkyl or —C(O)(C1-C6) alkyl) or a pharmaceutically acceptable salt thereof.
[0012] Described below are embodiments of this first aspect of the invention, where, for convenience, E1 is identical thereto.
[0013] E1 A compound of formula (I) as defined above or a pharmaceutically acceptable salt thereof.
[0014] E2 R 0 is H and R 1 The compound according to embodiment E1, or a pharmaceutically acceptable salt thereof, wherein is methyl. E3 Formula (Ia) or (Ib)
[0015] [ka] A compound according to embodiment E1, or a pharmaceutically acceptable salt thereof.
[0016] E4 A compound according to embodiment E3 of formula (Ia) or a pharmaceutically acceptable salt thereof.
[0017] E5 A compound according to embodiment E2 of formula (Ib) or a pharmaceutically acceptable salt thereof.
[0018] E6 R 2 A compound according to any one of embodiments E1 to E5, or a pharmaceutically acceptable salt thereof, wherein is H, methyl, ethyl, or hydroxyethyl.
[0019] E7 R 2 The compound according to embodiment E6, or a pharmaceutically acceptable salt thereof, wherein is methyl.
[0020] E8 R 3 A compound according to any one of embodiments E1 to E7, or a pharmaceutically acceptable salt thereof, wherein each is independently H, F, or (C1-C3)alkyl.
[0021] E9 R 3 are each H or R 3 The compound according to embodiment E8, or a pharmaceutically acceptable salt thereof, wherein each is methyl.
[0022] E10 R 3 or a pharmaceutically acceptable salt thereof.
[0023] E11 One side R 3 is H and the other R 3 The compound according to embodiment E8, or a pharmaceutically acceptable salt thereof, wherein is methyl.
[0024] E12 formula (Ic)
[0025] [ka] A compound according to embodiment E11, or a pharmaceutically acceptable salt thereof.
[0026] E13 R 3 together with the carbon atoms to which they are attached, (C4-C7)cycloalkyl, (C4-C7)cycloalkyl substituted by 1, 2 or 3 F, 1 or 2 R 6 (C4-C7)cycloalkyl substituted by (C5-C7)bicycloalkyl, (C5-C7)bicycloalkyl substituted by one or two F, C-bonded 6-membered saturated heterocycloalkyl containing one N or one O and optionally substituted by oxo, or C-bonded 6-membered saturated heterobicycloalkyl containing one N or one O and optionally substituted by oxo or a pharmaceutically acceptable salt thereof.
[0027] E14 R 3 are both taken together with the carbon atom to which they are attached to form a (C4-C7)cycloalkyl, a (C4-C7)cycloalkyl substituted by one, two or three F, or one or two R 6 or a pharmaceutically acceptable salt thereof. A compound according to embodiment E13, wherein the compound forms a (C4-C7)cycloalkyl substituted by:
[0028] E15 R 3 or a pharmaceutically acceptable salt thereof. A compound according to embodiment E14, wherein both of
[0029] E16 R 3 and R are both taken together with the carbon atom to which they are attached to form a (C5-C7)bicycloalkyl or a (C5-C7)bicycloalkyl substituted with one or two F; or a pharmaceutically acceptable salt thereof.
[0030] E17 R 3 and R 1 and R 2 together with the carbon atom to which they are attached form a (C5-C7)bicycloalkyl substituted with one or two F; or a pharmaceutically acceptable salt thereof.
[0031] E18 R 3 or a pharmaceutically acceptable salt thereof. A compound according to embodiment E13, wherein both of are taken together with the carbon atoms to which they are attached to form a C-linked 6-membered saturated heterocycloalkyl containing one N or one O and optionally substituted by oxo, or a C-linked 6-membered saturated heterobicycloalkyl containing one N or one O and optionally substituted by oxo.
[0032] E19 R 3 and R are both taken together with the carbon atom to which they are attached to form a C-linked 6-membered saturated heterocycloalkyl containing one O; or a pharmaceutically acceptable salt thereof.
[0033] E20 R 3 and R are both taken together with the carbon atom to which they are attached to form a C-linked 6-membered saturated heterobicycloalkyl containing one O; or a pharmaceutically acceptable salt thereof.
[0034] E21 R 4 is H, F, (C1-C4) alkyl optionally substituted by 1 or 2 F, -NR 7 R 8or a pharmaceutically acceptable salt thereof.
[0035] E22 R 4 is H, F, (C1-C4) alkyl optionally substituted by 1 or 2 F, or —NR 7 R 8 or a pharmaceutically acceptable salt thereof.
[0036] E23 R 7 A compound according to any one of embodiments E1 to E22, or a pharmaceutically acceptable salt thereof, wherein is (C1-C3)alkyl.
[0037] E24 R 8 A compound according to any one of embodiments E1 to E23, or a pharmaceutically acceptable salt thereof, wherein is -C(O)(C1-C3)alkyl.
[0038] E26 R 4 A compound according to embodiment E22, wherein is H or F, or a pharmaceutically acceptable salt thereof.
[0039] E27 R 4 A compound according to embodiment E26, wherein is H, or a pharmaceutically acceptable salt thereof.
[0040] E28 R 4is (C4-C7)cycloalkyl, C-linked 6-membered saturated heterocycloalkyl containing one O, N-linked 6-, 7-, or 8-membered saturated heterocycloalkyl containing one N and optionally one O and optionally substituted by oxo, N-linked 6-, 7-, or 8-membered saturated heterobicycloalkyl containing one N and optionally one O, or N-linked 5-membered heteroaryl containing two Ns; or a pharmaceutically acceptable salt thereof.
[0041] E29 R 4 is (C4-C6)cycloalkyl, C-linked 6-membered saturated heterocycloalkyl containing one O, N-linked 6- or 7-membered saturated heterocycloalkyl containing one N and optionally one O and optionally substituted by oxo, N-linked 7- or 8-membered saturated heterobicycloalkyl containing one N and one O, or N-linked 5-membered heteroaryl containing two Ns; or a pharmaceutically acceptable salt thereof.
[0042] E30 R 4 is (C4-C6)cycloalkyl, C-linked 6-membered saturated heterocycloalkyl containing one O, N-linked 6-membered saturated heterocycloalkyl containing one N and one O and optionally substituted by oxo, N-linked 7- or 8-membered saturated heterobicycloalkyl containing one N and one O, or N-linked pyrazole; or a pharmaceutically acceptable salt thereof.
[0043] E31 R 4 A compound according to embodiment E30, wherein is C-linked 6-membered saturated heterocycloalkyl containing one O; or a pharmaceutically acceptable salt thereof.
[0044] E32 R 4 A compound according to embodiment E31, or a pharmaceutically acceptable salt thereof, wherein is tetrahydro-2H-pyran-4-yl.
[0045] E33 R 4A compound according to embodiment E30, or a pharmaceutically acceptable salt thereof, wherein is N-linked 6-membered saturated heterocycloalkyl containing one N and one O and optionally substituted with oxo.
[0046] E34 R 4 A compound according to embodiment E33, or a pharmaceutically acceptable salt thereof, wherein is N-linked morpholinyl.
[0047] E35 R 4 A compound according to embodiment E30, wherein is N-linked 7- or 8-membered saturated heterobicycloalkyl containing one N and one O; or a pharmaceutically acceptable salt thereof.
[0048] E36 R 4 but,
[0049] [ka] or a pharmaceutically acceptable salt thereof.
[0050] E37 R 4 A compound according to embodiment E30, or a pharmaceutically acceptable salt thereof, wherein is an N-linked pyrazole.
[0051] E38 R 5 A compound according to any one of embodiments E1 to E37, or a pharmaceutically acceptable salt thereof, wherein is H, F, (C1-C3)alkyl, (C1-C3)alkoxy, or (C1-C3)alkoxy substituted with (C1-C3)alkoxy.
[0052] E39 R 5 A compound according to embodiment E38, or a pharmaceutically acceptable salt thereof, wherein is H, F, methyl, -OCH3, or -OC2H5OCH3.
[0053] E40 R 5 A compound according to embodiment E39, or a pharmaceutically acceptable salt thereof, wherein:
[0054] E41 A compound according to embodiment E1 selected from any one of Examples 1 to 120, or a pharmaceutically acceptable salt thereof.
[0055] E42 (R)-N-methyl-N-(2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-(tetrahydro-2H-pyran-4-yl)propenamide, and 2,2-Difluoro-N-methyl-N-(2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-(tetrahydro-2H-pyran-4-yl)acetamide or a pharmaceutically acceptable salt thereof. DETAILED DESCRIPTION OF THE INVENTION
[0056] In the compound of formula (I), Alkyl is a group of the formula -C n H (2n+1) Examples of alkyl include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, and t-butyl. Alkyloxy refers to an alkyl substituent attached via an oxygen atom. Examples of alkyloxy include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, sec-butoxy, and t-butoxy. Cycloalkyl is a group of the formula -C containing at least 3 carbon atoms. n H (2n-1) Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Bicycloalkyl means a bicyclic hydrocarbon group in which two rings are fused, spirofused, or bridged. Examples of (C5-C7)bicycloalkyl include:
[0057] [ka] Examples include: Examples of C-bonded 6-membered saturated heterocycloalkyl containing one N or one O include tetrahydro-2H-pyran-2-yl, tetrahydro-2H-pyran-3-yl and tetrahydro-2H-pyran-4-yl. Examples of C-bonded 6-membered saturated heterobicycloalkyl containing one N or one O include:
[0058] [ka] Examples include: Examples of N-linked 6-, 7- or 8-membered saturated heterocycloalkyl containing one N and optionally one O include piperidinyl, morpholinyl, 1,3-oxazinan-3-yl and 1,4-oxazepan-4-yl. Oxo refers to a double-bonded oxygen (=O). Preferably, the oxo substituent in an N-linked heterocycloalkyl or heterobicycloalkyl containing one N and optionally one O is alpha to the N atom, for example, as follows:
[0059] [ka] Examples of N-linked 6-, 7- or 8-membered saturated heterobicycloalkyl containing one N and optionally one O include:
[0060] [ka] Examples include: Examples of halogens include fluoro (F), chloro (Cl), bromo (Br) and iodo (I).
[0061] Hereinafter, all references to a compound of the invention include a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or multi-component complex thereof, or a pharmaceutically acceptable solvate or multi-component complex of a pharmaceutically acceptable salt of a compound of formula (I), as discussed in more detail below.
[0062] A preferred compound of the present invention is a compound of formula (I) or a pharmaceutically acceptable salt thereof:
[0063] Suitable acid addition salts are formed from acids which form non-toxic salts, examples of which include acetate, adipate, aspartate, benzoate, besylate, bicarbonate / carbonate, bisulfate / sulfate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hybenzate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, lactate, lysine, thiamin ... Salts of hydroxybenzoates include benzoate, maleate, malonate, mesylate, methylsulfate, 1,5-naphthalenedisulfonate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / dihydrogenphosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate, and xinafoate.
[0064] Hemi-salts of the acids can also be formed, for example, hemisulfate and hemitartrate salts.
[0065] Those skilled in the art will recognize that the above salts include those wherein the counterion is optically active, for example, d-lactate, or racemic, for example, dl-tartrate.
[0066] For a review of suitable bases, see "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth, (Wiley-VCH, Weinheim, Germany, 2002).
[0067] Pharmaceutically acceptable salts of compounds of formula (I) can be prepared by one or more of three methods: (i) by reacting a compound of formula (I) with a desired acid; (ii) by removing an acid-labile protecting group from a suitable precursor of a compound of formula (I) using a desired acid; or (iii) by converting one salt of a compound of formula (I) to another salt by reaction with an appropriate acid or using a suitable ion exchange column; It can be prepared.
[0068] All three reactions are typically carried out in solution. The resulting salt precipitates and can be collected by filtration or recovered by evaporation of the solvent. The degree of ionization in the resulting salt may vary from completely ionized to nearly non-ionized.
[0069] The compound of formula (I) or its pharmaceutically acceptable salt may exist in both unsolvated and solvated forms. The term "solvate" is used herein to describe a molecular complex comprising a compound of formula (I) or its pharmaceutically acceptable salt and one or more pharmaceutically acceptable solvent molecules, such as ethanol. The term "hydrate" is used when the solvent is water. Pharmaceutically acceptable solvates according to the present invention include those in which the solvent of crystallization may be isotopically substituted, such as DO, d-acetone, and d-DMSO.
[0070] A currently accepted classification system for organic hydrates defines isolated site, channel, or metal ion coordinated hydrates - see KR Morris, Polymorphism in Pharmaceutical Solids (HG Brittain, Marcel Dekker (eds.), 1995), incorporated herein by reference. Isolated site hydrates are those in which the water molecules are isolated from direct contact with each other by intervening organic molecules. In channel hydrates, the water molecules lie in lattice channels next to other water molecules. In metal ion coordinated hydrates, the water molecules are bound to the metal ion.
[0071] If the solvent or water is tightly bound, the complex will have a well-defined stoichiometry independent of humidity. However, if the solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water / solvent content will depend on humidity and drying conditions. In such cases, non-stoichiometry will be the norm.
[0072] Also included within the scope of the present invention are multicomponent complexes (other than salts and solvates) of the compound of Formula (I) or a pharmaceutically acceptable salt thereof, where the drug and at least one other component are present in stoichiometric or non-stoichiometric amounts. Complexes of this type include clathrates (drug-host inclusion complexes) and cocrystals. The latter are typically defined as crystalline complexes of neutral molecular components bound together by non-covalent interactions, but may also be complexes of neutral molecules and salts. Cocrystals can be prepared by melt crystallization, recrystallization from solvents, or by physically grinding the components together—see O. Almarsson and MJ Zaworotko, Chem Commun, 17, 1889-1896 (2004), incorporated herein by reference. For a general review of multicomponent complexes, see Haleblian, J Pharm Sci, 64(8), 1269-1288 (August 1975), incorporated herein by reference.
[0073] The compounds of the present invention may exist in a range of solid states, from completely amorphous to completely crystalline. The term "amorphous" refers to a state in which the substance lacks long-range order at the molecular level and, depending on temperature, may exhibit the physical properties of a solid or a liquid. Typically, such substances do not give a distinctive X-ray diffraction pattern and exhibit the properties of a solid, but are more formally described as liquids. Upon heating, a change from solid to liquid properties occurs, typically characterized by a second-order change of state ("glass transition"). The term "crystalline" refers to a solid phase in which the substance has a regularly ordered internal structure at the molecular level and gives a distinctive X-ray diffraction pattern with defined peaks. When heated sufficiently, such substances also exhibit the properties of a liquid, but the change from solid to liquid is typically characterized by a first-order phase change ("melting point").
[0074] The compounds of the present invention may also exist in a mesomorphic state (mesophase or liquid crystal) when subjected to suitable conditions. A mesomorphic state is intermediate between a true crystalline state and a true liquid state (melt or solution). Liquid crystallinity resulting from a change in temperature is described as "thermotropic," while that resulting from the addition of a second component, such as water or another solvent, is described as "lyotropic." Compounds capable of forming lyotropic mesophases are described as "amphiphilic," and may be ionic (-COO - Na + , -COO - K + , or -SO3 - Na + ) or non-ionic (-N - N + They consist of molecules with polar head groups such as (CH3)3. For further information, see N.H. Hartshorne and A. Stuart, Crystals and the Polarizing Microscope, 4th Edition (Edward Arnold, 1970), which is incorporated herein by reference.
[0075] The compounds of the present invention can be administered as prodrugs.Therefore, certain derivatives of the compound of formula (I), which themselves have little or no pharmacological activity, can be converted into the compound of formula (I) with the desired activity when administered into or on the body, for example, by hydrolytic cleavage.Such derivatives are called "prodrugs".Further information on the use of prodrugs can be found in "Prodrugs as Novel Delivery Systems", Vol. 14, ACS Symposium Series (T Higuchi and W Stella) and "Bioreversible Carriers in Drug Design", Pergamon Press, 1987 (EB Roche (ed.), American Pharmaceutical Association).
[0076] Prodrugs can be produced, for example, by replacing appropriate functional groups present in compounds of formula (I) with certain moieties known to those skilled in the art as "promoieties," for example, as described in "Design of Prodrugs" by H. Bundgaard (Elsevier, 1985).
[0077] Examples of prodrugs include phosphate prodrugs, such as dihydrogen phosphate or dialkyl (e.g., di-tert-butyl) phosphate prodrugs. Further examples of substituents according to the above examples and examples of other prodrug types can be found in the references listed above.
[0078] Also included within the scope of the present invention are metabolites of compounds of formula (I), which are compounds formed in vivo upon administration of the drug. Examples of metabolites according to the present invention include: (i) when the compound of formula (I) contains an alkoxy group, its hydroxy derivative (-(C1-C6)alkoxy → -OH); and (ii) When the compound of formula (I) contains a phenyl moiety, it includes its phenol derivative (-Ph→-PhOH).
[0079] Formula (I) contains an asymmetric cyclopropaindazolyl moiety and is stereospecifically defined (as the "4aS,5aR" stereoisomer).
[0080] Those skilled in the art will appreciate that one or more of the substituents in formula (I) may introduce one or more additional asymmetric centers. For example, additional asymmetric centers may be present in R 3 are different, and R 4 R 3 Such asymmetric centers are present in compounds of formula (I) that are not the same as those in Example 1, compounds of formulas (I) and (Ic). One skilled in the art will further appreciate that stereoisomers of Example 1 may be depicted as being chemically identical but different, for example, as shown below, in which case the additional asymmetric center is marked with an asterisk (*).
[0081] [ka]
[0082] Compounds of the invention containing said one or more additional asymmetric centers may exist as two or more stereoisomers; all such stereoisomers (including epimers) of the compounds of the invention and mixtures of two or more thereof are included within the scope of the invention.
[0083] Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from suitable optically pure precursors or resolution of the racemate (or racemate of a salt or derivative) using, for example, chiral high-pressure liquid chromatography (HPLC).
[0084] Alternatively, the racemate (or racemic precursor) can be reacted with a suitable optically active compound, for example, an alcohol, or, if the compound of formula (I) contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid. The resulting diastereomeric mixture can be separated by chromatography and / or fractional crystallization, and one or both of the diastereoisomers can be converted into the corresponding pure enantiomer by means well known to those skilled in the art.
[0085] The chiral compounds of the invention (and their chiral precursors) can be obtained in enantiomerically enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing 0-50% by volume isopropanol, typically 2-20% by volume, and 0-5% by volume of an alkylamine, typically 0.1% diethylamine. Concentration of the eluate affords the enriched mixture.
[0086] Chiral chromatography using subcritical and supercritical fluids can also be used.The chiral chromatography method useful in some embodiments of the present invention is known; for example, see Smith, Roger M., Loughborough University, Loughborough, UK; Chromatographic Science Series (1998), 75 (Supercritical Fluid Chromatography with Packed Columns), pp. 223-249 and the references cited therein.
[0087] Mixtures of stereoisomers can be separated by conventional techniques known to those skilled in the art; see, for example, "Stereochemistry of Organic Compounds" by EL Eliel and SH Wilen (Wiley, New York, 1994).
[0088] Where structural isomers are interconvertible via a low energy barrier, tautomeric isomerism ('tautomerism') and conformational isomerism can occur.
[0089] Tautomerism may take the form of proton tautomerism in the compounds of formula (I) in general, and in Example 1, with respect to the imidazopyridine group, as shown below:
[0090] [ka]
[0091] Those skilled in the art will appreciate that proton tautomerism may also occur on the pyrazole ring in compounds of formula (I).
[0092] For simplicity, the compounds of formula (I) are depicted herein in a single tautomeric form; however, all possible tautomeric forms, and mixtures thereof, are included within the scope of the present invention.
[0093] Conformational isomerism is a stereoisomeric form in which the isomers of a compound can be interconverted solely by rotation around a single bond. Such isomers are generally referred to as conformers or conformers, specifically rotamers. A "rotational isomer mixture" or "mixture of rotamers" describes a compound that exists as a mixture of more than one possible conformational isomer. For simplicity, the compound of formula (I) is depicted in a single conformational form, but all possible conformers, and mixtures thereof, are within the scope of the present invention.
[0094] The scope of the present invention includes all crystalline forms of the compounds of the present invention, including racemates and racemic mixtures (conglomerates). Stereoisomeric conglomerates can also be separated by conventional techniques as described immediately hereinabove.
[0095] The scope of the present invention includes all pharmaceutically acceptable isotopically labeled compounds of the present invention in which one or more atoms are replaced by an atom having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number predominant in nature.
[0096] Examples of isotopes suitable for inclusion in the compounds of the invention include: 2 H and 3 hydrogen such as H; 11 C. 13 C and 14 carbon, such as C; 18 fluorine, such as F; 36 chlorine, such as Cl; 123 I and 125 iodine, such as I; 13 N and 15 nitrogen such as N; 15 O. 17 O and 18 Examples include isotopes of oxygen such as O.
[0097] Certain isotopically labeled compounds of the present invention, for example, those incorporating a radioactive isotope, are useful in drug and / or substrate tissue distribution studies. The radioactive isotope tritium, i.e., 3 H, and carbon-14, i.e., 14 C is particularly useful for this purpose given its ease of incorporation and ready means of detection. Deuterium (D), i.e., 2 Substitution with heavier isotopes, such as H, can offer certain therapeutic benefits resulting from greater metabolic stability, such as increased half-life in vivo or reduced dosage requirements, and therefore may be preferable in some circumstances. 11 C. 15 O and 13 Substitution with positron emitting isotopes, such as N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
[0098] Isotopically labeled compounds of formula (I) may generally be prepared by conventional techniques known to those skilled in the art, or by processes analogous to those described in the accompanying examples and preparations employing appropriate isotopically labeled reagents in place of previously used unlabeled reagents.
[0099] Also within the scope of the present invention are the intermediate compounds defined hereinafter, all salts, solvates and complexes thereof, and all solvates and complexes of the salts thereof defined hereinbefore for the compounds of formula (I). The present invention includes all polymorphs of the above species and their crystal phases.
[0100] When preparing compounds of formula (I) according to the present invention, one skilled in the art can routinely select the form of the intermediate that provides the best combination of characteristics for this purpose, including the melting point, solubility, processability and yield of the intermediate form and the resulting ease with which the product can be purified upon isolation.
[0101] The compounds of the present invention can be prepared by any method known in the art for the preparation of compounds of similar structure. In particular, the compounds of the present invention can be prepared by the procedures described with reference to the following schemes, or by the specific methods described in the Examples, or by processes analogous to any of them.
[0102] Those skilled in the art will understand that the experimental conditions described in the following schemes are illustrative of suitable conditions for carrying out the transformations shown, and that it may be necessary or desirable to vary the exact conditions used for the preparation of compounds of formula (I). Furthermore, it will be understood that it may be necessary or desirable to carry out the transformations in a different order than described in the schemes, or to modify one or more transformations in order to provide the desired compounds of the invention.
[0103] The compounds of the present invention contain two or more stereocenters, along with the stereochemical designation (R) or (S). Those skilled in the art will appreciate that all synthetic transformations can be performed on either enantiomerically enriched or racemic compounds using well-known methods described herein and / or known in the art, and that resolution to the desired stereoisomer can occur at any point in the synthesis.
[0104] Furthermore, those skilled in the art will understand that it may be necessary or desirable to protect one or more sensitive groups at any stage in the synthesis of the compound of the present invention in order to prevent undesired side reactions.In particular, it may be necessary or desirable to protect hydroxyl, carboxyl and / or amino group.The protecting group used in the preparation of the compound of the present invention can be used in a conventional manner; for example, see "Greene's Protective Groups in Organic Synthesis", 5th edition (John Wiley and Sons, 2014) by Theodora W Greene and Peter GM Wuts, which is incorporated herein by reference, in particular those described in chapters 2, 5 and 7, respectively, which also describe the method for removing such groups.
[0105] In the general process below, unless otherwise stated: ·R 1 ~R 6 is as previously defined for compounds of formula (I); R is alkyl, such as methyl or ethyl, or in the case of formulas 3 and 4, two R together with the oxygen atom to which they are attached may form a cyclic acetal; PG is a suitable amino-protecting group, such as a silyl ether (e.g., SEM), alkoxycarbonyl (e.g., BOC), acetyl (Ac), benzyl (e.g., PMB) or dihydropyran (DHP) protecting group; and X is F or Cl.
[0106] Substituted pyrazoles of formula 11 can be prepared as shown in Scheme 1.
[0107] Compound 1 (3-methoxytoluene) can be reduced to the corresponding 1,4-diene compound 2 by Birch reduction (Mander, L.N. Comprehensive Organic Synthesis; Trost, B.M. and Fleming, I. (eds.); Pergamon: Oxford, 1991, Vol. 8, pp. 489-521) using an alkali metal such as Li or Na in liquid ammonia at temperatures below -30°C.
[0108] Preparation of olefin acetals of formula 3 from 1,4-diene compounds 2 can proceed under catalytic acid conditions, for example, using pTSA or CSA in the presence of alkyl primary alcohols such as methanol or ethanol, or diols such as ethylene glycol, with or without a solvent such as DCM or other aprotic solvents, at temperatures between 0 and 100°C, such as between 0 and 25°C.
[0109] Conversion of olefins of formula 3 to cyclopropanes of formula 4 may proceed via dihalocarbene addition or Simmons-Smith cyclopropanation (Charette, AB; Beauchemin, A. Simmons-Smith Cyclopropanation Reaction. Org. React. 2001, 58, 1-415).
[0110] [ka]
[0111] Deprotection of the acetal of formula 4 to give the ketone of formula 5 can be carried out under acidic conditions, for example, using an organic acid such as HCl, H2SO4, or pTSA in a mixture of water and a solvent such as THF.
[0112] Preparation of diketones of formula 6 can be achieved by reacting ketones of formula 5 with i) a dialkyl oxalate and 1-3 equivalents of a strong base, such as LDA, LiHMDS, or KOtBu, in a polar aprotic solvent such as THF at -78°C to 25°C; or ii) an alkoxide in a corresponding alcoholic solvent (e.g., sodium ethoxide in ethanol) at temperatures from 0°C to reflux.
[0113] Condensation of the diketone of formula 6 with hydrazine or hydrazine hydrate in a protic solvent such as methanol or ethanol at temperatures from 25° C. to reflux can provide the pyrazole of formula 7. A hydrazine salt, such as the HCl salt, can also be used with the corresponding molar equivalent of an inorganic base (e.g., KCO) or an organic base (e.g., EtN or iPrNEt).
[0114] Protection of pyrazoles of formula 7 can be carried out with SEM-Cl, DHP or another suitable protecting group to give pyrazoles of formula 8, and resolution to give the corresponding enantiomers of formula 9 can be carried out by supercritical fluid chromatography using a chiral solid phase.
[0115] Reduction of the ester of formula 9 to the alcohol of formula 10 can be carried out using LAH in an aprotic solvent such as THF at temperatures between 0° C. and reflux.
[0116] Oxidation of alcohols of formula 10 to aldehydes of formula 11 can be carried out i) in aprotic solvents using agents such as PCC, PDC, or MnO2, or ii) catalyzed, for example, by using TEMPO / bleach and TRAP / NMO (Caron, S., Dugger, RW, Gut Ruggeri, S., Ragan, JA, Brown Ripin, DH, Chem. Rev. 2006, 106, 2943-2989) or Swern oxidation conditions.
[0117] Substituted pyrazoles of formula 17 can be prepared as shown in Scheme 2.
[0118] [ka]
[0119] Treatment of the ketone of formula 12 with an alkoxide base such as sodium ethoxide or KOtBu, or other bases such as LDA or LiHMDS, and a formylating agent such as ethyl formate in an aprotic solvent such as THF at −78° C. to 80° C. can provide the dicarbonyl of formula 13.
[0120] Condensation of the dicarbonyl of formula 13 with hydrazine or hydrazine hydrate in a protic solvent such as methanol or ethanol at 25° C. to reflux can provide the pyrazole of formula 14. A hydrazine salt, such as the HCl salt, can also be used with the corresponding molar equivalent of an inorganic base (e.g., KCO) or an organic base (e.g., EtN or iPrNEt).
[0121] Pyrazoles of formula 14 can be iodized by treatment with iodine in a polar aprotic solvent such as DMF with the addition of an alkali hydroxide such as KOH at temperatures between 0° C. and 50° C. to provide iodo-pyrazoles of formula 15.
[0122] Protection of pyrazoles of formula 15 can be carried out with SEM-Cl, DHP or another suitable protecting group to give pyrazoles of formula 16.
[0123] Iodo-pyrazoles of formula 16 can be converted to formylpyrazoles of formula 17 by treatment with a palladium-ligand complex such as Pd(dppf)Cl in the presence of a base such as EtN and a hydride source such as triethylsilane in a polar aprotic solvent such as DMF under a pressurized atmosphere of CO (2-5 atm) at temperatures ranging from 30°C to 100°C.
[0124] Compounds of formula (I) can be prepared as shown in Scheme 3.
[0125] Nucleophilic aromatic substitution (S) with benzylamine at 25 to 100°C; in the presence of a base such as an inorganic base (e.g., carbonate, bicarbonate, hydroxide, or acetate of sodium, potassium, or cesium) or an organic amine base such as EtN; in a polar aprotic solvent such as THF, DMF, DMAC, DMSO, or NMP, or a protic solvent such as water, MeOH, EtOH, or isopropanol, or a mixture thereof N Nitroanilines of formula 19 can be prepared via substitution of X in compounds of formula 18 by the Ar) reaction.
[0126] Esters of formula 19 can be hydrolyzed to provide acids of formula 20 using aqueous lithium, sodium, or potassium hydroxide in solvents such as MeOH, EtOH, or THF, or mixtures thereof, at temperatures from 20° C. to reflux.
[0127] [ka]
[0128] Preparation of carbamates of formula 21 can proceed from acids of formula 20 by treatment with diphenylphosphoryl azide in the presence of a base such as EtN and an alcohol such as tert-butyl alcohol or alternative alcohols such as methanol, ethanol and benzyl alcohol in a solvent such as toluene at temperatures from 60°C to 120°C.
[0129] Alkylation of carbamates of formula 21 to provide carbamates of formula 22 can be carried out with an alkylating agent such as an alkyl halide or alkyl tosylate in the presence of a base such as KOtBu or LiHMDS in a polar aprotic solvent such as DMF or THF.
[0130] Reduction of the nitroaniline of formula 22 (with simultaneous deprotection) can be carried out under hydrogenation conditions using a Pd catalyst such as 10% Pd / C or Pd(OH) / C under 1-5 atoms of H in an alcoholic solvent such as methanol or ethanol at temperatures between 20-100 °C to give the diamine of formula 23.
[0131] Diamines of formula 23 can be condensed with aldehydes of formula 11 or 17 in a polar solvent such as DMF containing 0-5 equivalents of DMSO with an oxidizing agent such as sodium metabisulfite at temperatures between 90 and 150°C to provide imidazopyridines of formula 24. Alternatively, the condensation of compounds of formula 23 with compounds of formula 11 or 17 can proceed in the presence of aqueous sodium bisulfite and ethanol or other alcoholic solvents at temperatures between 60°C and reflux.
[0132] Selective deprotection of the protected amine of formula 24 to give the amine of formula 25 can be achieved by reaction with ZnBr2 (R = t-butyl) in a non-polar solvent such as DCM.
[0133] Amines of formula 25 can be acylated using standard amide coupling reagents such as EDCI, HATU, HBTU, BTFFH, or T3P; or by reaction with another acylating agent such as an acid chloride, acid anhydride, or acylimidazole in the presence of an organic base such as Et3N in a solvent such as DCM or DMF at temperatures from 0° C. to reflux to provide amides of formula 26 with carboxylic acids.
[0134] Removal of the protecting group in a compound of formula 26 to give the corresponding compound of formula (I) can be carried out under conditions well known to those skilled in the art. For example, when PG=SEM, the protecting group can be removed by using TFA in DCM, optionally with the addition of triethylsilane.
[0135] Those skilled in the art will recognize that R 2It will be appreciated that compounds of formula 23 where is H (and subsequently compounds of formulas 24 to 26, and (I)) can be prepared directly from compounds of formula 21 according to Scheme 3.
[0136] Amides of formula 26 can be prepared as shown in Scheme 4.
[0137] [ka]
[0138] The protected amine of formula 22 can be deprotected under conditions well known to those skilled in the art to provide the amine of formula 27. For example, when R=t-butyl, the carbamate can be removed by using TFA in DCM or HCl (e.g., 4 M HCl in 1,4 dioxane).
[0139] Amines of formula 27 can be acylated as described in Scheme 3 for the preparation of amides of formula 26 to give amides of formula 28.
[0140] Reduction of nitroanilines of formula 28 (with simultaneous deprotection, if necessary) can be carried out under the hydrogenation conditions described in Scheme 3 for the preparation of diamines of formula 23 to provide diamines of formula 29.
[0141] Diamines of formula 29 can be condensed with aldehydes of formula 11 or 17 to give compounds of formula 26 as described in Scheme 3 for preparing compounds of formula 24.
[0142] Compounds of formula 35 can be prepared as described in Scheme 5.
[0143] [ka]
[0144] The nitro-aniline of formula 31 is reacted with the S-nitroaniline described above in Scheme 3 for the preparation of the nitro-aniline of formula 19. N Under Ar conditions, R 5 Alternatively, nitroanilines of formula 32 can be brominated with an electrophilic brominating reagent such as NBS or Br2 under conditions well known to those skilled in the art following the rules of electrophilic aromatic substitution to give R 5 Nitro-anilines of formula 31, where is Br, can be obtained.
[0145] Nitro-anilines of formula 30 can be protected with a protecting group such as BOC to provide compounds of formula 33. Protected nitroanilines of formula 34 can be prepared by displacement of X in compounds of formula 33 under the conditions immediately described for the preparation of compounds of formula 31. Removal of the protecting group in compounds of formula 34 to provide nitro-anilines of formula 31 can be accomplished by one skilled in the art using standard methods.
[0146] Compounds of formula 35 can be prepared by reduction of nitro-anilines of formula 31 with aqueous ammonium chloride in a mixture of organic solvents such as AcOH or THF as solvent using a metal such as Zn or Fe at temperatures from 20 to 100°C.
[0147] Compounds of formula 38 can be prepared as described in Scheme 6.
[0148] [ka]
[0149] Compounds of formula 36 can be displaced by nitrogen nucleophiles such as benzylamine or 4-methoxybenzylamine to provide nitro-anilines of formula 37, which can be reduced to give diamines of formula 38 as previously described in Scheme 5 for the preparation of diamines of formula 35.
[0150] Compounds of formula 40 can be prepared as described in Scheme 7.
[0151] [ka]
[0152] Diamines of formula 35 can be condensed with aldehydes of formula 11 or 17 in a polar solvent such as DMF containing 0-5 equivalents of DMSO with an oxidizing agent such as NaSO at temperatures between 90 and 150°C to give imidazopyridines of formula 39. Protection of imidazopyridines of formula 39 can be carried out with SEM-Cl, DHP, or another suitable protecting group to give compounds of formula 40, which may exist as a mixture of regioisomers.
[0153] Additionally, diamines of formula 38 can be condensed with aldehydes of formula 11 or 17 as described above for the preparation of imidazopyridines of formula 39 to provide imidazopyridines of formula 40.
[0154] Compounds of formula (I) can also be prepared as described in Scheme 8.
[0155] [ka]
[0156] Compounds of formula 40 can be directly converted to amines of formula 41, 42, or 43 by transition metal-catalyzed cross-coupling reactions such as the Buchwald-Hartwig coupling (Bernhardson, DJ, Widlicka, DW, Singer, RA, Cu-Catalyzed Couplings of Heteroaryl Primary Amines and (Hetero)aryl Bromides with 6-Hydroxypicolinamide Ligands, Org. Process Res. Dev. 2019, 23, 1538-1551).
[0157] Compounds of formula 41 can be protected (eg, PG=BOC or CBZ) to give compounds of formula 42 under conventional conditions.
[0158] Amines of formula 43 can be prepared by alkylation of compounds of formula 42 as described in Scheme 3 for the preparation of compounds of formula 22, followed by deprotection as described in Scheme 3 for the preparation of amines of formula 25.
[0159] Acylation of an amine of formula 43 can give an amide of formula 44, which can be subsequently deprotected as described in Scheme 3 for the preparation of an amide of formula 26 and its deprotection to a compound of formula (I) to provide a compound of formula (I).
[0160] Those skilled in the art will recognize that R 2 is H can be prepared directly from compounds of formula 42 according to Scheme 8, and similarly, compounds of formula 44 (and subsequently compounds of formula (I)) where R 2 It will be appreciated that compounds of formula (I) where is H can be prepared directly from compounds of formula 45.
[0161] Those skilled in the art will appreciate that amines of formula 41 can be converted to amides of formula 44 via amides of formula 45 by reversing the alkylation and acylation steps, i.e., acylation first, then alkylation.
[0162] Compounds of Formula 1, Formula 12, Formula 18, Formula 30, Formula 32, Formula 35 and Formula 36 can be obtained from commercial sources, prepared analogously to literature methods, or obtained by the methods described in the experimental section below or variations thereof known to those skilled in the art.
[0163] The compounds of the present invention intended for pharmaceutical use may be administered in amorphous or crystalline form, or may exist in a range of solid states from completely amorphous to completely crystalline. They can be obtained as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze-drying, spray-drying, or evaporative drying. Microwave or radio frequency drying can be used for this purpose.
[0164] The compound of the present invention can be administered by any suitable route in the form of pharmaceutical compositions adapted to such route, in a dose effective for intended treatment.Generally, they will be administered as a preparation associated with one or more pharmaceutically acceptable excipients.The term "excipient" is used herein to describe any component other than the compound of the present invention.The choice of excipient will depend largely on factors such as the mode of administration, the effect of excipient on solubility and stability, and the nature of dosage form.
[0165] Modes of administration for the compounds of the present invention include oral, parenteral, topical, rectal, vaginal, ocular and otic administration.
[0166] Oral administration may involve swallowing, so that the compound of the present invention enters the gastrointestinal tract, or buccal or sublingual administration by which the compound enters the blood stream directly from the mouth.
[0167] Parenteral administration may involve injection of the compounds of the invention into the blood stream, muscle, or an internal organ, and the injection may be intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, or subcutaneous. Parenteral administration may also use needle (including microneedle) injectors, needle-free injectors, and infusion techniques.
[0168] Topical administration is preferred, · Administration to the skin, nails, hair, claws, hooves, or mucous membranes; ·Dermal or transdermal administration; ·Administered intranasally or by inhalation; Rectal or vaginal administration; and Direct administration to the eye or ear Examples include:
[0169] The term "transdermal administration" refers to the diffusion of a compound of the invention across the barrier of the skin, nail, hair, claw, or hoof resulting from topical administration or other application of the composition. Transdermal delivery includes delivery through any part of the skin, nail, hair, claw, or hoof and absorption or penetration through the remainder.
[0170] Local administration of the compound of the present invention can result in the distribution of the compound limited to the skin and surrounding tissue, or can result in the systemic exposure of the compound of the present invention when the compound is removed from the treatment area by bloodstream.Preferably, local administration of the compound of the present invention results in the distribution of the compound limited to the skin and surrounding tissue.When the systemic exposure of the compound of the present invention occurs, it is preferable that the compound is rapidly metabolized, so that the systemic exposure of the compound of the present invention is minimized.Minimizing systemic exposure can reduce undesirable biological effects (i.e., side effects).
[0171] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable excipient.
[0172] Pharmaceutical compositions suitable for delivery of compounds of the invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for preparation can be found, for example, in "Remington's Pharmaceutical Sciences," 19th Edition (Mack Publishing Company, 1995).
[0173] Pharmaceutical compositions are typically prepared by mixing the compounds of the present invention with one or more excipients. Excipients include carbohydrates, waxes, water-soluble and / or swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, buffers, stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opacifiers, glidants, processing aids, colorants, sweeteners, fragrances, flavoring agents, and the like. Solvents may include water, ethanol, propylene glycol, polyethylene glycol (e.g., PEG400, PEG300), and mixtures thereof. Excipients are selected to facilitate the manufacture or use of the pharmaceutical composition.
[0174] Pharmaceutical compositions can be prepared by conventional dissolution and mixing.For example, the compound of the present invention can be dissolved in a solvent in the presence of one or more excipients as described above.The dissolution rate of weakly water-soluble compounds can be enhanced by using spray-drying dispersion, such as that described by Takeuchi, H. et al. in "Enhancement of the dissolution rate of a poorly water-soluble drug (tolbutamide) by a spray-drying solvent deposition method and disintegrants", J.Pharm.Pharmacol., 39, 769-773 (1987); and US2002 / 009494, which are incorporated herein by reference.
[0175] The solid dosage form for oral administration of the compound of the present invention includes, for example, tablets, hard or soft capsules, lozenges, granules or powder, each of which contains at least one compound of the present invention.In such solid dosage form, the compound of the present invention is usually combined with one or more pharmaceutically acceptable excipients.The solid dosage form for oral administration such as tablets and capsules can be prepared with enteric coating.
[0176] Liquid dosage forms for oral administration of the compounds of the present invention include, for example, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art (e.g., water). Such compositions may also contain excipients such as wetting agents, emulsifying agents, suspending agents, flavoring agents (e.g., sweeteners), and / or perfuming agents.
[0177] Parenteral formulations of the compounds of the invention are typically aqueous solutions which may contain excipients such as salts, carbohydrates, and buffers (preferably buffered to a pH of 3 to 9). Formulations for parenteral administration may also be sterile non-aqueous solutions administered upon reconstitution with a suitable vehicle, such as sterile, pyrogen-free water, or in dried (e.g., lyophilized) form.
[0178] The pharmaceutical compositions for topical or transdermal administration of the compound of the present invention include ointments, pastes, creams, lotions, gels, suppositories, powders, solutions, sprays, drops, inhalants and patches.The compound of the present invention is mixed with a pharmaceutically acceptable topical carrier and any preservatives or buffers that may be required under sterile conditions.Volatile compounds may need to be mixed with compounding agents or packaging materials to ensure appropriate dosage delivery.Compounds of the present invention that have low skin permeability may need one or more penetration enhancers, while compounds that are rapidly absorbed through the skin may need to be formulated with absorption retardants or barriers.
[0179] The term " pharmaceutically acceptable topical carrier " refers to a carrier medium suitable for topical application, such as an inert liquid or cream vehicle that can suspend or dissolve the compound, and provides an effective amount of the compound of the present invention.Those skilled in the art will understand that this term also includes the carrier material approved for use in topical cosmetics.
[0180] The term "penetration enhancer" refers to increasing the permeability of skin, nails, hair, claws, or hooves to the compounds of the present invention to increase the rate and extent of penetration of the compound. Penetration enhancement can be observed, for example, by measuring the diffusion rate of the drug through animal or human skin, nails, hair, claws, or hooves using a diffusion cell apparatus. Diffusion cells are described by Merritt et al., Diffusion Apparatus for Skin Penetration, J of Controlled Release, 1 (1984), pp. 161-162.
[0181] Ointments, pastes, creams, lotions, gels, suppositories, powders, solutions, sprays, drops, inhalants, and patches for topical administration may contain, in addition to the compounds of the present invention, one or more pharmaceutically acceptable excipients, such as animal or vegetable fats, oils, waxes, paraffins, starches, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite, silicic acid, talc, zinc oxide, preservatives, antioxidants, fragrances, emulsifiers, dyes, inert fillers, anti-irritants, tackifiers, fragrances, opacifiers, antioxidants, gelling agents, stabilizers, surfactants, emollients, colorants, preservatives, buffers, penetration enhancers, etc. Such excipients should not interfere with the effectiveness of the biological activity of the active agent and should not be harmful to epithelial cells or their function.
[0182] Transdermal administration can be accomplished by means of a transdermal patch, which may be of the "reservoir and porous membrane" type or may utilize a "matrix system."
[0183] The solubility of compounds of the invention used in preparing pharmaceutical compositions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
[0184] The pharmaceutical compositions may be formulated to be immediate and / or modified release. Advantageously, the compounds of the present invention are formulated for immediate release.
[0185] Modified release preparations include delayed, sustained, pulsed, controlled, targeted and programmed release.Therefore, the compound of the present invention can be formulated as solid, semi-solid or thixotropic liquid for administration as implanted depot preparations that provide the controlled release of active compound.The example of such preparations includes poly(dl-lactic-coglycolic) acid (PGLA) microspheres.
[0186] The compounds of the invention may be combined with soluble polymeric entities, such as cyclodextrins and suitable derivatives thereof, or polyethylene glycol-containing polymers, to improve their solubility, dissolution rate, taste masking, bioavailability and / or stability for use in any of the above modes of administration.
[0187] For administration to human patients, the total daily dose of the compounds of the present invention typically ranges from 60 mg to 6 g, e.g., 1 mg to 10 g, such as 100 mg to 1.5 g, depending on the mode of administration and efficacy. For example, administration may require a total daily dose of 200 mg to 1 g, such as 250 mg to 750 mg. The total daily dose may be administered in single or divided doses and, at the physician's discretion, may fall outside the typical ranges given herein. These dosages are based on an average human subject weighing approximately 60 kg to 70 kg. A physician will be able to readily determine dosages for subjects whose weight falls outside this range, such as infants and the elderly.
[0188] As noted above, the compounds of the present invention are useful because they exhibit pharmacological activity in animals, i.e., inhibition of ITK. More specifically, the compounds of the present invention are useful in treating disorders for which ITK inhibitors are indicated.
[0189] Preferably, the animal is a mammal, more preferably a human.
[0190] Preferably, the compounds of the invention also inhibit TRKA.
[0191] In a further aspect of the invention there is provided a compound of the invention for use as a pharmaceutical.
[0192] In a further aspect of the invention, there is provided a compound of the invention for use in the treatment of a disorder in which an ITK inhibitor is indicated.
[0193] In a further aspect of the invention there is provided the use of a compound of the invention for the preparation of a medicament for the treatment of a disorder for which an ITK inhibitor is indicated.
[0194] In a further aspect of the present invention, there is provided a method for treating a disorder in an animal (preferably a mammal, more preferably a human) for which an ITK inhibitor is indicated, comprising administering to the animal a therapeutically effective amount of a compound of the present invention.
[0195] Disorders or conditions for which ITK inhibitors are indicated include inflammatory diseases, autoimmune diseases, skin diseases, eye diseases, respiratory diseases, joint diseases, cardiovascular diseases and neuroinflammatory diseases. Those skilled in the art will understand that a given disease, disorder or condition may fall into more than one of the above categories.
[0196] More specifically, disorders or conditions for which ITK inhibitors are indicated include: Inflammatory disorders such as allergic conjunctivitis, celiac disease, proctitis, eosinophilic gastroenteritis, mastocytosis, inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, microscopic colitis (such as collagenous colitis or lymphocytic colitis), diversion colitis, Behcet's disease, and indeterminate colitis), nephritis, retinitis, retinopathy, myositis, vasculitis, Sjögren's syndrome, Wegener's granulomatosis, arteritis, sclerosing cholangitis, and eosinophilic esophagitis; · Autoimmune disorders such as lupus nephritis, autoimmune hepatitis, myasthenia gravis, Guillain-Barré syndrome, and Graves' disease; eye disorders or conditions, including ocular autoimmune diseases, keratoconjunctivitis, vernal keratoconjunctivitis, non-infectious uveitis (e.g., uveitis associated with Behçet's disease and phacogenic uveitis), keratitis (e.g., herpetic keratitis and keratoconus), corneal epithelial dystrophy, corneal leukoplakia, ocular pemphigus, Mooren's ulcer, scleritis, retinitis, retinopathy, Graves' ophthalmopathy, Vogt-Koyanagi-Harada syndrome, keratoconjunctivitis sicca (dry eye), phlyctenosis, iridocyclitis, sarcoidosis, endocrine ophthalmopathy, sympathetic ophthalmia, allergic conjunctivitis, and ocular neovascularization; Eczema (e.g., chronic and dyshidrotic eczema), chronic pruritus, dermatitis (e.g., atopic dermatitis, irritant contact dermatitis, allergic contact dermatitis, occupational dermatitis, perioral dermatitis, stasis dermatitis, nummular dermatitis, seborrheic dermatitis, xerosis, eyelid dermatitis, diaper dermatitis, and hand dermatitis), vitiligo, alopecia areata, pruritus (e.g., chronic idiopathic pruritus), psoriasis (e.g., plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, palmoplantar psoriasis, facial psoriasis, or erythrodermic psoriasis), scleroderma, pemphigus, dermatomyositis, neurodermatitis, skin flushing, urticaria, cutaneous lupus erythematosus (e.g., acute cutaneous lupus, subacute cutaneous lupus), and dermatological conditions such as cutaneous lupus (disciform lupus), keloids, photodermatitis, hypertrophic scars, idiopathic thrombotic thrombocytopenic purpura (also known as immune thrombocytopenic purpura (ITP)), ichthyosis (e.g., ichthyosis vulgaris), epidermal hyperplasia, acne, lichen planus, lichen sclerosus, rosacea, epidermolysis bullosa, intertrigo, keratosis pilaris, urticaria (e.g., chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria), molluscum contagiosum, Netherton syndrome, Vogt-Koyanagi-Harada syndrome, Sweet syndrome, pityriasis alba, vulvovaginitis, Sutton nevus, post-inflammatory hypopigmentation, senile vitiligo, chemical / drug-induced vitiligo, palmoplantar pustulosis, pemphigoid, and hidradenitis suppurativa; respiratory conditions such as rhinitis (e.g., allergic rhinitis and perennial rhinitis), rhinorrhea, nasal congestion, nasal inflammation, asthma (e.g., chronic asthma, refractory asthma, late-onset asthma, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, and dust-induced asthma), chronic obstructive pulmonary disease (COPD), chronic and acute bronchoconstriction, chronic bronchitis, emphysema, chronic eosinophilic pneumonia, acute lung injury (ACI), adult respiratory distress syndrome (ARDS), pulmonary vascular disease (PVD), pulmonary arterial hypertension (PAH), bronchiectasis, sinusitis, pulmonary sarcoidosis, and silicosis; joint disorders such as arthritis (e.g., osteoarthritis, as well as psoriatic arthritis, rheumatoid arthritis, juvenile arthritis, and gouty arthritis), spondyloarthropathy (e.g., reactive arthritis (also known as Reiter's syndrome) and axial spondyloarthritis (including ankylosing spondylitis)), cartilage inflammation, bone degradation, and Still's disease; Cardiovascular and metabolic disorders such as diabetes (type 1 and type 2), diabetic neuropathy, cachexia, and celiac disease; and Neuroinflammatory disorders such as lupus (e.g., CNS, systemic, and discoid lupus), diabetic neuropathy, and multiple sclerosis Examples include:
[0197] Allergic contact dermatitis (ACD) is contact dermatitis characterized by an allergic reaction to contact with a substance. An example of ACD is urushiol-induced contact dermatitis (also called toxicodendron dermatitis or sumac dermatitis), which is caused by urushiol, an oil found in various plants, including poison ivy, poison oak, poison sumac, and Chinese sumac trees. Other allergens that can induce ACD include chromium, gold, and nickel.
[0198] Irritant contact dermatitis (ICD) is a form of contact dermatitis that can be divided into forms caused by chemical irritants and forms caused by physical irritants. Common chemical irritants include acids, alkalis, latex, oils, fragrances, and preservatives in cosmetics, solvents, and surfactants.
[0199] Occupational dermatitis is ACD or ICD resulting from exposure to allergens or irritants in the work environment.
[0200] Additionally, ITK inhibitors may be useful in the treatment of certain viral and bacterial infections, transplant rejection, septic shock, acute or chronic graft-versus-host disease, polymyalgia rheumatica, sarcoidosis, Addison's disease, and Raynaud's syndrome.
[0201] In one embodiment, the disorder or condition for which an ITK inhibitor is indicated is a dermatological condition. In another embodiment, the dermatological condition for which an ITK inhibitor is indicated is dermatitis. In another embodiment, the dermatitis for which an ITK inhibitor is indicated is atopic dermatitis.
[0202] The compounds of the present invention can be usefully combined with one or more other pharmacologically active compounds. Such combinations offer significant potential advantages, including patient compliance, ease of administration, and synergistic activity.
[0203] In a further aspect of the invention, there is provided a compound of the invention in combination with another pharmacologically active compound, or with two or more other pharmacologically active compounds.
[0204] In such combinations, the compound of the present invention and the other pharmacologically active compound may be administered simultaneously, sequentially, or separately, such as in a single dosage form (e.g., a composition for topical administration such as a cream or ointment).
[0205] The one or more additional therapeutic agents may be selected from any of the following agents or types of agents: agents for treating autoimmune and / or inflammatory disorders, such as sulfasalazine, mesalazine, azathioprine, antibodies (e.g., infliximab, adalimumab, belimumab, tanezumab, ranibizumab, bevacizumab, mepolizumab, certolizumab, natalizumab, and vedolizumab), 6-mercaptopurine, hydroxychloroquine, mofetil, mycophenolate sodium, leflunomide, Rituxan, solumedrol, depomedrol, nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin, ibuprofen, celecoxib, valdecoxib, WBI-1001, and MRX-6), and corticosteroids (e.g., betamethasone, dexamethasone, and prednisone); medications for treating dermatological conditions, such as immunosuppressants (e.g., cyclosporine, tacrolimus, and pimecrolimus), antibodies (e.g., infliximab, adalimumab, dupilumab, omalizumab, and efalizumab), TNF inhibitors (e.g., etanercept), PDE4 inhibitors (e.g., crisaborole), and topical corticosteroids (e.g., fluocinonide, mapracorat, hydrocortisone, desonide, alclometasone, triamcinolone, and desoximetasone); medications for treating respiratory conditions, such as oxymetazoline, rifampin, antihistamines (e.g., fexofenadine, loratidine, desloratidine, levocetirizine, methapyrilene, cetirizine), leukotriene receptor antagonists (e.g., montelukast and zafirlukast), 5-lipoxygenase-activating protein (FLAP) antagonists, muscarinic receptor antagonists (e.g., tiotropium and ipratropium), sodium cromoglycate, nedocromil sodium, corticosteroids (e.g., budesonide, fluticasone, mometasone, dexamethasone, prednisolone, ciclesonide, and beclomethasone), beta-2 agonists (e.g., salmeterol, albuterol, salbutamol, fenoterol, and formoterol), and antibodies (e.g., omalizumab); · Medications for treating joint disorders, such as methotrexate, azathioprine, and NSAIDs (e.g., aspirin, ibuprofen, celecoxib, valdecoxib, WBI-1001, and MRX-6); Agents for treating cardiovascular and metabolic disorders, such as ursodeoxycholic acid, chloroquine, quinacrine, methylnorephrine, phenylephrine, methoxamine, oxymetazoline, theophylline, PDE5 inhibitors (e.g., sildenafil, vardenafil, and tadalafil), PDE4 inhibitors (e.g., crisaborole, ibudilast, cilomilast, roflumilast, and ampremilast), and kinin B1 or B2 receptor antagonists; and ·Medications for treating neuroinflammatory disorders, such as cyclophosphamide.
[0206] The one or more additional therapeutic agents may also be selected from any of the following agents: JAK inhibitors, such as abrocitinib, baricitinib, brepositinib, cerdulatinib, decernotinib, delgocitinib, fedratinib, filgotinib, gandotinib, irginatinib, itacitinib, lestaurtinib, momelotinib, oclacitinib, pacritinib, peficitinib, ritretinib, ruxolitinib, tofacitinib, upadacitinib, ATI-502, BMS-986165, JTE052, PF-06826647, SNA-152, and SHR-0302; · Aryl hydrocarbon receptor agonists, such as tapinarof; · IRAK4 inhibitors such as PF-06650833; Vitamin D analogues such as calcipotriene; Retinoic acid derivatives such as alitretinoin; · Liver X receptor (LXR) selective agonists such as VTP-38543; ·H4 receptor antagonists such as ZPL-389; ·NKI receptor antagonists such as aprepitant and tradipitant; · CRTH2 receptor antagonists such as fevipiprant and OC-459; ·Chymase inhibitors such as SUN13834; · GATA-3 inhibitors such as SB-011 and GR-MD-02; ROR inverse agonists such as VTP-43742, ARN6039, TAK-828 and JTE-451; Immunomodulators such as PF-06763809; and Inhibitors of SYK and BTK such as, but not limited to, R-348, fostamatinib, mastinib, mivabotinib, sperbrutinib, fenebrutinib, cerdulatinib, ibrutinib, entospletinib, and tirabrutinib.
[0207] It is within the scope of the present invention that two or more pharmaceutical compositions, at least one of which contains the compound of the present invention, can be conveniently combined in the form of a kit suitable for simultaneous administration of the compositions.Therefore, the kit of the present invention comprises two or more separate pharmaceutical compositions, at least one of which contains the compound of the present invention, and includes a means for keeping the compositions separate, such as a container, a divided bottle, or a divided foil packet.An example of such a kit is the convenient blister pack used for packaging tablets, capsules, etc.The kit of the present invention is particularly suitable for administering different dosage forms (e.g., topical, oral, parenteral, etc.), administering different compositions at different dosage intervals, or titrating different compositions relative to each other.To aid compliance, the kit typically includes instructions for administration and can be provided with a so-called memory aid.
[0208] In another aspect, the present invention provides a pharmaceutical product (e.g., in the form of a kit) comprising a compound of the invention together with one or more additional therapeutically active agents as a combined preparation for simultaneous, separate or sequential use in the treatment of disorders for which an ITK inhibitor is indicated.
[0209] It should be understood that all references herein to treatment include curative, palliative and prophylactic treatment.
[0210] In the non-limiting examples and preparations described below, which illustrate the invention, as well as in the schemes above, the abbreviations, definitions and analytical procedures may refer to the following: AcOH is acetic acid; Ac2O is acetic anhydride; APC is allophycocyanin; aq. is aqueous; atm is atmospheric pressure; ATP is adenosine 5'-triphosphate disodium salt trihydrate; BINAP is (2,2'-bis(diphenylphosphino)-1,1'-binaphthyl); Boc is tert-butoxycarbonyl; BOC2O is BOC anhydride, di-tert-butyldicarboxylic acid; br is broad; BTFFH is fluorobis(tetramethylene)formamidinium hexafluorophosphate; BTK is Bruton's tyrosine kinase; °C is the temperature in degrees Celsius; CBZ is carboxybenzyl (also known as benzyloxycarbonyl); CD3OD is deuterium-methanol; CDCl3 is deuterated chloroform; CMPI is 2-chloro-1-methylpyridinium iodide, Mukaiyama's reagent; Conc. is concentrated; CSA is camphorsulfonic acid; δ is the chemical shift; d is a doublet; dd is a doublet of doublets; ddd is a doublet of a doublet of a doublet; ddq is a doublet of a doublet of a quartet; dt is the doublet of the triplet; DAST is diethylaminosulfur trifluoride; DCM is dichloromethane; DCE is 1,2-dichloroethane; Dess-Martin periodinane is a 3-oxo-1,3-dihydro-1λ 5 ,2-benzoiodoxol-1,1,1-triyl triacetate; DHP is dihydropyran; DMAP is 4-dimethylaminopyridine; DMAC is dimethylacetamide; DMF is N,N-dimethylformamide; DMSO is dimethyl sulfoxide; DPPA is diphenylphosphoryl azide; EDCI is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; ee is the enantiomeric excess; eq is equivalent weight; EDTA is ethylenediaminetetraacetic acid; ESI-MS is electrospray ionization mass spectrometry; EtOAc is ethyl acetate; EtOH is ethanol; EtONa is sodium ethoxide; Et3N is triethylamine; Et3SiH is triethylsilane; g is grams; h is the time; HATU is 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide, hexafluorophosphate; HBTU is N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate; HEPES is (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid); HPLC is high pressure liquid chromatography; iPr2NEt is N,N-diisopropylethylamine, also known as Hunig's base; iPrOH is isopropanol, also known as 2-propanol; Kg is kilogram; KOAc is potassium acetate; KOtBu is potassium tert-butoxide; L is liters; LCMS is liquid chromatography mass spectrometry; LDA is lithium diisopropylamide; LiHMDS is lithium hexamethyldisilazide, also known as lithium bis(trimethylsilyl)amide; m is a multiplet; M is the molar concentration; MeCN is acetonitrile; MeNH2 is methylamine; MeOH is methanol; MHz is megahertz; min is minutes; mL is milliliters; mm is millimeters; mmol is millimole; mol is mole; MS m / z is the mass spectrum peak; MTBE is methyl tert-butyl ether; n-BuLi is n-butyllithium; N in the context of cardinality is a standard NaHMDS is sodium bis(trimethylsilyl)amide; NaOtBu is sodium tert-butoxide; NBS is N-bromosuccinimide; NH4OH is 33M aqueous ammonia; NMP is N-methyl-2-pyrrolidone; NMR is nuclear magnetic resonance; PCC is pyridinium chlorochromate; PDC is pyridinium dichromate; Pd2(dba)3 is tris(dibenzylideneacetone)dipalladium(0); Pd / C is palladium on carbon; Pd(dppf)Cl2 is [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II); Pd(OAc)2 is palladium(II) acetate; Pd(OH)2 / C is palladium(II) hydroxide on carbon; Pd(Ph3P)4 is tetrakis(triphenylphosphine)palladium(0); PE is petroleum ether; PhCH3 is toluene; PMB is para-methoxybenzyl; PSI is pounds per square inch; pTSA is p-toluenesulfonic acid monohydrate; q is a quartet; Qphos is 1,2,3,4,5-pentaphenyl-1'-(di-tert-butylphosphino)ferrocene; quint is a quintet; RT is room temperature; s is singlet; sat. is saturated; SEM-Cl is 2-(trimethylsilyl)ethoxymethyl chloride; SFC is supercritical fluid chromatography; SPhos is 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl; t is a triplet; tt is a triplet of triplets; t-BuDavePhos is 2-di-tert-butylphosphino-2'-(N,N-dimethylamino)biphenyl; t-BuOH is tert-butanol; TCEP is tris(2-carboxyethyl)phosphine; TCFH is N,N,N′,N′-tetramethylchloroformamidinium hexafluorophosphate; TEMPO is tetramethylpiperidine N-oxyl; TFA is trifluoroacetic acid; TFAA is trifluoroacetic anhydride; TGA is thermogravimetric analysis; THF is tetrahydrofuran; TMSCF3 is trifluoromethyltrimethylsilane; TMSOTf is trimethylsilyl trifluoromethanesulfonate; T3P is propylphosphonic anhydride; Tris is tris(hydroxymethyl)aminomethane; μL is microliter; μm is micrometer; μmol is micromolar; v / v is volume / volume; w / v is weight / volume; XantPhos is 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; and ZnEt2 is diethylzinc.
[0211] Unless otherwise stated, all reactions are carried out under a nitrogen atmosphere. RT (room temperature) is generally taken to mean about 22° C. (±5° C.). Unless otherwise stated, the term "concentration" refers to the process of removing volatile compounds, such as solvents, by use of a rotary evaporator under reduced pressure.
[0212] 1 1 H NMR spectra were consistent with the proposed structures in all cases. 1 Characteristic δ for H-NMR is reported relative to the residual solvent signal using conventional abbreviations for major peak designations (δ = 7.27 ppm for CDCl3; δ = 2.50 ppm for DMSO-d6, δ = 3.30 ppm for CD3OD). Those skilled in the art will understand that tautomers may be recorded in the NMR data and that some exchangeable protons may not be visible. Similarly, those skilled in the art will understand that mixtures of rotamers may be recorded in the NMR data.
[0213] Mass spectra were recorded using either ESI-MS. Where relevant and unless otherwise stated, m / z data provided are isotopic 19 F, 35 Cl, 79 Br and / or 81 It concerns Br.
[0214] The term "chromatography" refers to silica gel chromatography using a mobile phase consisting of a mixture or gradient of either EtOAc / heptane or methanol / DCM or some combination thereof.
[0215] When silica gel chromatography, preparative HPLC, or SFC chromatography is used, one skilled in the art will appreciate that any suitable solvent or combination of solvents can be used to purify the desired compound.
[0216] Nomenclature for the compounds of the following preparations and examples was generated according to IUPAC (International Union of Pure and Applied Chemistry) using ChemDraw Professional 19.0, Perkin Elmer.
[0217] preparation Preparation 1: 1-Methoxy-5-methylcyclohexa-1,4-diene (Compound 2)
[0218] [ka]
[0219] Anhydrous ammonia (1.40 kg, 82.2 mol) was bubbled through a solution of 1-methoxy-3-methylbenzene (compound 1, 500 g, 4.09 mol) in t-BuOH (1.50 L) and THF (1.0 L) at approximately −55° C. Lithium sand (62.5 g, 9.0 mol) was added to the mixture while maintaining the temperature between approximately −50° C. and −60° C. After the addition, the reaction mixture was stirred between approximately −50° C. and −60° C. for approximately 2 hours and then slowly warmed to approximately 15° C. The ammonia was evaporated, and the mixture was treated with NH4Cl (500 g, 9.35 mol) followed by water (500 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (2×500 mL). The combined EtOAc layers were washed with brine, dried (Na2SO4), filtered, and concentrated to give the title compound. Yield: 404 g (80%). 1 H NMR (400 MHz, CDCl3) δ = 5.41 (tt, 1H), 4.67 - 4.60 (m, 1H), 3.56 (s, 3H), 2.77 (ddq, 2H), 2.65 - 2.56 (m, 2H), 1.70 (dq, 3H).
[0220] Preparation 2 7-Methyl-1,4-dioxaspiro[4.5]dec-7-ene
[0221] [ka]
[0222] A solution of compound 2 (500 g, 4.03 mol) in DCM (4.0 L) was treated with (±)-10-camphorsulfonic acid (46.8 g, 201 mmol) and ethylene glycol (399 g, 6.04 mol) at about −10° C. to 0° C. The mixture was stirred at about 0° C. for about 30 minutes. The reaction mixture was washed successively with saturated aqueous NaHCO (2 L) and then water (2×2 L), dried (NaSO), filtered, and concentrated to give the title compound. Yield: 621 g (100%). 1 H NMR (400 MHz, CDCl3) δ = 5.38 (td, 1H), 3.95 (t, 4H), 2.21 - 2.12 (m, 6H), 1.67 (d, 3H).
[0223] Preparation 3 1-Methylspiro[bicyclo[4.1.0]heptane-3,2'-[1,3]dioxolane]
[0224] [ka]
[0225] A solution of ZnEt2 (1.00 M, 3.89 L) in DCM (2.0 L) was cooled to about 0 °C and treated dropwise with TFA (444 g, 3.89 mol, 288 mL) at about 0 °C. The mixture was stirred at about 0 °C for about 30 minutes, after which CHCl (314 mL, 3.89 mol) was added dropwise at about 0 °C. The mixture was stirred at about 0 °C for about 30 minutes. Preparation 2 (300 g, 1.95 mol) was added dropwise, maintaining the temperature at about 0 °C, and the resulting mixture was stirred at about 0 °C for about 30 minutes. The reaction mixture was poured into water (1 L) and extracted with DCM (3 × 1.75 L). The combined organic phases were dried (Na2SO4), filtered, and concentrated to give the title compound. Yield: 300 g (92%). 1 H NMR (400 MHz, CDCl3) δ = 3.78 - 3.93 (m, 4H), 2.01 - 2.13 (m, 1H), 1.79 - 1.84 (m, 1H), 1.67 - 1.75 (m, 2H), 1.36 - 1.47 (m, 1H), 1.27 (m, 1H), 1.03 (s, 3H), 0.61 - 0.73 (m, 1H), 0.25 - 0.35 (m, 2H).
[0226] Preparation 4 1-Methylbicyclo[4.1.0]heptan-3-one
[0227] [ka]
[0228] A solution of Preparation 3 (300 g, 1.78 mol) in THF (1.5 L) and water (300 mL) was treated with pTSA·HO (34.0 g, 178 mmol). The mixture was stirred at about 60 °C for about 3 h, cooled to RT, and treated with saturated aqueous NaHCO until the pH was 6-7. The mixture was extracted with MTBE (3 × 500 mL), dried (NaSO), filtered, and concentrated. The crude product was purified by chromatography to give the title compound. Yield: 85.7 g (39%). 1 H NMR (400 MHz, CDCl3) δ = 2.60 - 2.40 (m, 2H), 2.32 - 2.18 (m, 2H), 2.11 - 1.93 (m, 2H), 1.13 (s, 3H), 1.03 - 0.94 (m, 1H), 0.48 - 0.39 (m, 2H).
[0229] Preparation 5 2-(6-methyl-4-oxobicyclo[4.1.0]heptan-3-yl)-2-oxoethyl acetate (5)
[0230] [ka]
[0231] A solution of Preparation 4 (200 g, 1.61 mol) in ethanol (1.0 L) was treated with sodium ethoxide (126 g, 1.77 mol) at about 0° C. Diethyl oxalate (259 g, 1.77 mol, 242 mL) was added at about 0° C., and the mixture was gradually warmed to RT and stirred for about 1 h. The mixture was poured into 1 N HCl (1.25 L) and extracted with DCM (3×1 L). The combined organic extracts were dried (NaSO), filtered, and concentrated. The crude product was purified by chromatography to provide the title compound. Yield: 350 g (97%). LC / MS m / z (M+H) + =225.1
[0232] Preparation 6 Ethyl 5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole-3-carboxylate
[0233] [ka]
[0234] To a solution of Preparation 5 (350 g, 1.56 mol) in ethanol (1.5 L) was added hydrazine hydrate (79.7 g, 1.56 mol) at about 0 °C. The resulting mixture was stirred at RT for about 2 h. The mixture was treated with HO (2.5 L) and extracted with DCM (3 × 2 L). The combined organic layers were dried (NaSO), filtered, and concentrated. The crude product was purified by chromatography to provide the title compound. Yield: 200 g (58%). 1 H NMR (400 MHz, CDCl3) δ = 8.95 (s, 1H), 4.36 (q, 2H), 3.30 - 3.21 (m, 1H), 3.06 (d, 1H), 2.94 (dd, 1H), 2.71 (dd, 1H), 1.38 (t, 3H), 1.24 (s, 3H), 1.09 - 0.99 (m, 1H), 0.37 - 0.29 (m, 1H), 0.18 (t, 1H); LC / MS m / z (M+H) + = 221.1.
[0235] Preparations 6a and 6b (4aR,5aS)-ethyl 5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole-3-carboxylate (6a) and (4aS,5aR)-ethyl 5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole-3-carboxylate (6b)
[0236] [ka]
[0237] Preparation 6 was separated by chiral SFC (Chiral Tech OZ-H 250 mm × 4.6 mm, 5 μm column, using a mobile phase of 20% methanol (0.2% v / v 7 M NH3 / methanol) and 80% CO2; flow rate 3.0 mL / min) to give the title compound. Preparation 6a: Retention time = 3.89 min, 100%ee, [α] 20 D = +67.1 (c = 4.2, methanol); LC / MS m / z (M+H) + = 221.1. Preparation 6b: Retention time = 4.76 min, 98.9%ee, [α] 20 D =-80.2 (c=4.7, methanol), 1 H NMR (400 MHz, CDCl3) δ = 4.33 (q, 2H), 3.46 (s, 2H), 3.27 - 3.18 (m, 1H), 3.04 (d, 1H), 2.91 (dd, 1H), 2.72 - 2.63 (m, 1H), 1.34 (t, 3H), 1.21 (s, 3H), 1.07 - 0.96 (m, 1H), 0.34 - 0.26 (m, 1H), 0.16 (t, 1H); LC / MS m / z (M+H) + = 221.1.
[0238] Preparations 7a and 7b (4aS,5aR)-5a-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole-3-carboxylate (7a) and (4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole-3-carboxylate (7b).
[0239] [ka]
[0240] A suspension of sodium hydride (60% suspension, 19.3 g, 483 mmol) in THF (500 mL) was treated with a solution of Preparation 6b (103 g, 467.6 mmol) in THF (1.25 L) at about 0 °C. After about 30 minutes, SEM-Cl (81.9 g, 491 mmol) was added at about 0 °C, and the mixture was stirred at about 0 °C for about 3 hours. The mixture was treated with saturated aqueous NH4Cl (500 mL) at about 0 °C. The mixture was extracted with EtOAc (3 x 500 mL), washed with brine (500 mL), dried (MgSO4), filtered, and concentrated. The crude product was purified by chromatography to provide the title compound. Preparation 7a: Yield: 5.5 g (3.3%), 1 H NMR (400 MHz, DMSO-d6) δ = 5.63 (s, 2H), 4.27 (qt, 2H), 3.53 - 3.41 (m, 2H), 3.18 (d, 1H), 2.97 - 2.84 (m, 2H), 2.64 (d, 1H), 1.30 (t, 3H), 1.21 (s, 3H), 1.05 (dt, 1H), 0.78 - 0.68 (m, 2H), 0.31(dd, 1H), 0.02 (d, 1H), -0.11 (s, 9H); LC / MS m / z (M+H) + = 351.3 Preparation 7b: Yield: 138 g (84%) 1 H NMR (400 MHz, CDCl3) δ = 5.48 - 5.30 (m, 2H), 4.37 (q, 2H), 3.59 - 3.41 (m, 2H), 3.23 (dd, 1H), 3.07 (d, 1H), 3.02 - 2.86 (m, 1H), 2.73 - 2.58 (m, 1H), 1.36 (t, 3H), 1.23 (s, 3H), 1.13 - 0.95 (m, 1H), 0.85 (ddt, 2H), 0.42 - 0.27 (m, 1H), 0.18 (t, 1H), -0.05 (s, 9H); LC / MS m / z (M+H) + = 351.3, [α] 20 D =-30.9 (c=1, methanol)
[0241] Preparation 8 ((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)methanol
[0242] [ka]
[0243] A suspension of LiAlH (14.94 g, 393.7 mmol) in THF (500 mL) at about 0 °C was treated dropwise with a solution of Preparation 7b (138 g, 393.7 mmol) in THF (1 L). The mixture was stirred at about 15 °C for about 2 h. The mixture was cooled to about 0 °C and treated sequentially with HO (15 mL), 15% aqueous NaOH (15 mL), and HO (30 mL) dropwise, followed by MgSO. The resulting mixture was stirred for about 30 min, diluted with EtOAc (500 mL), and filtered. The filtrate was concentrated to give the title compound. Yield: 110 g (91%). 1 H NMR (400 MHz, CDCl3) δ = 5.35 - 5.23 (m, 2H), 4.59 (dd, 2H), 3.51 (t, 2H), 3.03 (d, 1H), 2.86 - 2.81 (m, 2H), 2.64 (d, 1H), 1.90 (t, 1H), 1.24 (s, 3H), 1.04 (dq, 1H), 0.88 (td, 2H), 0.36 (dd, 1H), 0.23 (t, 1H), -0.03 (d, 9H); LC / MS m / z (M+H) + = 309.3, [α] 20 D =-18.3 (c=1, methanol).
[0244] Preparation 9 (4aS,5aR)-5a-Methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole-3-carbaldehyde (9)
[0245] [ka]
[0246] A solution of Preparation 8 (110.13 g, 0.36 mol) in DCM (1.5 L) was treated with activated MnO (310 g, 3.57 mol), and the resulting mixture was stirred at RT for approximately 16 hours. The mixture was filtered through a pad of Celite®. The filtrate was concentrated, and the crude product was purified by chromatography to give the title compound. Yield: 96 g (88%). 1 H NMR (400 MHz, DMSO-d6) δ = 9.86 (s, 1H), 5.52 - 5.38 (m, 2H), 3.50 (dd, 2H), 3.11 (dd, 2H), 2.93 - 2.82 (m, 1H), 2.67 (d, 1H), 1.22 (s, 3H), 1.08 - 1.02 (m, 1H), 0.81 (td, 2H), 0.39 (dd, 1H), 0.08 (t, 1H), -0.07 (s, 9H); LC / MS m / z (M+H) + = 307.3, [α] 20 D =-38.9 (c=1, methanol).
[0247] Preparation 10 7,7-Difluoro-1-methylspiro[bicyclo[4.1.0]heptane-3,2'-[1,3]dioxolane]
[0248] [ka]
[0249] The following reaction was carried out in 26 parallel batches. A solution of compound 2 (150 g, 972 mmol) in THF (1.20 L) was treated with TMSCF (276 g, 1.95 mol) and sodium iodide (75.8 g, 506 mmol). The mixture was stirred at about 70 °C for about 16 hours. The 26 reaction mixtures were cooled to room temperature and combined. The mixture was diluted with water (10 L) and extracted with MTBE (4 × 3 L). The organic phase was washed with brine (8 L), dried (NaSO), filtered, and concentrated to provide the title compound. Yield: 4.30 kg (83%).
[0250] Preparation 11 7,7-Difluoro-1-methylbicyclo[4.1.0]heptan-3-one
[0251] [ka]
[0252] The following reaction was carried out in five parallel batches. A mixture of Preparation 10 (860 g, 4.21 mol) in THF (10 L) was treated with 3 M HCl (2.6 L) at RT. The mixture was stirred at RT for approximately 16 h. The five reaction mixtures were combined, extracted with MTBE (4 x 2.5 L), and washed with saturated aqueous NaHCO (5 L) and brine (5 L). The organic phase was dried (NaSO), filtered, and concentrated to provide the title compound. Yield: 3.50 kg. 1 H NMR (400 MHz, CDCl3) δ = 2.56 (br d, 1H), 2.38 - 2.13 (m, 4H), 2.01 - 1.89 (m, 1H), 1.49 - 1.38 (m, 1H), 1.27 (br s, 3H).
[0253] Preparation 12 2-(7,7-difluoro-6-methyl-4-oxobicyclo[4.1.0]heptan-3-yl)-2-oxoacetic acid ethyl ester
[0254] [ka]
[0255] The following reaction was carried out in eight parallel batches. A solution of Preparation 11 (250 g, 1.56 mol) in ethanol (1.25 L) was treated with sodium ethoxide (112 g, 1.65 mol) in portions at about 0° C. The resulting mixture was treated with diethyl oxalate (242 g, 1.65 mol) at about 0° C. The reaction mixture was stirred at RT for about 1 h. The eight batches were combined. The mixture was poured into 3 M aqueous HCl (8.00 L) and extracted with DCM (3×2 L). The organic extract was washed with brine (5 L), dried (NaSO), filtered, and concentrated to provide the title compound. Yield: 3.20 kg (98%).
[0256] Preparation 13 Ethyl 5,5-difluoro-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole-3-carboxylate
[0257] [ka]
[0258] The following reaction was carried out in eight parallel batches. A suspension of Preparation 12 (400 g, 1.54 mol) in ethanol (2 L) was treated with hydrazine hydrate (76.9 g, 1.54 mol) at about 0° C. The reaction mixture was stirred at RT for about 16 h. The eight reaction mixtures were combined for workup. The reaction mixture was concentrated, and the residue was taken up in H2O (5 L) and extracted with EtOAc (5 x 2 L). The combined organic extracts were dried (Na2SO4), filtered, and concentrated. The crude product was triturated from 6:1 (v / v) EtOAc / ethanol (3 L) at RT to provide the title compound. Yield: 1.0 Kg. 1 H NMR (400 MHz, CDCl3) δ = 12.03 - 10.65 (br m, 1H), 4.38 (q, 2H), 3.30 - 3.04 (m, 3H), 2.79 (dd, 1H), 1.57 (br dd, 1H), 1.34 - 1.43 (m, 6H); LC / MS m / z (M+H) + = 257.1.
[0259] Preparations 14 and 15 Ethyl (4aR,5aS)-5,5-difluoro-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole-3-carboxylate (14) and ethyl (4aS,5aR)-5,5-difluoro-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole-3-carboxylate (15)
[0260] [ka]
[0261] Preparation 13 was purified by chiral SFC using a Chiral Tech AD-H 250 mm x 21.2 mm 5 μm column, CO 2(g) Separation was performed using a mobile phase of 80:20 ethanol / methanol and 0.2% 7N NH3 in methanol at a flow rate of 200 mL / min.
[0262] SFC analytical method: Chiral Tech AD-H 250 mm x 4.6 mm x 5 μm, A = CO2, B = 0.2% v / v NH3 in methanol (as 7N NH3 in methanol), gradient = 5% B from 0 to 1 min, 5 to 60% B gradient from 1 to 9.5 min, 60 to 5% B gradient from 9.5 to 10 min. Preparation 14: 100% ee by SFC analytical method, retention time = 4.605 min Preparation 15: 99.85% ee by SFC analytical method, retention time = 5.565 min
[0263] Preparation 16 (4aS,5aR)-5,5-difluoro-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole-3-carboxylate
[0264] [ka]
[0265] A mixture of sodium hydride (60% suspension, 4.25 g, 106 mmol) in THF (20 mL) cooled to about 0 °C was treated dropwise with a solution of Preparation 15 (18.16 g, 70.87 mmol) in THF (100 mL) over about 45 minutes. The mixture was stirred at about 0 °C for about 1 hour and then treated dropwise with SEM-Cl (17.7 g, 106 mmol) in THF (80 mL). The resulting mixture was stirred at RT for about 48 hours. The reaction mixture was poured slowly onto ice and extracted 3x with EtOAc. The organic extracts were combined, washed with brine, dried (MgSO), filtered, and concentrated. The crude product was purified by chromatography (silica, EtOAc / heptane = 0-20%) to provide 25.8 g (94%) of the title compound. 1 H NMR (400 MHz, CDCl3) δ 5.50 - 5.40 (m, 2H), 4.40 (q, 2H), 3.55 - 3.47 (m, 2H), 3.26 - 3.05 (m, 3H), 2.76 (br dd, 1H), 1.62 - 1.54 (m, 1H), 1.44 - 1.35 (m, 6H), 0.94 - 0.81 (m, 2H), -0.03 (s, 9H); LC-MS m / z (M+H) + = 387.4.
[0266] Preparation 17 ((4aS,5aR)-5,5-difluoro-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)methanol
[0267] [ka]
[0268] A solution of Preparation 16 (25.84 g, 66.86 mmol) in THF (100 mL) at about −5° C. was treated dropwise with a solution of LiAlH (100 mL, 1 M in THF) at such a rate as to control the temperature between 0 and 10° C. The mixture was stirred at about 0° C. for about 1 hour, gradually warmed to RT, and stirred for about 4 hours. The mixture was cooled to about −10° C. and treated dropwise with 6 N NaOH (45 mL) over about 30 minutes. EtOAc was added to aid in stirring the thick mixture, and the slurry was allowed to warm to RT. Anhydrous MgSO was added, and stirring was continued for about 30 minutes. The mixture was filtered, and the solid was rinsed with EtOAc. The filtrate was concentrated to provide the title compound (21.89 g, 95%). 1 H NMR (400 MHz, CDCl3) δ 5.38 - 5.21 (m, 2H), 4.60 (s, 2H), 3.55 - 3.41 (m, 2H), 3.08 (br d, 1H), 2.98 - 2.83 (m, 2H), 2.79 - 2.65 (m, 1H), 2.24 (br s, 1H), 1.60 - 1.49 (m, 1H), 1.40 (br s, 3H), 0.94 - 0.80 (m, 2H), -0.03 (s, 9H); LC-MS m / z (M+H) + = 345.5.
[0269] Preparation 18 (4aS,5aR)-5,5-Difluoro-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole-3-carbaldehyde
[0270] [ka]
[0271] A solution of Preparation 17 (21.89 g, 63.55 mmol) in DCM (25 mL) was cooled to about 0 °C. A solution of Dess-Martin periodinane (33.7 g, 79.4 mmol) in DCM (250 mL) was added dropwise over about 20 minutes at 0 °C. The mixture was treated dropwise with 2.2% water / DCM (50 mL) over about 45 minutes at about 0 °C. The mixture was warmed to RT and stirred for about 4 hours. The mixture was treated with 1 N NaOH (380 mL) and stirred for about 30 minutes. The biphasic mixture was separated. The organic phase was washed with brine, dried (MgSO), filtered, and concentrated. The crude product was purified by chromatography (silica, EtOAc / heptane = 0-50%) to provide the title compound (17.8 g, 82%). 1 H NMR (400 MHz, CDCl3) 9.98 (s, 1H), 5.52-5.35 (m, 2H), 3.61-3.43 (m, 2H), 3.27-3.05 (m, 4H), 2.82-2.66 (m, 1H), 1.42 (m., 3H), 0.98-0.80 (m, 2H), 0.08 - -0.13 (m, 9H); LC-MS m / z (M+H) + = 343.3.
[0272] Preparation 19 6,6-Dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-1H-indazole-3-carbaldehyde and 6,6-dimethyl-2-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-2H-indazole-3-carbaldehyde
[0273] [ka]
[0274] Step 1: 4,4-Dimethyl-2-oxocyclohexane-1-carbaldehyde (19a)
[0275] [ka]
[0276] To a suspension of sodium hydride (60% suspension, 43.6 g, 1.09 mol) in THF (2.6 L) was added 3,3-dimethylcyclohexan-1-one (125 g, 991 mmol) at about 30° C. The reaction mixture was stirred for about 1 hour. Ethyl formate (147 g, 1.98 mol) was added at about 35° C. and stirred at about 40° C. for about 18 hours. The reaction mixture was combined with an identical reaction using 125 g of 3,3-dimethylcyclohexan-1-one and similar proportions of other reagents. The mixture was acidified to about pH 3 with 1 M HCl. The mixture was extracted with EtOAc (2 L×2). The EtOAc extracts were combined and concentrated to give the title compound (240 g, 79%). 1 H NMR (400 MHz, CDCl3) δ = 14.60 - 14.21 (m, 1H), 8.88 - 8.64 (m, 1H), 2.39 (t, 2H), 2.14 (s, 2H), 1.46 (t, 2H), 0.98 (s, 6H).
[0277] Step 2: 6,6-Dimethyl-4,5,6,7-tetrahydro-1H-indazole (19b)
[0278] [ka]
[0279] A solution of Preparation 19a (240 g, 1.27 mol) in methanol (2 L) was treated with hydrazine (76.0 g, 1.52 mol) at about 30° C. The reaction mixture was heated to about 70° C. and stirred for about 18 hours. Water (100 mL) was added to the mixture. Most of the methanol was removed by rotary evaporation, and the residue was extracted into EtOAc. The EtOAc extract was concentrated. The resulting residue was purified by chromatography to give the title compound (150 g, 79%). 1H NMR (400 MHz, CDCl3) δ = 7.33 (s, 1H), 2.56 (t, 2H), 2.43 (s, 2H), 1.53 (t, 2H), 1.02 (s, 6H); LC / MS m / z (M+H) + = 150.8
[0280] Step 3: 3-iodo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole (19c)
[0281] [ka]
[0282] A solution of Preparation 19b (75.0 g, 0.5 mol) in DMF (350 mL) was treated with KOH (84 g, 1.5 mol) and iodine (253 g, 1 mol) at room temperature. The reaction mixture was stirred for approximately 18 hours. A saturated aqueous solution of NaSO (300 mL) was added to the reaction mixture. The mixture was combined with an identical reaction using 75 g of Preparation 19b and similar proportions of other reagents. The combined reaction mixture was extracted with MTBE (2 × 1 L). The organic extracts were combined, dried (NaSO), filtered, and concentrated. The resulting residue was purified by chromatography to give the title compound (72 g, 26%). 1 H NMR (400 MHz, CDCl3) δ = 2.54 - 2.43 (m, 2H), 2.35 (t, 2H), 1.56 (t, 2H), 1.02 (s, 6H); LC / MS m / z (M+H) + = 277.0.
[0283] Step 4: 3-iodo-6,6-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-1H-indazole and 3-iodo-6,6-dimethyl-2-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-2H-indazole (19d)
[0284] [ka]
[0285] A solution of Preparation 19c (60 g, 217 mmol) in THF (600 mL) was treated with sodium hydride (60% suspension, 11.3 g, 282 mmol) at about 0 °C. The suspension was stirred for about 30 minutes. The mixture was treated with SEM-Cl (42.5 mL, 239 mmol) at a temperature between 0 and 5 °C. The reaction mixture was stirred at a temperature between 0 and 10 °C for about 2 hours. A saturated aqueous solution of NH4Cl (50 mL) was added at about 5 °C, and the mixture was stirred for about 18 hours. Water (100 mL) was added, and the mixture was extracted with EtOAc (500 mL x 2). The EtOAc extracts were combined and concentrated. The resulting residue was purified by chromatography to give the title compound (73 g, 83%) as a mixture of regioisomers. LC / MS m / z (M+H) + = 407.1, retention time = 0.994 minutes.
[0286] Step 5: 6,6-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-1H-indazole-3-carbaldehyde and 6,6-dimethyl-2-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-2H-indazole-3-carbaldehyde
[0287] [ka]
[0288] A solution of Preparation 19d (73 g, 180 mmol) in DMF (900 mL) was treated with triethylsilane (41.8 g, 359 mmol), EtN (36.4 g, 359 mmol), and Pd(dppf)Cl (13.1 g, 18.0 mmol). The reaction mixture was cooled to room temperature. (g)The mixture was purged with HCl and stirred under a CO atmosphere (50 PSI) at about 80° C. for about 16 hours. The reaction mixture was concentrated and the resulting residue was purified by column chromatography to give the title compounds as a mixture (35 g, 63%). LC / MS m / z (M+H) + = 309.1.
[0289] Preparation 20 (S)-2-Morpholinopropanoic acid
[0290] [ka]
[0291] Step 1: Benzyl (S)-2-morpholinopropanoate (20a)
[0292] [ka]
[0293] A solution of benzyl L-alaninate 4-methylbenzenesulfonate (500 g, 1.42 mol) in DMSO (3 L) was treated with EtN (624 g, 6.17 mol), and the mixture was cooled to about 0 °C. A solution of 1-bromo-2-(2-bromotoxy)ethane (429 g, 1.85 mol) in DMSO (1 L) was slowly added to the reaction. The resulting mixture was stirred at RT for about 36 h. Water (3 L) and EtOAc (2 L) were added to the mixture. The aqueous phase was extracted with EtOAc (2 × 1 L). The combined EtOAc extracts were dried (NaSO), filtered, and concentrated. The crude product was purified by chromatography (silica, EtOAc / PE = 11%) to provide the title compound (290 g, 82%). 1 H NMR (400 MHz, DMSO-d6) δ 7.42 - 7.31 (m, 5H), 5.19 (s, 2H), 3.79 - 3.66 (m, 4H), 3.35 - 3.30 (m, 1H), 2.69 - 2.56 (m, 4H), 1.32 - 1.29 (m, 3H).
[0294] Step 2: (S)-2-Morpholinopropanoic acid
[0295] [ka]
[0296] A solution of Preparation 20a (290 g, 1.56 mol) in methanol (2.9 L) was treated with 10% Pd(OH) / C (29 g) at RT. The mixture was stirred under an atmosphere of H for about 36 hours. The solids were removed by filtration, and the filtrate was concentrated. The resulting residue was triturated with MTBE (200 mL x 2) to provide the title compound (146 g, 79%). 1 H NMR (400 MHz, DMSO-d6) δ 3.56 (s, 4H), 3.18 - 3.16 (m, 1H), 2.54 - 2.53 (m, 4H), 1.17 - 1.15 (m, 3H); LC / MS m / z (M+H) + = 160.1, SFC method: Chiral Tech IC 250 mm × 4.6 mm, 5 μm, gradient: 5–60% 0.2% v / v (7N NH3 in methanol) in methanol / CO2 (g), 3.0 mL / min, retention time = 5.88 min, 100% ee.
[0297] Preparation 21 (R)-2-(tetrahydro-2H-pyran-4-yl)propanoic acid
[0298] [ka]
[0299] Step 1: 2-(tetrahydro-2H-pyran-4-yl)acetyl chloride (21a)
[0300] [ka]
[0301] A solution of 2-(tetrahydro-2H-pyran-4-yl)acetic acid (17.3 g, 120 mmol) in DCM (400 mL) and DMF (1 mL) at about 0° C. was treated with oxalyl chloride (30.5 g, 240 mmol). The mixture was then warmed to RT and stirred for about 16 hours. The mixture was concentrated to provide the title compound (19.5 g).
[0302] Step 2: (R)-4-benzyl-3-(2-(tetrahydro-2H-pyran-4-yl)acetyl)oxazolidin-2-one (21b)
[0303] [ka]
[0304] A solution of (R)-4-benzyloxazolidin-2-one (14.2 g, 79.9 mmol) in THF (500 mL) at about −78° C. was treated with 2.5 M n-BuLi in hexanes (48 mL). The mixture was then stirred at about −78° C. for about 2 hours. A solution of Preparation 21a (19.5 g, 120 mmol) in THF (100 mL) was added at about −78° C., and the reaction mixture was stirred for about 2 hours. The mixture was then warmed to RT and stirred for about 16 hours. The reaction mixture was treated with saturated aqueous NH4Cl (400 mL), and the resulting biphasic mixture was separated. The organic phase was dried (Na2SO4) and concentrated. The residue was suspended in DCM / PE (50 mL / 300 mL) and stirred at −50° C. for 30 minutes. The solid was collected and dried to provide the title compound (21.5 g, 89%). LC / MS m / z(M+H)=303.8.
[0305] Step 3: (R)-4-benzyl-3-((R)-2-(tetrahydro-2H-pyran-4-yl)propanoyl)oxazolidin-2-one (21c)
[0306] [ka]
[0307] A solution of Preparation 21b (21.5 g, 70.8 mmol) in THF (200 mL) at about −78° C. was treated with NaHMDS (1 M in THF, 106 mL). The mixture was stirred for about 1 hour and treated with methyl iodide (50.3 g, 354 mmol) at about −78° C. The reaction mixture was stirred at about −78° C. for about 2 hours and then gradually warmed to RT over about 16 hours. The reaction mixture was treated with saturated aqueous NH4Cl (300 mL) and the biphasic mixture separated. The organic layer was washed with brine, dried (MgSO4), filtered, and concentrated. The crude product was purified by chromatography (silica, EtOAc / PE: 0-100%) to provide the title compound (15.5 g, 69%). 1 H NMR (400 MHz, CDCl3) δ 7.32 - 7.11 (m, 5H), 4.62 (ddt, 1H), 4.20 - 4.07 (m, 2H), 4.02 (dd, 1H), 3.94 (dd, 1H), 3.65 - 3.54 (m, 1H), 3.33 (tt, 2H), 3.22 (dd, 1H), 2.72 (dd, 1H), 1.97 - 1.87 (m, 1H), 1.64 - 1.56 (m, 1H), 1.58 - 1.51 (m, 1H), 1.41 - 1.26 (m, 2H), 1.15 (d, 3H); LC / MS m / z (M+H) + = 318.3.
[0308] Step 4: (R)-2-(tetrahydro-2H-pyran-4-yl)propanoic acid
[0309] [ka]
[0310] A solution of Preparation 21c (15.5 g, 48.8 mmol) in THF (410 mL) and HO (255 mL) at about 0 °C was treated with LiOH·HO (10.2 g, 244 mmol) and 30% aqueous HO (27.7 g, 244 mmol). The mixture was stirred at about 0 °C for about 1.5 h and then at RT for about 1.5 h. The mixture was treated with saturated aqueous NaSO (300 mL), and the organic solvents were removed under reduced pressure. The mixture was washed with DCM (2 × 200 mL), and the DCM washes were discarded. The aqueous phase was acidified to pH 1 with 12 N HCl. The mixture was extracted with DCM (3 × 200 mL), and the DCM extracts were combined, dried (NaSO), filtered, and concentrated to provide the title compound (6.12 g, 79%). 1 H NMR (400 MHz, CDCl3) δ 4.07 - 3.93 (m, 2H), 3.39 (dt, 2H), 2.30 (quint, 1H), 1.87 - 1.77 (m, 1H), 1.68 - 1.56 (m, 2H), 1.51 - 1.28 (m, 2H), 1.17 (d, 3H).[a] 20 D = -17.98 (c = 0.3, ethanol), Chiral SFC (Chiral Tech IG 250 × 4.6 mm, 5 μm; 5–60% methanol / CO gradient over 10 min): retention time -3.42 min, 97% ee.
[0311] Preparation 22 2-Methyl-2-morpholinopropanoic acid
[0312] [ka]
[0313] Step 1: tert-Butyl 2-methyl-2-morpholinopropanoate (22a)
[0314] [ka]
[0315] A solution of tert-butyl 2-bromo-2-methylpropanoate (2.00 g, 8.97 mmol) in DMF (15 mL) was treated with KCO (3.72 g, 26.9 mmol) and morpholine (0.94 g, 10.8 mmol) at about 10 °C. The reaction mixture was stirred at about 60 °C for about 18 hours. Water (20 mL) was added, and the mixture was extracted with EtOAc (20 mL × 3). The EtOAc extracts were combined, dried (NaSO), filtered, and concentrated. The resulting residue was purified by chromatography to provide the title compound (1.35 g, 66%). 1 H NMR (400 MHz, CDCl3) δ = 3.69 (t, 4H), 2.64 (t, 4H), 1.47 (s, 9H), 1.27 (s, 6H)
[0316] Step 2: 2-Methyl-2-morpholinopropanoic acid
[0317] [ka]
[0318] A solution of Preparation 22a (1.30 g, 5.67 mmol) in 1,4-dioxane (10 mL) was treated with 4 M HCl in 1,4-dioxane (2 mL). The reaction mixture was stirred at about 60° C. for about 15 hours. The solvent was removed under reduced pressure to give the title compound (790 mg, 81%). 1 H NMR (400 MHz, CD3OD) δ = 4.20 - 4.00 (m, 2H), 4.00 - 3.81 (m, 2H), 3.49 - 3.32 (m, 4H), 1.66 (s, 6H)
[0319] Preparation 23 (S)-3-Methyl-2-morpholinobutanoic acid
[0320] [ka]
[0321] Step 1: (S)-tert-butyl 3-methyl-2-morpholinobutanoate (23a)
[0322] [ka]
[0323] A solution of tert-butyl L-valinate (800 mg, 3.81 mmol) in DMSO (30 mL) was treated with EtN (2.7 mL, 19.1 mmol) at about 10 °C. 1-Bromo-2-(2-bromoethoxy)ethane (0.97 g, 4.20 mmol) was added dropwise over about 30 minutes. The reaction mixture was stirred for about 18 hours. Water was added and the mixture was extracted into EtOAc (3x). The organic extracts were combined, dried (NaSO), filtered, and concentrated. The crude product was purified by chromatography to give the title compound (800 mg, 86%). 1 H NMR (400 MHz, CDCl3) δ = 3.71 - 3.60 (m, 4H), 2.69 - 2.50 (m, 5H), 2.07 - 1.92 (m, 1H), 1.49 (s, 9H), 0.97 (d, 3H), 0.89 (d, 3H)
[0324] Step 2: (S)-3-Methyl-2-morpholinobutanoic acid
[0325] [ka]
[0326] A solution of Preparation 23a (800 mg, 3.29 mmol) in 1,4-dioxane (5 mL) was treated with 4 M HCl in 1,4-dioxane (5 mL) at about 10° C. The reaction mixture was stirred at about 50° C. for about 18 hours. The solvent was removed to give the title compound (700 mg, 95%). 1 H NMR (400 MHz, CD3OD) δ = 4.05 - 3.88 (m, 5H), 3.56 - 3.34 (m, 4H), 2.63 - 2.49 (m, 1H), 1.19 (d, 3H), 1.05 (d, 3H)
[0327] Preparation 24 (S)-2-Morpholinobutanoic acid
[0328] [ka]
[0329] Step 1: (S)-tert-butyl 2-morpholinobutanoate (24a)
[0330] [ka]
[0331] A solution of (S)-tert-butyl 2-aminobutanoate (1.5 g, 7.67 mmol) in DMSO (20 mL) was treated with EtN (5.3 mL, 38.3 mmol) and 1-bromo-2-(2-bromoethoxy)ethane (1.96 g, 8.43 mmol) at about 10 °C. The reaction mixture was stirred for about 18 h. Water was added and the mixture was extracted with EtOAc (3x). The organic extracts were combined, dried over NaSO, filtered, and concentrated. The resulting residue was purified by chromatography to give the title compound (1.20 g, 68%). 1 H NMR (400 MHz, CDCl3) δ = 3.77 - 3.61 (m, 4H), 2.94 (t, 1H), 2.72 - 2.53 (m, 4H), 1.81 - 1.68 (m, 1H), 1.68 - 1.59 (m, 1H), 1.49 (s, 9H), 0.93 (t, 3H).
[0332] Step 2: (S)-2-Morpholinobutanoic acid
[0333] [ka]
[0334] A solution of Preparation 24a (1.10 g, 4.80 mmol) in 1,4-dioxane (5 mL) was treated with 4 M HCl in 1,4-dioxane (5 mL) at about 10° C. The reaction mixture was stirred at about 50° C. for about 18 hours. The solvent was removed under reduced pressure to give the title compound (0.90 g, 90%). 1 H NMR (400 MHz, CD3OD) δ = 4.21 - 3.74 (m, 5H), 3.57 - 3.33 (m, 4H), 2.24 - 2.08 (m, 1H), 2.02 (d, 1H), 1.07 (t, 3H)
[0335] Preparation 25 tert-Butyl (5,6-diaminopyridin-3-yl)(methyl)carbamate
[0336] [ka]
[0337] Step 1: Methyl 6-(dibenzylamino)-5-nitronicotinate (25a)
[0338] [ka]
[0339] The following reaction was carried out in four parallel batches. A solution of methyl 6-chloro-5-nitronicotinate (375 g, 1.73 mol) in THF (3 L) was treated with EtN (482 mL, 3.46 mol) at room temperature. The resulting solution was cooled to approximately 5 °C. Dibenzylamine (338 mL, 1.77 mol) was added dropwise at approximately 10-15 °C. The reaction mixture was stirred at room temperature for approximately 16 h. The four reaction mixtures were individually concentrated and the residues combined. The resulting material was diluted with EtOAc (8 L) and washed with saturated aqueous NHCl (3 × 1 L). The aqueous washes were combined and extracted with EtOAc (2 × 1 L). The combined EtOAc extracts were washed with brine (2 L), dried (NaSO), filtered, and concentrated to give the title compound (2.80 Kg). 1 H NMR (400 MHz, CDCl3) δ = 8.93 (d, 1H), 8.64 (d, 1H), 7.37 - 7.21 (m, 5H), 7.12 (br dd, 5H), 4.68 (s, 4H), 3.91 (s, 3H).
[0340] Step 2: 6-(Dibenzylamino)-5-nitronicotinic acid (25b)
[0341] [ka]
[0342] The following reaction was carried out in five parallel batches. A solution of Preparation 25a (656 g, 1.74 mol) in THF (1.3 L) and methanol (1.3 L) at room temperature was slowly treated with a solution of NaOH (146 g, 3.65 mol) in HO (650 mL). The resulting mixture was stirred at 50 °C for approximately 16 hours and then cooled to a temperature between 10 and 15 °C. The mixture was acidified to pH 3 with 2 N HCl. The five reaction mixtures were combined and the resulting suspension was filtered. The collected solid was dissolved in DCM (15 L), washed with brine (2 L), dried (NaSO), filtered, and concentrated to give the title compound (3.1 kg). 1H NMR (400 MHz, CDCl3) δ = 9.00 (d, 1H), 8.71 (d, 1H), 7.36 - 7.28 (m, 6H), 7.15 (dd, 4H), 5.31 (s, 1H), 4.73 (s, 4H); LC / MS m / z (M+H) + = 364.1.
[0343] Step 3: tert-Butyl (6-(dibenzylamino)-5-nitropyridin-3-yl)carbamate (25c)
[0344] [ka]
[0345] The following reaction was carried out in 16 parallel batches. A solution of Preparation 25b (180 g, 495 mmol), t-BuOH (284 mL, 2.97 mol), EtN (207 mL, 1.49 mol), and diphenylphosphoryl azide (140 mL, 644 mmol) in toluene (1.8 L) was stirred over molecular sieves (4 Å, 70 g), and the mixture was fed to a flow reactor (reactor: four parallel Hastelloy coils (6 mm diameter, 6 m length); residence time: 200 min) at approximately 130 °C. The 16 reaction batches were cooled to room temperature and combined with two additional identical reactions using 170 g and 50 g of Preparation 25b and similar proportions of other reagents. The combined reaction mixture was washed with saturated aqueous NaHCO (3 × 5 L). The aqueous washes were combined and extracted with EtOAc (3 × 3 L). The combined EtOAc extracts were washed with brine (2 x 5 L), dried (NaSO), filtered, and concentrated. The crude product was purified by chromatography (EtOAc / PE (containing 0.5% v / v EtN) = 0-30%) to give the title compound (2.5 kg, 66%). 1 H NMR (400 MHz, CDCl3) δ = 8.38 (br s, 1H), 8.32 - 8.26 (m, 1H), 7.31 - 7.21 (m, 6H), 7.19 - 7.13 (m, 4H), 6.48 (s, 1H), 4.52 (s, 4H), 1.52 (s, 9H); LC / MS m / z (M+H) + = 435.2.
[0346] Step 4: tert-Butyl (6-(dibenzylamino)-5-nitropyridin-3-yl)(methyl)carbamate (25d)
[0347] [ka]
[0348] The following reaction was carried out in three parallel batches. A solution of Preparation 25c (400 g, 921 mmol) in THF (2.4 L) at about 0 °C was treated portionwise with KOtBu (113.6 g, 1.01 mol). The resulting mixture was stirred at about 0 °C for about 1 h. The mixture was treated with methyl iodide (68.7 mL, 1.10 mol) at about 0 °C. The mixture was warmed to room temperature and stirred for about 16 h. The three batches were combined, filtered through Celite®, and concentrated. The resulting residue was diluted with EtOAc (6 L) and washed with saturated aqueous NH4Cl (3 × 2 L). The aqueous washes were combined and extracted with EtOAc (2 × 1 L). The EtOAc extracts were combined, washed with brine (2 × 1 L), dried (Na2SO4), filtered, and concentrated. The resulting crude material was purified by chromatography (silica, 0-20% EtOAc / PE (containing 0.5% v / v EtN). The residue was triturated with PE (2 L) and stirred at room temperature for approximately 16 h. The resulting solid was collected by filtration and washed with PE (500 mL). The collected solid was dried under vacuum to give the title compound (970 g, 77%). 1 H NMR (400 MHz, CDCl3) δ = 8.36 (br s, 1H), 8.05 (br s, 1H), 7.34 - 7.24 (m, 6H), 7.22 - 7.15 (m, 4H), 4.60 (s, 4H), 3.28 (s, 3H), 1.49 (s, 9H); LC / MS m / z (M+H) + = 449.2.
[0349] Step 5: tert-Butyl (5,6-diaminopyridin-3-yl)(methyl)carbamate
[0350] [ka]
[0351] The following reaction was carried out in four parallel batches. A solution of Preparation 25d (103 g, 229 mmol) in ethanol (1 L) was treated with Pd(OH)2 / C (20.55 g) at room temperature. The suspension was stirred at approximately 80°C and H2 (50 PSI) for approximately 120 hours. The reaction mixture was cooled to room temperature and filtered. The filter cake was washed with ethanol (200 mL x 3). The filtrate was concentrated to a volume of approximately 600 mL. The solution was treated with Pd(OH)2 / C (20.5 g), and the resulting suspension was stirred at approximately 80°C and H2 (50 PSI) for approximately 48 hours. The reaction mixture was cooled to room temperature. The four batches were combined with 120 g and 360 g, respectively, of tert-butyl (6-(dibenzylamino)-5-nitropyridin-3-yl)(methyl)carbamate, and two other batches from the same reaction using similar proportions of other reagents. The resulting mixture was filtered and the filter cake was rinsed with ethanol (3 x 500 mL). The filtrate was concentrated and the resulting residue was purified by chromatography (silica, 0-10% DCM / methanol) to give the title compound (245 g, 52%). 1 H NMR (400 MHz, CDCl3) δ = 7.55 (d, 1H), 6.84 (br s, 1H), 4.17 (br LC / MS m / z (M+H) + = 239.2.
[0352] Preparation 26 N 2 ,N 2 -Dibenzyl-3-nitropyridine-2,5-diamine
[0353] [ka]
[0354] A solution of Preparation 25c (1.0 g, 2.3 mmol) in DCM (10 mL) was treated with TFA (2 mL) at about 30° C. and stirred for about 18 hours. The solvent was evaporated, and the residue was treated with saturated aqueous NaHCO. The mixture was extracted with EtOAc (15 mL x 3). The EtOAc extracts were combined, dried (NaSO), filtered, and concentrated to give the title compound (0.77 g). 1 H NMR (400 MHz, CDCl3) δ = 7.99 (d, 1H), 7.50 (d, 1H), 7.33 - 7.17 (m, 10H), 4.43 (s, 4H), 3.58 (br s, 2H).
[0355] Preparation 27 tert-Butyl methyl(2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)carbamate
[0356] [ka]
[0357] A mixture of Preparation 25 (5.00 g, 20.1 mmol) and sodium metabisulfite (1.99 g, 10.5 mmol) in DMF (105 mL) was treated with Preparation 9 (6.43 g, 21.0 mmol) and DMSO (3.72 mL, 52.5 mmol). The reaction mixture was heated at about 110° C. for about 16 hours. The reaction mixture was poured into 3% aqueous LiCl (250 mL). The resulting precipitate was collected by filtration, and the filtrate was extracted with EtOAc (3×200 mL). The EtOAc extract was combined with the collected precipitate and concentrated. The crude product was purified by chromatography (silica; PE / EtOAc: 0-100%, then EtOAc / ethanol: 0-20%) to give the title compound (7.2 g, 65%). 1 H NMR (400 MHz, CDCl3) δ = 11.74 - 11.28 (m, 1H), 8.39 (br d, 1H), 7.93 (d, 1H), 5.50 - 5.34 (m, 2H), 3.58 (t, 2H), 3.34 (s, 3H), 3.24 - 3.10 (m, 2H), 2.76 (br d, 1H), 1.68 (s, 2H), 1.43 (br s, 9H), 1.31 (s, 3H), 1.21 - 1.13 (m, 1H), 0.97 - 0.84 (m, 2H), 0.44 (dd, 1H), 0.30 (br t, 1H), -0.03 (s, 9H); LC / MS m / z (M+H) + = 525.3.
[0358] Preparation 28 N-Methyl-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-amine
[0359] [ka]
[0360] A solution of Preparation 27 (7.2 g, 13.7 mmol) in DCM (343 mL) was treated with ZnBr (15.6 g, 68.6 mmol) at about 0 °C. The reaction mixture was stirred at about 15 °C for about 16 hours. The mixture was poured into a mixture of ice and saturated aqueous NaHCO (300 mL). The mixture was filtered, and the filtrate was extracted with DCM (3 × 200 mL). The combined DCM extracts were concentrated. The resulting residue was purified by chromatography (silica, 15-100% EtOAc / PE, then 20% ethanol / EtOAc) to give the title compound (5.0 g, 86%). 1 H NMR (400 MHz, CD3OD) δ = 8.00 (br s, 1H), 7.15 (br s, 1H), 5.29 (br s, 2H), 3.43 - 3.27 (m, 2H), 3.13 - 2.94 (m, 2H), 2.80 (br s, 4H), 2.68 - 2.42 (m, 1H), 1.23 (s, 3H), 1.07 - 0.93 (m, 1H), 0.77 - 0.59 (m, 2H), 0.47 - 0.28 (m, 1H), 0.18 - 0.03 (m, 1H), -0.01 - -0.26 (m, 9H); LC / MS m / z (M+H) + = 425.3.
[0361] Preparation 29 (4aS,5aR)-3-(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole
[0362] [ka]
[0363] A mixture of 2,3-diamino-5-bromopyridine (3.07 g, 16.3 mmol) and sodium metabisulfite (1.55 g, 8.16 mmol) in DMF (82 mL) was treated with Preparation 9 (5.0 g, 16.3 mmol) and DMSO (2.90 mL, 40.8 mmol) at about 15° C. The resulting mixture was stirred at about 110° C. for about 16 hours. The reaction mixture was combined with that from an identical reaction using 20 mg of 2,3-diamino-5-bromopyridine and similar proportions of other reagents. To the combined reaction mixture was added HO (100 mL). The mixture was filtered, and the precipitate was collected and triturated with 10% v / v EtOAc in PE (80 mL) and stirred at about 15° C. for about 2 hours. The solid was filtered, washed with PE (50 mL), and dried to give the title compound (6.65 g, 85%). 1 H NMR (400 MHz, CDCl3) δ = 12.92 - 12.83 (m, 1H), 8.66 (br s, 1H), 8.25 (br s, 1H), 5.51 (q, 2H), 3.66 (t, 2H), 3.57 (d, 1H), 3.24 - 3.11 (m, 2H), 2.78 (d, 1H), 1.32 (s, 3H), 1.23 - 1.13 (m, 1H), 0.94 (t, 2H), 0.49 - 0.41 (m, 1H), 0.34 - 0.27 (m, 1H), -0.05 (s, 9H); LC / MS m / z (M+H) + = 476.1.
[0364] Preparations 30a and 30b (4aS,5aR)-3-(6-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-2-yl)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole (30a) and (4aS,5aR)-3-(6-bromo-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-2-yl)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole (30b).
[0365] [ka]
[0366] A solution of Preparation 29 (20.8 g, 43.8 mmol) in THF (219 mL) at about 0° C. was treated with sodium hydride (60% suspension, 1.75 g, 43.8 mmol) added portionwise. The resulting mixture was stirred for about 30 minutes. The mixture was treated with SEM-Cl (2.55 g, 15.3 mmol) at about 0° C. The reaction mixture was stirred at about 15° C. for about 3 hours. The mixture was cooled to about 0° C. and treated with water (10 mL). The mixture was purified by chromatography (silica, EtOAc / PE 0-100%) to give Preparation 30a (4.8 g, 18%) and a mixture of Preparations 30a and 30b. This mixture was again chromatographed (silica gel, EtOAc / PE 0-100%) to give additional Preparation 30a (6.0 g, 23%) and Preparation 30b (3.7 g, 14%). Preparation 30a: Yield: 10.8 g (41%); 1 H NMR (400 MHz, CDCl3) δ = 8.58 (d, 1H), 8.02 (d, 1H), 6.26 - 6.11 (m, 2H), 5.51 - 5.31 (m, 2H), 3.68 - 3.47 (m, 5H), 3.25 - 3.05 (m, 2H), 2.74 (d, 1H), 1.29 (s, 3H), 1.19 - 1.07 (m, 1H), 0.95 - 0.82 (m, 4H), 0.41 (dd, 1H), 0.25 (t, 1H), -0.01 (s, 9H), -0.10 (s, 9H). Preparation 30b: Yield: 3.7 g (14%); 1 H NMR (400 MHz, CDCl3) δ = 8.42 (d, 1H), 8.19 (d, 1H), 6.28 - 6.12 (m, 2H), 5.52 - 5.36 (m, 2H), 3.66 - 3.53 (m, 4H), 3.48 (br d, 1H), 3.18 - 3.09 (m, 2H), 2.75 (d, 1H), 1.29 (s, 3H), 1.14 (td, 1H), 0.99 - 0.81 (m, 4H), 0.42 (dd, 1H), 0.28 (t, 1H), -0.01 (s, 9H), -0.13 (s, 9H).
[0367] Preparation 31 2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-amine
[0368] [ka]
[0369] A solution of Preparation 30b (0.72 g, 1.19 mmol) in NMP (8 mL) was treated with CuO (0.17 g, 1.2 mmol) and concentrated NHOH (8 mL) at room temperature. The resulting suspension was stirred under N 2(g)The mixture was degassed at 100° C. for approximately 2 minutes. The mixture was sealed in a microwave tube and irradiated in a microwave at 100° C. for approximately 10 hours. The reaction mixture was partitioned between EtOAc (20 mL) and HO (20 mL) and the layers were separated. The aqueous layer was extracted with EtOAc (20 mL). The EtOAc extracts were combined, dried, and concentrated. The residue was purified by chromatography (silica, EtOAc / PE 0-100%) to give the title compound (0.50 g, 77%). 1 H NMR (400 MHz, CDCl3) δ = 8.11 - 8.01 (m, 1H), 7.15 (d, 1H), 6.09 (q, 2H), 5.40 (q, 2H), 3.59 - 3.46 (m, 5H), 3.20 - 3.05 (m, 2H), 2.72 (d, 1H), 1.28 (s, 3H), 1.18 - 1.07 (m, 1H), 0.91 (t, 2H), 0.86 - 0.79 (m, 2H), 0.41 - 0.35 (m, 1H), 0.24 (t, 1H), -0.03 (s, 9H), -0.12 (s, 9H).
[0370] Preparation 32 tert-Butyl (2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-6-yl)carbamate
[0371] [ka]
[0372] A mixture of Preparation 30a (6.00 g, 9.92 mmol), t-butyl carbamate (0.77 g, 0.66 mmol), and cesium carbonate (6.47 g, 19.8 mmol) in t-amyl alcohol (124 mL) under nitrogen was treated with Pd(dba) (0.45 g, 0.50 mmol) and t-BuDavePhos (0.98 g, 1.98 mmol). The flask was sealed and the mixture was stirred at about 100 °C for about 48 hours. Additional Pd(dba) (0.23 g, 0.25 mmol) and t-BuDavePhos (340 mg, 0.99 mmol) were added, and the mixture was stirred at about 100 °C for about 15 hours. The mixture was cooled to room temperature and concentrated. The residue was purified by chromatography (silica, PE / EtOAc; 0-100%) to give the title compound (2.76 g, 43%). 1 H NMR (400 MHz, CDCl3) δ = 8.47 - 8.33 (m, 1H), 8.21 (d, 1H), 6.71 (br s, 1H), 6.24 - 6.12 (m, 1H), 5.50 - 5.35 (m, 2H), 3.67 - 3.47 (m, 5H), 3.27 - 3.07 (m, 2H), 2.73 (br d, 1H), 1.55 (s, 9H), 1.28 (s, 3H), 1.16 - 1.11 (m, 1H), 0.96 - 0.82 (m, 4H), 0.40 (dd, 1H), 0.29 - 0.25 (m, 1H), -0.01 (s, 9H), -0.12 (s, 9H)
[0373] Preparation 33 tert-Butyl methyl(2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-6-yl)carbamate
[0374] [ka]
[0375] A solution of Preparation 32 (3.16 g, 4.93 mmol) in THF (25 mL) at about 0° C. was treated with sodium hydride (60% suspension, 217 mg 5.42 mmol). The mixture was treated with methyl iodide (0.36 mL, 5.92 mmol) at about 0° C., and the reaction mixture was stirred at about 15° C. for about 15 hours. The reaction mixture was quenched with saturated aqueous NH4Cl (1 mL) and then water (10 mL). The mixture was extracted with EtOAc (50 mL). The EtOAc layer was concentrated under reduced pressure. The residue was purified by chromatography (silica, PE / EtOAc 0 to 100%) to give the title compound (3 g, 93%). 1 H NMR (400 MHz, CDCl3) δ = 8.43 (d, 1H), 7.74 (br s, 1H), 6.26 - 6.11 (m, 2H), 5.49 - 5.36 (m, 2H), 3.62 - 3.50 (m, 5H), 3.35 (s, 3H), 3.26 - 3.10 (m, 2H), 2.74 (br d, 1H), 1.44 (br s, 9H), 1.29 (s, 3H), 1.19 - 1.11 (m, 1H), 0.98 - 0.88 (m, 2H), 0.88 - 0.82 (m, 2H), 0.41 (dd, 1H), 0.29 - 0.16 (m, 1H), 0.06 - -0.06 (m, 9H), -0.09 - -0.18 (m, 9H).
[0376] Preparation 34 N-Methyl-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-6-amine
[0377] [ka]
[0378] A solution of Preparation 33 (2.90 g, 4.43 mmol) in DCM (50 mL) was treated with ZnBr (4.99 g, 22.1 mmol) at about 0 °C. The mixture was stirred at about 10 °C for about 16 h. The reaction mixture was poured into a mixture of ice and saturated aqueous NaHCO (10 mL). The mixture was extracted with DCM (3 × 100 mL). The combined DCM layers were dried (NaSO), filtered, and concentrated. The crude product was purified by chromatography (silica, PE / EtOAc 0-70%) to give the title compound (660 mg, 27%). LC / MS m / z (M+H) + = 555.0.
[0379] Preparation 35 2-(6,6-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-N-methyl-3H-imidazo[4,5-b]pyridin-6-amine and 2-(6,6-dimethyl-2-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl)-N-methyl-3H-imidazo[4,5-b]pyridin-6-amine
[0380] [ka]
[0381] Step 1: tert-butyl (2-(6,6-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)(methyl)carbamate and tert-butyl (2-(6,6-dimethyl-2-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)(methyl)carbamate (35a)
[0382] [ka]
[0383] A solution of Preparation 19 (1.00 g, 3.24 mmol) in DMF (10 mL) and DMSO (2 mL) was treated with Preparation 25 (0.77 g, 3.24 mmol) and sodium metabisulfite (0.31 g, 1.62 mmol) at about 30° C. The reaction mixture was stirred at about 110° C. for about 18 hours. Water (40 mL) was added and the precipitate was collected by filtration, washed with water, and dried under vacuum to give the title compound (1.7 g, 99%) as a mixture of regioisomers. LC / MS m / z (M+H) + = 527.3.
[0384] Step 2: 2-(6,6-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-N-methyl-3H-imidazo[4,5-b]pyridin-6-amine and 2-(6,6-dimethyl-2-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl)-N-methyl-3H-imidazo[4,5-b]pyridin-6-amine
[0385] [ka]
[0386] A solution of Preparation 35a (1.0 g, 1.9 mmol) in DCM (25 mL) was treated with ZnBr (2.14 g, 9.49 mmol) at about 30° C. The reaction mixture was stirred at about 30° C. for about 2 hours. Water (25 mL) was added and the mixture was extracted into DCM (2×25 mL). The organic extracts were combined, dried (NaSO), filtered, and concentrated to give the title compound (0.81 g, 99%) as a mixture of regioisomers. LC / MS m / z (M+H) + = 427.2.
[0387] Preparation 36 N-(5,6-diaminopyridin-3-yl)-N-methylacetamide
[0388] [ka]
[0389] Step 1: N-(6-(dibenzylamino)-5-nitropyridin-3-yl)-N-methylacetamide (36a)
[0390] [ka]
[0391] A solution of Preparation 26 (2.0 g, 5.74 mmol) in DCM (20 mL) at about 0 °C was treated with EtN (1.6 mL, 11.5 mmol), DMAP (70 mg, 0.57 mmol), and AcO (0.65 mL, 6.89 mmol). The reaction mixture was stirred at about 15 °C for about 17 h. The reaction mixture was combined with 100 mg of Preparation 26 from an identical reaction using similar proportions of other reagents. The combined mixture was partitioned between saturated aqueous NHCl (20 mL) and DCM (20 mL). The aqueous layer was extracted with DCM (10 mL). The combined DCM extracts were dried (NaSO), filtered, and concentrated. The resulting residue was purified by chromatography (silica, EtOAc / PE = 30-50%) to give the title compound (2.4 g). 1 H NMR (400 MHz, CDCl3) δ = 8.28 (d, 1H), 7.96 (d, 1H), 7.35 - 7.28 (m, 6H), 7.19 - 7.14 (m, 4H), 4.65 (s, 4H), 3.26 (s, 3H), 1.92 (s, 3H).
[0392] Step 2: N-(5,6-diaminopyridin-3-yl)-N-methylacetamide
[0393] [ka]
[0394] A solution of Preparation 36 (2.4 g, 6.15 mmol) in ethanol (30 mL) was treated with 10% Pd / C (300 mg) at about 10° C. The mixture was stirred under 50 PSI of H at about 70° C. for about 18 hours. The reaction mixture was filtered and the filter cake was rinsed with ethanol. The filtrate was treated with 10% Pd / C (300 mg) and the mixture was stirred under 50 PSI of H at about 70° C. for about 18 hours. The reaction mixture was filtered. The filtrate was concentrated to give the title compound (1.1 g, 99%). 1 H NMR (400 MHz, CD3OD) δ = 7.27 (d, 1H), 6.73 (d, 1H), 3.38 - 3.25 (m, 3H), 1.87 (s, 3H).
[0395] Preparation 37 (S)-N-(5,6-diaminopyridin-3-yl)-N-methyl-2-morpholinopropanamide
[0396] [ka]
[0397] Step 1:N 2 ,N 2 -Dibenzyl-N 5 -Methyl-3-nitropyridine-2,5-diamine (37a)
[0398] [ka]
[0399] A solution of Preparation 25d (7.31 g, 16.3 mmol) in DCM (24.5 mL) was treated with TFA (16.4 mL, 8.12 mmol). The reaction mixture was stirred for approximately 2 hours and concentrated. The resulting residue was triturated with toluene (2x) and heptane (2x). The residue was dissolved in 1:1 (v / v) THF / methanol (100 mL) and solid K2CO3 was added until a pH of 10 was achieved. The resulting mixture was stirred for approximately 30 minutes to 1 hour and concentrated. EtOAc was added to the residue and the resulting mixture was washed with water and brine. The combined aqueous washes were extracted with EtOAc (2x), and the organic extracts were combined, dried (MgSO4), filtered, and concentrated. The resulting residue was triturated with diethyl ether (2x) to give the title compound (5.3 g). LC / MS m / z (M+H) + = 349.3.
[0400] Step 2: (S)-N-(6-(dibenzylamino)-5-nitropyridin-3-yl)-N-methyl-2-morpholinopropanamide (37b)
[0401] [ka]
[0402] A solution of Preparation 37a (5.3 g, 15.2 mmol) in pyridine (101 mL) was treated with EDCI (9.75 g, 45.6 mmol) and Preparation 20 (3.63 g, 22.8 mmol). The reaction mixture was stirred at room temperature for approximately 18 hours. The mixture was treated with 0.1 N HCl and extracted with EtOAc (2×). The combined EtOAc extracts were washed with brine, dried (MgSO4), filtered, and concentrated. The crude product was purified by chromatography (silica, 5-59% EtOAc / heptane) to give the title compound (5.53 g, 74%). 1 H NMR (400 MHz, CD3OD) δ = 8.43 (d, 1H), 8.24 (d, 1H), 7.32 - 7.13 (m, 10H), 4.73 (q, 4H), 3.57 - 3.45 (m, 4H), 3.22 (s, 3H), 3.10 (q, 1H), 2.48 - 2.37 (m, 2H), 2.13 - 2.03 (m, 2H), 1.06 (d, 3H).
[0403] Step 3: (S)—N-(5,6-diaminopyridin-3-yl)-N-methyl-2-morpholinopropanamide
[0404] [ka]
[0405] A solution of Preparation 37b (7.80 g, 15.9 mmol) in ethanol (150 mL) was treated with 5% Pd / C (60% water content, 7.80 g). The mixture was stirred at about 70 °C under an H atmosphere at 125 PSI for about 60 hours. The reaction mixture was filtered through Celite® and the filter was washed with methanol and EtOAc. The filtrate was concentrated and the residue was triturated twice with diethyl ether. The crude product was purified by chromatography (silica, 0-16% methanol / DCM) to give the title compound (3.65 g, 82%). 1 H NMR (400 MHz, DMSO-d6) δ = 7.20 (d, 1H), 6.62 (d, 1H), 5.55 (br s, 2H), 4.89 (br s, 2H), 3.56 - 3.43 (m, 4H), 3.21 (q, 1H), 3.05 (s, 3H), 2.48 - 2.41 (m, 2H), 2.31 - 2.22 (m, 2H), 1.00 (d, 3H).
[0406] Preparation 38 (S)-N-(5,6-diaminopyridin-3-yl)-N-ethyl-2-morpholinopropanamide
[0407] [ka]
[0408] Step 1: tert-butyl (6-(dibenzylamino)-5-nitropyridin-3-yl)(ethyl)carbamate (38a)
[0409] [ka]
[0410] A solution of Preparation 25c (1.0 g, 2.30 mmol) in THF (20 mL) was treated with sodium hydride (60% suspension, 0.14 g, 3.45 mmol) at about 0° C. for about 30 minutes. Ethyl iodide (0.37 mL, 4.60 mmol) was added dropwise at about 0° C., and the mixture was stirred at about 30° C. for about 60 hours. Water (20 mL) was added, and the mixture was extracted with EtOAc (3×50 mL). The combined EtOAc extracts were washed with brine and concentrated. The residue was purified by chromatography (silica, 0-10% EtOAc / PE) to give the title compound (0.70 g, 66%). 1 H NMR (400 MHz, CDCl3) δ = 8.27 (br s, 1H), 7.97 (br s, 1H), 7.27 (s, 6H), 7.19 - 7.13 (m, 4H), 4.59 (s, 4H), 3.66 (q, 2H), 1.45 (br s, 9H), 1.18 (t, 3H)
[0411] Step 2:N 2 ,N 2 -Dibenzyl-N5-ethyl-3-nitropyridine-2,5-diamine (38b)
[0412] [ka]
[0413] A solution of Preparation 38a (0.70 g, 1.51 mmol) in DCM (5 mL) was treated with TFA (2 mL) at about 15° C. The reaction mixture was stirred at about 30° C. for about 18 hours. The mixture was concentrated. The residue was dissolved in DCM (15 mL) and washed with saturated aqueous NaHCO (15 mL). The organic extract was dried over NaSO and concentrated to give the title compound (0.60 g). LC / MS m / z (M+H) + = 363.1.
[0414] Step 3: (S)-N-(6-(dibenzylamino)-5-nitropyridin-3-yl)-N-ethyl-2-morpholinopropanamide (38c)
[0415] [ka]
[0416] A solution of Preparation 38b (0.35 g, 0.97 mmol) in pyridine (10 mL) was treated with EDCI (0.56 g, 2.90 mmol) and Preparation 20 (0.20 g, 1.26 mmol) at approximately 30° C. The reaction mixture was stirred for approximately 2 hours. Water (20 mL) was added and the mixture was extracted with EtOAc (2×20 mL). The combined EtOAc extracts were dried (NaSO) and concentrated. The residue was purified by chromatography (silica, 40-80% EtOAc / PE) to give the title compound (0.40 g, 82%). LC / MS m / z (M+H) + = 504.2.
[0417] Step 4: (S)—N-(5,6-diaminopyridin-3-yl)-N-ethyl-2-morpholinopropanamide
[0418] [ka]
[0419] A solution of Preparation 38c (0.40 g, 0.79 mmol) in ethanol (30 mL) was treated with Pd(OH) / C (112 mg) and 10% Pd / C (85 mg). The reaction mixture was stirred at about 70° C. for about 18 hours under an atmosphere of H at 50 PSI. The reaction mixture was filtered and the filtrate was concentrated to give the title compound (233 mg). LC / MS m / z (M+H) + = 294.0.
[0420] Preparation 39 (R)-N-(5,6-diaminopyridin-3-yl)-N-ethyl-2-(tetrahydro-2H-pyran-4-yl)propenamide
[0421] [ka]
[0422] Step 1: (R)-N-(6-(dibenzylamino)-5-nitropyridin-3-yl)-2-(tetrahydro-2H-pyran-4-yl)propenamide (39a)
[0423] [ka]
[0424] A solution of Preparation 26 (740 mg, 2.21 mmol) in pyridine (10 mL) was treated with Preparation 21 (420 mg, 2.66 mmol) and EDCI (849 mg, 4.43 mmol) at approximately 30° C. and stirred for approximately 2 hours. The reaction mixture was combined with another identical reaction carried out using 30 mg of Preparation 26 with similar proportions of other reagents. The combined reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2×20 mL). The combined EtOAc extracts were dried (NaSO), filtered, and concentrated. The crude product was purified by chromatography (silica, PE / EtOAc 10-30%) to give the title compound (1.0 g, 92%). LC / MS m / z (M+H) + = 475.2.
[0425] Step 2: (R)-N 2 ,N 2 -Dibenzyl-N 5 -Ethyl-3-nitro-N 5 -(1-(tetrahydro-2H-pyran-4-yl)ethyl)pyridine-2,5-diamine (39b)
[0426] [ka]
[0427] A solution of Preparation 39a (0.70 g, 0.21 mmol) in DMF (20 mL) was treated with sodium hydride (60% suspension, 89 mg, 2.21 mmol) at about 30° C. The mixture was stirred at about 60° C. for about 1 hour. The reaction mixture was cooled to about 30° C., and ethyl iodide (0.23 mL, 2.95 mmol) was added dropwise at about 30° C. The reaction mixture was stirred at about 60° C. for about 2 hours. Water (35 mL) was added, and the mixture was extracted with EtOAc (2×40 mL). The combined EtOAc extracts were dried (NaSO), filtered, and concentrated. The crude product was purified by chromatography to give the title compound (0.65 g, 88%). LC / MS m / z (M+H) + = 503.3.
[0428] Step 3: (R)-N-(5,6-diaminopyridin-3-yl)-N-ethyl-2-(tetrahydro-2H-pyran-4-yl)propenamide
[0429] [ka]
[0430] A solution of Preparation 39b (650 mg, 1.29 mmol) in ethanol (30 mL) was treated with Pd(OH)2 / C (18 mg) and 10% Pd / C (138 mg). The reaction mixture was stirred under an atmosphere of H2 at 50 PSI at about 70 °C for about 18 hours. The reaction mixture was filtered and the filtrate was concentrated. The residue was dissolved in ethanol (30 mL) and treated with Pd(OH)2 / C (18 mg) and 10% Pd / C (138 mg). The reaction mixture was stirred under an atmosphere of H2 at 50 PSI at about 70 °C for about 18 hours. The reaction mixture was filtered and the filtrate was concentrated to give the title compound (370 mg, 98%). LC / MS m / z (M+H) + = 293.3.
[0431] Preparation 40 2-((2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-6-yl)amino)ethan-1-ol
[0432] [ka]
[0433] A solution of Preparation 30a (1.0 g, 1.65 mmol) in DMF (10 mL) was treated with N-(2,6-dimethylphenyl)-6-hydroxypicolinamide (0.16 g, 0.66 mmol), KPO (1.05 g, 4.96 mmol), CuI (157 mg, 0.83 mmol), and 2-((tert-butyldimethylsilyl)oxy)ethan-1-amine (0.58 g, 3.31 mmol). The reaction mixture was stirred at about 110° C. for about 16 hours. The mixture was diluted with EtOAc (20 mL), washed with water (10 mL), concentrated, and purified by chromatography to give the title compound (430 mg, 88%). LC / MS m / z (M+H) + = 585.4.
[0434] Preparation 41 2-Chloro-N-methyl-N-(2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)propenamide
[0435] [ka]
[0436] A solution of Preparation 28 (5.5 g, 12.0 mmol) and 2-chloropropanoic acid (1.6 mL, 17.5 mmol) in pyridine (167 mL) was treated with EDCI (4.5 g, 23.3 mmol) at about 12° C. The reaction mixture was stirred at about 12° C. for about 3 hours. The mixture was treated with water and extracted with EtOAc. The EtOAc extract was dried, filtered, and concentrated to give the title compound (6.30 g). 1 H NMR (400 MHz, CDCl3) δ = 12.29 - 12.01 (m, 1H), 8.87 - 8.75 (m, 1H), 8.47 (br s, 1H), 8.03 (br s, 1H), 7.93 - 7.78 (m, 1H), 7.46 (dd, 1H), 5.55 - 5.34 (m, 2H), 4.31 (br d, 1H), 3.72 - 3.49 (m, 3H), 3.40 (s, 3H), 3.23 - 3.07 (m, 2H), 2.78 (br d, 1H), 1.60 (d, 2H), 1.31 (s, 3H), 1.21 - 1.13 (m, 1H), 0.92 (br dd, 2H), 0.45 (br dd, 1H), 0.29 (br t, 1H), -0.03 (s, 9H).
[0437] Preparation 42 (5-Methoxy-N-methyl-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-amine and 5-Methoxy-N-methyl-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-6-amine
[0438] [ka]
[0439] Step 1: 6-Methoxy-3-nitropyridin-2-amine (42a)
[0440] [ka]
[0441] A suspension of 2-chloro-6-methoxy-3-nitropyridine (1.0 g, 5.20 mmol) in methanol (6 mL) was treated with 7 M NH in methanol (2.2 mL) and concentrated NHOH (0.35 mL). The mixture was stirred at about 65° C. for about 18 hours. The reaction mixture was cooled to room temperature and treated with water (5 mL). The solid was filtered and dried to give the title compound. Yield: 762 mg (87%). 1 H NMR (400 MHz, CDCl3) δ = 8.30 (d, 1H), 6.15 (d, 1H), 3.94 (s, 3H).
[0442] Step 2: 5-Bromo-6-methoxy-3-nitropyridin-2-amine (42b)
[0443] [ka]
[0444] A suspension of Preparation 42a (762 mg, 4.51 mmol) and N-bromosuccinimide (900 mg, 4.96 mmol) in AcOH (20 mL) was stirred at about 65° C. for about 1 hour. The reaction mixture was poured into a mixture of saturated aqueous NaHCO3 and EtOAc. The aqueous phase was made basic with 1 N NaOH and extracted with EtOAc (2×). The combined organic extracts were dried (MgSO4), filtered, and concentrated. The crude product was purified by chromatography to give the title compound. Yield: 988 mg (88%). 1 H NMR (400 MHz, CDCl3) δ = 8.54 (s, 1H), 4.02 (s, 3H).
[0445] Step 3: 5-Bromo-6-methoxypyridine-2,3-diamine (42c)
[0446] [ka]
[0447] A suspension of Preparation 42b (500 mg, 2.02 mmol), NH4Cl (1.2 g, 22.2 mmol), and zinc powder (1.32 g, 20.2 mmol) in ethanol (17 mL) and water (0.17 mL) was stirred at room temperature for approximately 18 hours. The reaction mixture was filtered, and the filtrate was concentrated. The residue was taken up in water and extracted with EtOAc (2x). The combined EtOAc extracts were dried (MgSO4), filtered, and concentrated to give the title compound (440 mg). LC-MS m / z (M+H) + = 218.0, 220.0( 79 Br, 81 Br).
[0448] Step 4: (4aS,5aR)-3-(6-bromo-5-methoxy-3H-imidazo[4,5-b]pyridin-2-yl)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole (42d)
[0449] [ka]
[0450] A suspension of Preparation 42c (440 mg, 2.02 mmol), Preparation 9 (618 mg, 2.02 mmol), and sodium metabisulfite (199 mg, 1.05 mmol) in DMF (12 mL) was treated with DMSO (0.36 mL, 5.04 mmol), and the mixture was stirred at about 110° C. for about 18 hours. The mixture was cooled to room temperature, diluted with saturated aqueous NaHCO and extracted with DCM (3×). The combined DCM extracts were dried (MgSO), filtered, and concentrated. The crude product was purified by chromatography to give the title compound. Yield: 682 mg (67%). LC-MS m / z (M+H) + = 504.3, 506.3( 79 Br, 81 Br).
[0451] Step 5: (4aS,5aR)-3-(6-bromo-5-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-2-yl)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole and (4aS,5aR)-3-(6-bromo-5-methoxy-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-2-yl)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole (42e)
[0452] [ka]
[0453] A solution of Preparation 42d (682 mg, 1.35 mmol) in THF (3.5 mL) was washed with heptane (2×) and then added dropwise to sodium hydride (60% suspension, 71 mg, 1.76 mmol) suspended in THF (8 mL) at about 0° C. The mixture was stirred at about 0° C. for about 40 minutes. A solution of SEM-Cl (0.26 mL, 1.49 mmol) in THF (1.5 mL) was added dropwise and the mixture was stirred at about 0° C. for about 45 minutes, then at room temperature for about 2 hours. The reaction mixture was treated with saturated aqueous NH4Cl and extracted with EtOAc (2×). The combined EtOAc extracts were dried (MgSO4), filtered, and concentrated. The crude product was purified by chromatography to provide the title compound as a mixture of regioisomers. Yield: 731 mg (85%). LC-MS m / z (M+H) + = 636.4.
[0454] Step 6: (5-methoxy-N-methyl-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-amine and 5-methoxy-N-methyl-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-6-amine (42f)
[0455] [ka]
[0456] A suspension of Preparation 42e (380 mg, 0.60 mmol), CuI (17 mg, 0.09 mmol), KPO (445 mg, 2.10 mmol), and N-(2,6-dimethylphenyl)-6-hydroxypicolinamide (44 mg, 0.18 mmol) in DMF (4.5 mL) under nitrogen was treated with methylamine hydrochloride (81 mg, 1.2 mmol). The mixture was stirred at about 110 °C for about 18 h. The mixture was cooled to room temperature, diluted with 1:4 v / v NHOH / water, and extracted with EtOAc (2x). The combined EtOAc extracts were dried (MgSO), filtered, and concentrated. The crude product was purified by chromatography to afford the title compound as a mixture of regioisomers. Yield: 283 mg (85%). LC-MS m / z (M+H) + = 585.5.
[0457] Preparation 43 5-(2-Methoxyethoxy)-N-methyl-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-amine and and 5-(2-methoxyethoxy)-N-methyl-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-6-amine
[0458] [ka]
[0459] Step 1: 5-Bromo-6-(2-methoxyethoxy)-3-nitropyridin-2-amine (43a)
[0460] [ka]
[0461] A solution of 2-methoxyethanol (0.29 mmol, 3.65 mmol) in THF (1 mL) was added dropwise at about 0° C. to sodium hydride (60% suspension, 183 mg, 4.56 mmol) that had been washed with heptane (2×) and suspended in THF (12 mL). The mixture was stirred at about 0° C. for about 30 minutes. A solution of 2-amino-5-bromo-6-chloro-3-nitropyridine (800 mg, 3.0 mmol) in THF (9 mL) was added dropwise, and the mixture was stirred at about 0° C. for about 1 hour and then at room temperature for about 1 hour. The reaction mixture was treated with saturated aqueous NH4Cl and extracted with EtOAc (2×). The combined EtOAc extracts were dried (MgSO4), filtered, and concentrated. The crude product was combined with that from another identical reaction using 200 mg of 2-amino-5-bromo-6-chloro-3-nitropyridine and similar proportions of other reagents. The combined material was purified by chromatography to give the title compound. Yield: 890 mg (77%). 1 H NMR (400 MHz, CDCl3) δ = 8.55 (s, 1H), 4.61 - 4.49 (m, 2H), 3.82 - 3.73 (m, 2H), 3.47 (s, 3H).
[0462] Step 2: 5-Bromo-6-(2-methoxyethoxy)pyridine-2,3-diamine (43b)
[0463] [ka]
[0464] A suspension of Preparation 43a (500 mg, 1.71 mmol), NH4Cl (1.01 g, 18.8 mmol), and zinc powder (1.12 g, 17.1 mmol) in ethanol (17 mL) and water (0.17 mL) was stirred for approximately 18 hours at room temperature. The reaction mixture was filtered, and the filtrate was concentrated. The residue was taken up in water and extracted with EtOAc (2x). The combined EtOAc extracts were dried (MgSO4), filtered, and concentrated to give the title compound. Yield: 435 mg (97%), LC-MS m / z (M+H) + = 264.1.
[0465] Step 3: (4aS,5aR)-3-(6-bromo-5-(2-methoxyethoxy)-3H-imidazo[4,5-b]pyridin-2-yl)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole (43c)
[0466] [ka]
[0467] A suspension of Preparation 43b (435 mg, 1.66 mmol), Preparation 9 (509 mg, 1.66 mmol), and sodium metabisulfite (164 mg, 0.86 mmol) in DMF (12 mL) was treated with DMSO (0.29 mL, 4.15 mmol), and the mixture was stirred at about 110° C. for about 18 hours. The mixture was cooled to room temperature, diluted with saturated aqueous NaHCO and extracted with DCM (3×). The combined DCM extracts were dried (MgSO), filtered, and concentrated. The crude product was purified by chromatography to give the title compound. Yield: 551 mg (61%). LC-MS m / z (M+H) + = 550.2
[0468] Step 4: (4aS,5aR)-3-(6-bromo-5-(2-methoxyethoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-2-yl)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole and and (4aS,5aR)-3-(6-bromo-5-(2-methoxyethoxy)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-2-yl)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole (43d)
[0469] [ka]
[0470] A solution of Preparation 43c (550 mg, 1.0 mmol) in THF (2 mL) was washed with heptane (2×) and then added dropwise to sodium hydride (60% suspension, 52 mg, 1.30 mmol) suspended in THF (6 mL) at about 0° C. The mixture was stirred at about 0° C. for about 45 minutes. A solution of SEM-Cl (0.26 mL, 1.49 mmol) in THF (1 mL) was added dropwise, and the mixture was stirred at room temperature for about 18 hours. The reaction mixture was treated with saturated aqueous NH4Cl and extracted with EtOAc (2×). The combined EtOAc extracts were dried (MgSO4), filtered, and concentrated. The crude product was purified by chromatography to afford the title compound as a mixture of regioisomers. Yield: 654 mg (96%). LC-MS m / z (M+H) + = 680.3.
[0471] Step 5: 5-(2-methoxyethoxy)-N-methyl-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-6-yl amine and 5-(2-methoxyethoxy)-N-methyl-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-amine
[0472] [ka]
[0473] A suspension of Preparation 43d (654 mg, 0.96 mmol), CuI (27 mg, 0.15 mmol), KPO (716 mg, 3.40 mmol), and N-(2,6-dimethylphenyl)-6-hydroxypicolinamide (70 mg, 0.29 mmol) in DMF (6 mL) under nitrogen was treated with methylamine hydrochloride (130 mg, 1.93 mmol). The mixture was stirred at about 110 °C for about 18 h. The mixture was cooled to room temperature, diluted with 1:4 v / v NHOH / water, and extracted with EtOAc (2x). The combined EtOAc extracts were dried (MgSO), filtered, and concentrated. The crude product was purified by chromatography to afford the title compound as a mixture of regioisomers. Yield: 461 mg (76%). LC-MS m / z (M+H) + = 629.5.
[0474] Preparation 44 5-Ethyl-N-methyl-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-amine and 5-ethyl-N-methyl-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-6-amine
[0475] [ka]
[0476] Step 1: 5-Bromo-6-ethyl-3-nitropyridin-2-amine (44a)
[0477] [ka]
[0478] A suspension of 2-amino-6-ethyl-3-nitropyridine (868 mg, 5.19 mmol) and N-bromosuccinimide (1.04 g, 5.71 mmol) in AcOH (20 mL) was stirred at about 65 °C for about 1 h. The reaction mixture was poured into a biphasic mixture of saturated aqueous NaHCO and EtOAc. The mixture was treated with 1 N NaOH until basic and extracted with EtOAc (2x). The combined organic extracts were dried (MgSO), filtered, and concentrated. The residue was combined with that from an identical reaction using 100 mg of 2-amino-6-ethyl-3-nitropyridine with similar proportions of other reagents. The combined residue was purified by chromatography to give the title compound. Yield: 1.04 mg (71%). 1H NMR (400 MHz, CDCl3) δ = 8.52 (s, 1H), 2.88 (q, 2H), 1.27 (t, 3H).
[0479] Step 2: 5-Bromo-6-ethylpyridine-2,3-diamine (44b)
[0480] [ka]
[0481] A suspension of Preparation 44a (500 mg, 2.03 mmol), NH4Cl (1.2 g, 22.4 mmol), and zinc powder (1.33 g, 20.3 mmol) in ethanol (17 mL) and water (0.17 mL) was stirred at room temperature for approximately 18 hours. The reaction mixture was filtered, and the filtrate was concentrated. The residue was taken up in water and extracted with EtOAc (2x). The combined EtOAc extracts were dried (MgSO4), filtered, and concentrated to give the title compound. Yield: 276 mg (63%), LC-MS m / z (M+H) + = 216.1.
[0482] Step 3: (4aS,5aR)-3-(6-bromo-5-ethyl-3H-imidazo[4,5-b]pyridin-2-yl)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole (44c)
[0483] [ka]
[0484] A suspension of Preparation 44b (276 mg, 1.27 mmol), Preparation 9 (388 mg, 1.27 mmol), and sodium metabisulfite (125 mg, 0.66 mmol) in DMF (9 mL) was treated with DMSO (0.23 mL, 3.16 mmol), and the mixture was stirred at about 110° C. for about 18 hours. The mixture was cooled to room temperature, diluted with saturated aqueous NaHCO and extracted with DCM (3×). The combined DCM extracts were dried (MgSO), filtered, and concentrated. The crude product was purified by chromatography to give the title compound. Yield: 401 mg (63%). LC-MS m / z (M+H) + = 504.2.
[0485] Step 4: (4aS,5aR)-3-(6-bromo-5-ethyl-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-2-yl)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole and (4aS,5aR)-3-(6-bromo-5-ethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-2-yl)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole (44d)
[0486] [ka]
[0487] A solution of Preparation 44c (401 mg, 0.80 mmol) in THF (2 mL) was washed with heptane (2×) and then added dropwise to sodium hydride (60% suspension, 42 mg, 1.04 mmol) suspended in THF (4 mL) at about 0° C. The mixture was stirred at about 0° C. for about 45 minutes. A solution of SEM-Cl (0.16 mL, 0.88 mmol) in THF (1 mL) was added dropwise, and the mixture was stirred at room temperature for about 18 hours. The reaction mixture was treated with saturated aqueous NH4Cl and extracted with EtOAc (2×). The combined EtOAc extracts were dried (MgSO4), filtered, and concentrated. The crude product was purified by chromatography to afford the title compound as a mixture of regioisomers. Yield: 397 mg (79%). LC-MS m / z (M-CH2CH2TMS) + = 532.3.
[0488] Step 5: 5-ethyl-N-methyl-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-amine and 5-ethyl-N-methyl-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-6-amine
[0489] [ka]
[0490] A suspension of Preparation 44d (397 mg, 0.63 mmol), CuI (17 mg, 0.09 mmol), KPO (466 mg, 2.20 mmol), and N-(2,6-dimethylphenyl)-6-hydroxypicolinamide (46 mg, 0.19 mmol) in DMF (4.5 mL) under nitrogen was treated with methylamine hydrochloride (85 mg, 1.25 mmol). The mixture was stirred at about 110 °C for about 18 h. The mixture was cooled to room temperature, diluted with 1:4 v / v NHOH / water, and extracted with EtOAc (2x). The combined EtOAc extracts were dried (MgSO), filtered, and concentrated. The crude product was purified by chromatography to afford the title compound as a mixture of regioisomers. Yield: 93 mg (25%). LC-MS m / z (M+H) + = 583.5.
[0491] Preparation 45 (S)-N-(5-fluoro-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-yl)-N-methyl-2-morpholinopropanamide
[0492] [ka]
[0493] Step 1: 5-Bromo-6-chloro-3-nitropyridin-2-amine (45a)
[0494] [ka]
[0495] A suspension of 6-chloro-3-nitropyridin-2-amine (10.0 g, 57.6 mmol) in AcOH (200 mL) was treated with N-bromosuccinimide (11.3 g, 63.4 mmol) at room temperature. The reaction mixture was stirred at about 60° C. for about 16 hours. The precipitate was collected by filtration, washed with water (2×100 mL), and then dried under vacuum to give the title compound (13.4 g, 92%). 1 H NMR (400 MHz, DMSO-d6) δ = 8.63 (s, 1H), 8.31 (br s, 2H).
[0496] Step 2: tert-Butyl (5-bromo-6-chloro-3-nitropyridin-2-yl)(tert-butoxycarbonyl)carbamate (45b)
[0497] [ka]
[0498] A solution of Preparation 45a (11.2 g, 44.4 mmol) in THF (222 mL) was treated with DMAP (542 mg, 4.44 mmol) and BOC0 (19.4 g, 88.7 mmol) at room temperature. The reaction mixture was stirred at about 70 °C for about 16 hours. The reaction was cooled to room temperature, treated with water (100 mL), and extracted with EtOAc (3 × 100 mL). The combined EtOAc extracts were concentrated, and the residue was purified by chromatography (silica, EtOAc / PE = 0-10%) to give the title compound (17 g, 85%). 1 H NMR (400 MHz, CDCl3) δ = 8.67 (s, 1H), 1.45 (s, 18H).
[0499] Step 3: tert-butyl (5-bromo-6-fluoro-3-nitropyridin-2-yl)(tert-butoxycarbonyl)carbamate (45c)
[0500] [ka]
[0501] A solution of Preparation 45b (15.2 g, 33.6 mmol) in DMSO (168 mL) was treated with potassium fluoride (9.75 g, 168 mmol). The mixture was flushed with nitrogen for approximately 3 minutes and stirred at room temperature for approximately 16 hours. The reaction mixture was treated with 3% aqueous LiCl (100 mL) and extracted with EtOAc (3 x 100 mL). The combined EtOAc extracts were concentrated, and the residue was purified by chromatography (silica, EtOAc / PE = 0-5%) to give the title compound (9.9 g, 68%). 1 H NMR (400 MHz, CDCl3) δ = 8.76 (d, 1H), 1.45 (s, 18H).
[0502] Step 4: 5-Bromo-6-fluoro-3-nitropyridin-2-amine hydrochloride (45d)
[0503] [ka]
[0504] A solution of Preparation 45c (8.60 g, 19.71 mmol) in DCM (60 mL) at about 0° C. was treated dropwise with 4 N HCl in 1,4-dioxane (60 mL). The reaction mixture was stirred at room temperature for about 16 hours. The reaction mixture was concentrated to give the title compound (4.7 g, 87%). 1 H NMR (400 MHz, DMSO-d6) δ = 8.49 (d, 1H), 8.36 (br s, 3H).
[0505] Step 5: 5-Bromo-6-fluoropyridine-2,3-diamine (45e)
[0506] [ka]
[0507] A solution of Preparation 45d (2.70 g, 9.91 mmol) in ethanol (50 mL) and water (50 mL) was treated with NH4Cl (2.65 g, 49.5 mmol) and iron powder (2.77 g, 49.5 mmol) at room temperature. The reaction mixture was stirred at room temperature for approximately 16 hours. The reaction mixture was filtered through Celite®, and the filtrate was concentrated to remove most of the ethanol. The remaining mixture was extracted with EtOAc (3 × 50 mL). The combined EtOAc extracts were concentrated, and the residue was purified by chromatography (silica, EtOAc / PE = 20-80%). The isolated product was combined with that from an identical reaction using 1.4 g of Preparation 45d and similar proportions of other reagents to give the title compound (2.3 g, 74%). 1 H NMR (400 MHz, DMSO-d6) δ = 6.93 (d, 1H), 6.01 (br s, 2H), 4.77 (br s, 2H).
[0508] Step 6: (4aS,5aR)-3-(6-bromo-5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole (45f)
[0509] [ka]
[0510] A solution of Preparation 45e (720 mg, 3.49 mmol) and sodium metabisulfite (332 mg, 1.75 mmol) in DMF (20 mL) was treated with Preparation 9 (1.07 g, 3.49 mmol) and DMSO (0.62 mL, 8.74 mmol). The reaction mixture was stirred at about 110° C. for about 16 hours. The reaction mixture was then stirred at about 130° C. for about 16 hours. The reaction mixture was treated with 3% aqueous LiCl (50 mL) and extracted with EtOAc (2×50 mL). The combined EtOAc extracts were concentrated, and the residue was purified by chromatography (silica, EtOAc / PE=0 to 30%) to give the title compound (1.4 g, 81%). 1 H NMR (400 MHz, CD3OD) δ = 8.43 - 8.10 (m, 1H), 5.58 - 5.40 (m, 2H), 3.62 (t, 2H), 3.42 (br d, 1H), 3.24 - 3.16 (m, 1H), 3.11 (dd, 1H), 2.77 (d, 1H), 1.31 (s, 3H), 1.22 - 1.14 (m, 1H), 0.89 (dd, 2H), 0.45 (dd, 1H), 0.25 (t, 1H), -0.03 (s, 9H).
[0511] Step 7: (4aS,5aR)-3-(6-bromo-5-fluoro-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-2-yl)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole (45g)
[0512] [ka]
[0513] A solution of Preparation 45f (1.40 g, 2.84 mmol) in THF (24 mL) at about 0 °C was treated with sodium hydride (60% suspension, 171 mg, 4.26 mmol) added portionwise. The reaction mixture was stirred at about 0 °C for about 1 h. The reaction mixture was treated dropwise with SEM-Cl (0.50 mL, 2.84 mmol). The reaction mixture was stirred at about 0 °C for about 1 h. The reaction mixture was treated with saturated aqueous NH4Cl (20 mL) at about 5 °C. The mixture was extracted with EtOAc (2 × 20 mL). The combined EtOAc extracts were concentrated, and the residue was purified by chromatography (silica, EtOAc / PE = 0 to 30%) to give the title compound (830 mg, 47%). 1 H NMR (400 MHz, CDCl3) δ = 8.30 (d, 1H), 6.24 - 6.00 (m, 2H), 5.52 - 5.36 (m, 2H), 3.61 - 3.51 (m, 4H), 3.46 (br d, 1H), 3.24 - 3.04 (m, 2H), 2.75 (br d, 1H), 1.29 (s, 3H), 1.18 - 1.09 (m, 1H), 1.02 - 0.80 (m, 4H), 0.42 (dd, 1H), 0.28 (t, 1H), -0.01 (s, 9H), -0.08 - -0.19 (m, 9H).
[0514] Step 8: tert-butyl (5-fluoro-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-yl)carbamate (45h)
[0515] [ka]
[0516] A suspension of Preparation 45g (830 mg, 1.33 mmol), t-butyl carbamate (187 mg, 1.60 mmol), and cesium carbonate (869 mg, 2.67 mmol) in t-amyl alcohol (13 mL) under nitrogen was treated with Pd2(dba)3 (122 mg, 0.13 mmol) and t-BuDavePhos (91 mg, 0.27 mmol). The mixture was sealed and stirred at about 100 °C for about 20 h. Additional t-butyl carbamate (156 mg, 1.33 mmol), Pd2(dba)3 (122 mg, 0.13 mmol), and t-BuDavePhos (91 mg, 0.27 mmol) were added, and the reaction mixture was stirred at about 100 °C for about 20 h. The reaction mixture was cooled to room temperature and concentrated. The residue was purified by chromatography (silica, PE / EtOAc 0-30%) to give the title compound (220 mg, 25%). 1 H NMR (400 MHz, CDCl3) δ = 8.93 - 8.68 (m, 1H), 6.60 (br s, 1H), 6.22 - 6.00 (m, 2H), 5.47 - 5.36 (m, 2H), 3.64 - 3.52 (m, 4H), 3.45 (br d, 1H), 3.21 - 3.04 (m, 2H), 2.73 (br d, 1H), 2.59 - 2.49 (m, 1H), 1.55 (s, 9H), 1.29 (s, 3H), 1.20 - 1.10 (m, 1H), 0.99 - 0.80 (m, 4H), 0.41 (dd, 1H), 0.28 (t, 1H), -0.01 (s, 9H), -0.12 (s, 9H).
[0517] Step 9: 5-Fluoro-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-amine (45i)
[0518] [ka]
[0519] A solution of Preparation 45h (110 mg, 0.17 mmol) in DCM (5 mL) at about 5 °C was treated with ZnBr (188 mg, 0.84 mmol). The reaction mixture was stirred at room temperature for about 18 hours. The reaction mixture was poured into saturated aqueous NaHCO (20 mL) and extracted with DCM (2 x 20 mL). The combined DCM extracts were dried (MgSO), filtered, and concentrated to give the title compound (85 mg, 91%). LC-MS m / z (M+H) + = 559.3.
[0520] Step 10: (S)—N-(5-fluoro-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-morpholinopropanamide (45j)
[0521] [ka]
[0522] A solution of Preparation 45i (85 mg, 0.15 mmol) and Preparation 20 (29 mg, 0.18 mmol) in pyridine (4 mL) was treated with EDCI (58 mg, 0.30 mmol) at room temperature. The reaction mixture was stirred at room temperature for approximately 16 hours. Water (10 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (2 x 10 mL). The combined EtOAc extracts were concentrated, and the residue was purified by chromatography (silica, PE / EtOAc 0-50%) to give the title compound (60 mg, 56%). LC-MS m / z (M+H) + = 700.3.
[0523] Step 11: (S)—N-(5-fluoro-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-yl)-N-methyl-2-morpholinopropanamide
[0524] [ka]
[0525] A solution of Preparation 45j (60 mg, 0.09 mmol) in THF (5 mL) at about 0° C. was treated with 1 M KOtBu (95 μL) in THF. The mixture was stirred at about 0° C. for about 1 hour. The mixture was treated with methyl iodide (6 μL, 0.09 mmol) in THF (0.5 mL). The mixture was stirred at about 0° C. for about 1.5 hours. Additional 1 M KOtBu (25 μL) and methyl iodide (3 μL, 0.05 mmol) in THF were added at about 5° C., and the mixture was stirred at room temperature for about 16 hours. Additional 1 M KOtBu (25 μL) and methyl iodide (3 μL, 0.05 mmol) in THF were added at about 5° C., and the mixture was stirred at room temperature for about 1 hour. The reaction mixture was treated with saturated aqueous NH4Cl (5 mL) and extracted with EtOAc (2 × 5 mL). The combined organic extracts were concentrated to give the title compound (60 mg, 98%). LC-MS m / z (M+H) + = 714.5.
[0526] Preparation 46 N,5-Dimethyl-2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-amine
[0527] [ka]
[0528] Step 1: 5-Bromo-N-(4-methoxybenzyl)-6-methyl-3-nitropyridin-2-amine (46a)
[0529] [ka]
[0530] A suspension of 3-bromo-6-chloro-2-methyl-5-nitropyridine (4.19 g, 16.66 mmol) and potassium carbonate (5.76 g, 41.7 mmol) in THF (40 mL) at room temperature was treated dropwise with 4-methoxybenzylamine (3.27 mL, 25.0 mmol) dissolved in THF (15 mL). The mixture was stirred at room temperature for approximately 30 minutes. The reaction mixture was treated with water and extracted with EtOAc (2×). The combined EtOAc extracts were dried (NaSO), filtered, and concentrated to give the title compound (5.87 g). 1H NMR (400 MHz, CDCl3) δ = 8.51 (s, 1H), 8.45 - 8.38 (m, 1H), 7.30 (d, 2H), 6.89 (d, 2H), 4.76 (d, 2H), 3.81 (s, 3H), 2.61 (s, 3H).
[0531] Step 2: 5-Bromo-N 2 -(4-Methoxybenzyl)-6-methylpyridine-2,3-diamine (46b)
[0532] [ka]
[0533] A suspension of Preparation 46a (5.87 g, 16.7 mmol) and NH4Cl (9.84 g, 184 mmol) in ethanol (56 mL) was treated with water (30 mL) and zinc powder (10.9 g, 167 mmol) at room temperature. The reaction mixture was stirred at room temperature for approximately 2 hours. The reaction mixture was filtered through Celite®, and the filter was washed with EtOAc and water. The filtrate was extracted with EtOAc. The combined EtOAc extracts were washed with brine, dried (Na2SO4), filtered, and concentrated. The residue was triturated with diethyl ether, and the undissolved material was filtered. The filtrate was concentrated, and the residue was purified by chromatography (silica, EtOAc / heptane = 0 to 100%) to give the title compound (3.10 g, 57%). 1H NMR (400 MHz, CDCl3) δ = 7.33 (d, 2H), 6.98 (s, 1H), 6.88 (d, 2H), 4.54 (br s, 2H), 4.38 (br s, 1H), 3.81 (s, 3H), 3.13 (br s, 2H), 2.48 (s, 3H).
[0534] Step 3: (4aS,5aR)-3-(6-bromo-3-(4-methoxybenzyl)-5-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole (46c)
[0535] [ka]
[0536] A solution of Preparation 46b (500 mg, 1.55 mmol) and Preparation 9 (476 mg, 1.55 mmol) in DMF was treated with DMSO (0.28 mL, 3.88 mmol) and sodium metabisulfite (148 mg, 0.78 mmol). The reaction mixture was stirred at about 100° C. for about 18 hours. The reaction mixture was cooled to room temperature, treated with saturated aqueous NaHCO and extracted with EtOAc. The EtOAc extract was washed with water (3×), dried (NaSO), filtered and concentrated. The residue was triturated with MeCN and the solid was filtered, washed with MeCN and dried to give the title compound (359 mg, 38%). 1 H NMR (400 MHz, CDCl3) δ = 8.38 - 8.19 (m, 1H), 7.30 - 7.24 (m, 7H), 6.73 (d, 2H), 5.95 (s, 2H), 5.50 - 5.35 (m, 2H), 3.73 (s, 3H), 3.53 (t, 2H), 3.43 (br d, 1H), 3.13 (br d, 1H), 2.78 (s, 3H), 2.74 (br d, 1H), 1.29 (s, 3H), 1.18 - 1.08 (m, 1H), 0.94 - 0.86 (m, 2H), 0.40 (br dd, 1H), 0.23 (br t, 1H), -0.04 (s, 9H)
[0537] Step 4: 3-(4-Methoxybenzyl)-N,5-dimethyl-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-amine (46d)
[0538] [ka]
[0539] A suspension of Preparation 46c (357 mg, 0.59 mmol), methylamine hydrochloride (59 mg, 0.88 mmol), N-(2,6-dimethylphenyl)-6-hydroxypicolinamide (14 mg, 0.06 mmol), KPO (374 mg, 1.76 mmol), and CuI (11 mg, 0.06 mmol) in DMF (3 mL) was stirred under nitrogen at approximately 110 °C for approximately 18 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, and washed with water (3x). The EtOAc extract was dried (NaSO), filtered, and concentrated. The crude product was purified by chromatography (silica, EtOAc / heptane = 0 to 100%) to give the title compound (53 mg, 16%). 1H NMR (400 MHz, CDCl3) δ = 7.38 - 7.29 (m, 1H), 7.24 (br d, 2H), 6.72 (br d, 2H), 5.92 (s, 1H), 5.52 - 5.34 (m, 2H), 3.72 (s, 3H), 3.53 (br t, 2H), 3.18 - 3.09 (m, 1H), 2.96 (s, 3H), 2.73 (br d, 1H), 2.51 (s, 3H), 1.57 (br s, 2H), 1.28 (s, 3H), 1.19 - 1.06 (m, 1H), 0.98 - 0.84 (m, 2H), 0.38 (br dd, 1H), 0.24 (br dd, 1H), -0.04 (s, 9H).
[0540] Step 5: N,5-Dimethyl-2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-amine
[0541] [ka]
[0542] A suspension of Preparation 46d (53 mg, 0.095 mmol) in TFA (1 mL) was heated at about 75° C. for about 1 hour. The reaction mixture was cooled to room temperature, diluted with water, and made basic with 3N NaOH. The mixture was extracted with a mixture of EtOAc / methanol. The organic extract was washed with brine, dried (NaSO), filtered, and concentrated to give the title compound (29 mg, 99%). LC-MS m / z (M+H) + = 309.2.
[0543] Preparation 47 (S)-N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-N-(2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-morpholinopropanamide
[0544] [ka]
[0545] Step 1: (S)—N-(2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-morpholinopropanamide (47a)
[0546] [ka]
[0547] A solution of Preparation 31 (150 mg, 0.28 mmol) in pyridine (3 mL) was treated with EDCI (0.11 g, 0.56 mmol) and Preparation 20 (66 mg, 0.42 mmol). The reaction mixture was stirred at room temperature for approximately 16 hours. The mixture was diluted with EtOAc (15 mL) and washed with water (15 mL). The organic extract was dried, filtered, and concentrated. The residue was purified by chromatography to give the title compound (120 mg, 63%). LC / MS m / z (M+H) + = 682.3.
[0548] Step 2: (S)—N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-N-(2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-morpholinopropanamide
[0549] [ka]
[0550] A solution of Preparation 47a (120 mg, 0.18 mmol) in DMF (4 mL) at about 0 °C was treated with sodium hydride (60% suspension, 28 mg, 0.71 mmol). The mixture was stirred for about 30 minutes. The mixture was treated with (2-bromoethoxy)(tert-butyl)dimethylsilane (210 mg, 0.88 mmol). The reaction mixture was stirred at room temperature for about 20 hours. Water (10 mL) was added, and the resulting mixture was extracted with EtOAc (2 × 15 mL). The combined EtOAc extracts were dried, filtered, and concentrated. The resulting residue was purified by chromatography (silica gel, EtOAc / PE (0.2% NH4OH) = 5-50%) to give the title compound (60 mg, 41%). LC / MS m / z (M+H) + = 840.4.
[0551] Preparation 48 N,2-Dimethyl-N-(2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-morpholinopropanamide
[0552] [ka]
[0553] Step 1: 2-methyl-N-(2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-morpholinopropanamide (48a)
[0554] [ka]
[0555] A solution of Preparation 21 (96 mg, 0.56 mmol) in DMF (5 mL) was treated with iPrNEt (0.19 mL, 1.11 mmol) and HATU (211 mg, 0.56 mmol). The mixture was stirred at room temperature for approximately 1 hour. The mixture was treated with Preparation 31 (200 mg, 0.37 mmol), and the mixture was stirred at approximately 50° C. for approximately 16 hours. The mixture was treated with water (15 mL) and extracted with EtOAc (2×15 mL). The combined EtOAc extracts were dried, filtered, and concentrated. The residue was combined with that from an identical reaction using 50 mg of Preparation 31 and similar proportions of other reagents. The combined residue was purified by chromatography (silica, EtOAc / PE 5-70%) to give the title compound (130 mg, 40%). LC / MS m / z (M+H) + = 696.3.
[0556] Step 2: N,2-dimethyl-N-(2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-morpholinopropanamide
[0557] [ka]
[0558] A solution of Preparation 48a (130 mg, 0.19 mmol) in DMF (4 mL) at about 0° C. was treated with sodium hydride (60% suspension, 15 mg, 0.37 mmol). The mixture was stirred at about 0° C. for about 20 minutes. The mixture was treated with methyl iodide (35 μL, 0.56 mmol) at about 0° C., and the reaction mixture was stirred at room temperature for about 2 hours. The reaction mixture was quenched with water (10 mL). The mixture was extracted with EtOAc (20 mL). The EtOAc layer was dried, filtered, and concentrated to provide the title compound (140 mg, 90%). LC / MS m / z (M+H) + = 710.4.
[0559] Preparation 49 2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-amine
[0560] [ka]
[0561] Step 1: tert-Butyl (5,6-diaminopyridin-3-yl)carbamate (49a)
[0562] [ka]
[0563] A solution of Preparation 25c (1.80 g, 4.14 mmol) in ethanol (150 mL) was treated with 5% Pd / C (Johnson Matthey cat#: 5R39, 1.80 g) at room temperature. The reaction mixture was stirred at about 70°C and stirred under an atmosphere of hydrogen at 125 PSI for about 48 hours. The reaction mixture was cooled to room temperature and filtered through Celite®. The filter cake was washed with ethanol (3 x 100 mL). The filtrate was concentrated, and the residue was purified by chromatography to give the title compound (560 mg, 60%). 1H NMR (400 MHz, CD3OD) δ 7.57 (s, 1H), 7.09 (d, J = 2.1 Hz, 1H), 1.50 (s, 9H); LC / MS m / z (M+H) + = 225.1.
[0564] Step 2: tert-butyl (2-(6,6-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)carbamate (49b)
[0565] [ka]
[0566] A solution of Preparation 49a (670 mg, 3.0 mmol) and sodium metabisulfite (290 mg, 1.5 mmol) in DMF (12 mL) was treated with Preparation 19 (970 mg, 3.15 mmol) and DMSO (0.53 mL, 7.5 mmol). The reaction mixture was stirred at about 110 °C for about 16 hours. The reaction mixture was cooled to room temperature, diluted with EtOAc (150 mL), and washed with saturated aqueous NaHCO (50 mL) and brine (50 mL). The EtOAc extract was dried (MgSO), filtered, and concentrated. The crude product was purified by chromatography to provide the title compound (600 mg, 39%). 1H NMR (400 MHz, CD3OD) δ 8.27 (d, 2H), 5.46 (s, 2H), 3.68 - 3.54 (m, 2H), 2.94 (t, 2H), 2.54 (s, 2H), 1.63 (t, 2H), 1.55 (s, 9H), 1.08 (s, 6H), 0.96 - 0.83 (m, 2H), -0.04 (s, 9H); LC / MS m / z (M+H) + = 513.3.
[0567] Step 3: 2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-amine
[0568] [ka]
[0569] A solution of Preparation 49b (100 mg, 0.19 mmol) in 4 M HCl in dioxane (1.5 mL) was stirred at about 60° C. for about 24 hours. The reaction mixture was cooled to room temperature and concentrated. The residue was stirred with methanol (10 mL) and potassium carbonate (670 mg, 4.88 mmol) at room temperature for about 2 hours. The solvent was removed by evaporation, and the residue was dissolved in 20% MeOH / DCM v / v (100 mL) and water (100 mL). The organic layer was separated, washed with brine, dried (MgSO), filtered, and concentrated. The residue was purified by preparative HPLC (Column: Waters Sunfire C18, 19 × 100 mm, 5 μm; Mobile phase A: 0.05% TFA (v / v) in water; Mobile phase B: 0.05% TFA (v / v) in MeCN, Gradient: 5% B to 100% B over 8.5 min, hold at 100% B for 1.5 min, Flow rate: 25 mL / min) to give the title compound (10 mg, 19%). 1H NMR (400 MHz, CD3OD) δ 7.95 (d, 1H), 7.57 (d, 1H), 2.91 (t, 2H), 2.51 (s, 2H), 1.65 (t, 2H), 1.07 (s, 6H); LC / MS m / z (M+H) + = 283.3. [Example]
[0570] Example 1 (R)-N-Methyl-N-(2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-(tetrahydro-2H-pyran-4-yl)propenamide
[0571] [ka]
[0572] Step 1: (R)-N-methyl-N-(2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-(tetrahydro-2H-pyran-4-yl)propenamide
[0573] [ka]
[0574] A solution of Preparation 28 (2.26 g, 5.33 mmol) and Preparation 21 (1.39 g, 5.33 mmol) in pyridine (76 mL) was treated with EDCI (2.04 g, 10.7 mmol) at room temperature. The reaction mixture was stirred at room temperature for approximately 16 hours, water (100 mL) was added, and the mixture was extracted with EtOAc (2 x 80 mL). The EtOAc extracts were combined and concentrated. The resulting residue was purified by chromatography (silica, EtOAc / PE = 0 to 100%) to give the title compound (2.4 g, 80%). 1 H NMR (400 MHz, CD3OD) δ = 8.41 - 8.13 (m, 1H), 8.01 - 7.79 (m, 1H), 5.67 - 5.32 (m, 3H), 3.97 - 3.78 (m, 2H), 3.69 - 3.58 (m, 2H), 3.58 - 3.42 (m, 2H), 3.34 (s, 3H), 3.25 - 3.10 (m, 2H), 2.83 - 2.73 (m, 1H), 2.21 - 2.10 (m, 1H), 1.85 - 1.69 (m, 1H), 1.67 - 1.56 (m, 2H), 1.31 (s, 3H), 1.27 - 1.11 (m, 3H), 1.09 - 1.05 (m, 2H), 1.05 - 0.93 (m, 1H), 0.93 - 0.83 (m, 2H), 0.51 - 0.41 (m, 1H), 0.31 - 0.23 (m, 1H), -0.04 (s, 9H); LC / MS m / z (M+H) + = 565.3.
[0575] Step 2: (R)-N-methyl-N-(2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-(tetrahydro-2H-pyran-4-yl)propenamide
[0576] [ka]
[0577] A solution of Example 1, Step 1 (2.4 g, 4.25 mmol) in TFA (42.5 mL) was treated with triethylsilane (2.47 g, 21.2 mmol) at about 5° C. The reaction mixture was stirred at room temperature for about 2 hours. The mixture was concentrated and basified to about pH 8 with saturated aqueous NaHCO. The resulting mixture was extracted with EtOAc (2 × 30 mL). The combined EtOAc extracts were concentrated. The resulting residue was purified by preparative HPLC (column YMC Triart C18 250 × 50 mm, 7 μm; mobile phase A: water (0.05% v / v concentrated NHOH); mobile phase B: MeCN; 22–62% B gradient, 12 min; flow rate 60 mL / min) to give the title compound (1.35 g, 73%). 1 H NMR (400 MHz, CD3OD) δ = 8.29 (br s, 1H), 8.05 - 7.74 (m, 1H), 3.93 - 3.80 (m, 2H), 3.53 - 3.36 (m, 3H), 3.34 (s, 4H), 3.19 - 3.00 (m, 2H), 2.84 - 2.70 (m, 1H), 2.21 - 2.08 (m, 1H), 1.86 - 1.70 (m, 1H), 1.66 - 1.55 (m, 2H), 1.31 (s, 3H), 1.27 - 1.12 (m, 2H), 1.09 - 1.05 (m, 2H), 1.05 - 0.90 (m, 1H), 0.48 - 0.37 (m, 1H), 0.30 - 0.21 (m, 1H); LC / MS m / z (M+H) + = 435.1.
[0578] Example 2 2,2-Difluoro-N-methyl-N-(2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-(tetrahydro-2H-pyran-4-yl)acetamide
[0579] [ka]
[0580] Step 1: 2,2-Difluoro-N-methyl-N-(2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-(tetrahydro-2H-pyran-4-yl)acetamide
[0581] [ka]
[0582] A solution of Preparation 28 (1.00 g, 2.36 mmol) in pyridine (20 mL) was treated with EDCI (1.81 g, 9.42 mmol) and 2,2-difluoro-2-(tetrahydro-2H-pyran-4-yl)acetic acid (0.85 g, 4.71 mmol) at room temperature. The reaction mixture was stirred for approximately 2 hours. The mixture was combined with that from an identical reaction using 100 mg of Preparation 28 and similar proportions of other reagents. The combined reaction mixture was washed with HO (30 mL) and extracted with EtOAc (2 x 30 mL). The combined EtOAc extracts were dried (NaSO), filtered, and concentrated. The resulting residue was purified by chromatography to give the title compound (1.10 g, 72%). LC / MS m / z (M+H) + = 587.3.
[0583] Step 2: 2,2-Difluoro-N-methyl-N-(2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-(tetrahydro-2H-pyran-4-yl)acetamide
[0584] [ka]
[0585] A solution of Example 2, Step 1 (1.00 g, 1.70 mmol) in TFA (10 mL) was treated with triethylsilane (1.36 mL, 8.52 mmol) at room temperature and stirred for approximately 2 hours. The reaction mixture was concentrated, and the residue was treated with saturated aqueous NaHCO3 until the pH reached approximately 8-9. Water (30 mL) was added, and the mixture was extracted with EtOAc (30 mL). The EtOAc extract was dried (Na2SO4) and concentrated. The resulting residue was purified by chromatography to give the title compound (460 mg, 59%). 1 H NMR (400 MHz, CD3OD) δ = 8.43 - 8.18 (m, 1H), 7.93 (d, 1H), 4.09 - 3.86 (m, 2H), 3.52 - 3.42 (m, 1H), 3.40 (s, 3H), 3.37 - 3.32 (m, 2H), 3.20 - 3.02 (m, 2H), 2.78 (d, 1H), 2.52 - 2.31 (m, 1H), 1.70 - 1.58 (m, 2H), 1.54 - 1.37 (m, 2H), 1.30 (s, 3H), 1.22 - 1.12 (m, 1H), 0.48 - 0.38 (m, 1H), 0.27 (t, 1H); LC / MS m / z (M+H) + = 457.2.
[0586] The following examples were prepared similarly to Examples 1 and 2, where the observed LC-MS m / z is [M+H] in the table below. + is shown as:
[0587] [Table 1-1]
[0588] [Table 1-2]
[0589] [Table 1-3]
[0590] Example 14 (S)-N-(2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-N-methyl-2-morpholinopropanamide
[0591] [ka]
[0592] A solution of Preparation 49 (100 mg, 0.36 mmol) and Preparation 20 (110 mg, 0.71 mmol) in pyridine (4 mL) was treated with EDCI (270 mg, 1.42 mmol) at room temperature. The mixture was stirred at room temperature for approximately 16 hours. The reaction mixture was diluted with water and extracted with EtOAc (2 x 50 mL). The combined EtOAc extracts were washed with brine, dried (MgSO), filtered, and concentrated. The residue was stirred with 1:1 v / v methanol / THF (20 mL) and potassium carbonate (490 mg, 3.55 mmol) for approximately 2 hours. The mixture was concentrated, and the residue was taken up in water (100 mL) and extracted with EtOAc (100 mL). The EtOAc extracts were washed with brine, dried (MgSO), filtered, and concentrated. The crude product was purified by preparative HPLC (Column: Waters Sunfire C18, 19 × 100 mm, 5 μm; Mobile phase A: 0.05% TFA (v / v) in water; Mobile phase B: 0.05% TFA (v / v) in MeCN, Gradient: 5% B to 70% B over 8.5 min, hold at 100% B for 1.5 min, Flow rate: 25 mL / min) to give the title compound (60 mg, 44%). 1H NMR (400 MHz, CD3OD) δ 8.56 - 8.48 (m, 2H), 4.08 (q, 1H), 3.98 (s, 4H), 3.43 (d, 4H), 2.94 (t, 2H), 2.50 (s, 2H), 1.72 (d, 3H), 1.65 (t, 2H), 1.08 (s, 6H); LC / MS m / z (M+H) + = 424.2.
[0593] Example 15 (S)-N-(2-hydroxyethyl)-N-(2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-morpholinopropanamide
[0594] [ka]
[0595] A solution of Preparation 47 (60 mg, 0.07 mmol) in DCM (3 mL) was treated with TFA (1 mL) at room temperature. The reaction mixture was stirred for 2 hours. Additional TFA (2 mL) was added to the mixture, which was stirred at room temperature for approximately 1 hour. The reaction mixture was concentrated. The resulting residue was dissolved in methanol (5 mL), treated with NH4OH at approximately 30 °C, and stirred for approximately 16 hours. The mixture was concentrated and combined with 15 mg of Preparation 47 from an identical reaction using similar proportions of other reagents. The combined residue was purified by preparative HPLC (Column: Phenomenex Gemini-NX C18 75 × 30 mm, 3 μm; Gradient: Mobile phase A: water (0.225% formic acid); Mobile phase B: MeCN; 0-100% B gradient, flow rate = 25 mL / min) to give the title compound (18 mg, 38%). 1 H NMR (400 MHz, CD3OD) δ = 8.56 - 8.25 (m, 1H), 8.06 (br s, 1H), 4.00 - 3.83 (m, 2H), 3.77 - 3.70 (m, 2H), 3.68 - 3.57 (m, 4H), 3.43 (d, 1H), 3.21 (q, 1H), 3.18 - 3.04 (m, 2H), 2.78 (d, 1H), 2.63 - 2.53 (m, 2H), 2.43 - 2.33 (m, 2H), 1.30 (s, 3H), 1.18 (d, 4H), 0.47 - 0.39 (m, 1H), 0.25 (t, 1H). LC / MS m / z (M+H) + = 466.2.
[0596] The following examples were prepared similarly to Example 15, where the observed LC-MS m / z is [M+H] in the table below. + is shown as:
[0597] [Table 2]
[0598] Example 18 (R)-N-(2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-N-ethyl-2-(tetrahydro-2H-pyran-4-yl)propenamide
[0599] [ka]
[0600] Step 1: (R)—N-(2-(6,6-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-N-ethyl-2-(tetrahydro-2H-pyran-4-yl)propenamide
[0601] [ka]
[0602] A solution of Preparation 19 (371 mg, 1.20 mmol) in DMF (10 mL) and DMSO (2 mL) was treated with Preparation 39 (320 mg, 1.09 mmol) and sodium metabisulfite (104 mg, 0.55 mmol) at about 30° C. The reaction mixture was stirred at about 110° C. for about 18 hours. Water (40 mL) was added and the mixture was filtered. The filter cake was washed with water (2×15 mL). The solid was collected to give the title compound (500 mg, 79%). LC / MS m / z (M+H) + = 581.3.
[0603] Step 2: (R)—N-(2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-N-ethyl-2-(tetrahydro-2H-pyran-4-yl)propenamide
[0604] [ka]
[0605] A solution of Example 19, Step 1 (500 mg, 0.86 mmol) in TFA (5 mL) was treated with triethylsilane (0.28 mL, 1.72 mmol), and the mixture was stirred at about 30° C. for about 1 hour. The mixture was concentrated, and the residue was treated with saturated aqueous NaHCO to about pH 8 and extracted with EtOAc (2×15 mL). The combined organic extracts were dried (NaSO), filtered, and concentrated. The crude product was purified by preparative HPLC (column: Boston Prime C18 150×30 mm, 5 μm; mobile phase A: water (0.2% formic acid); mobile phase B: MeCN; gradient: 40-60% B; flow rate = 25 mL / min) to give the title compound (125 mg, 32%). 1 H NMR (400 MHz, CDCl3) δ = 14.96 - 14.58 (m, 1H), 8.35 - 8.11 (m, 1H), 8.03 - 7.87 (m, 1H), 4.04 - 3.75 (m, 4H), 3.48 - 3.27 (m, 2H), 3.19 - 3.06 (m, 2H), 2.79 - 2.63 (m, 2H), 2.16 - 2.03 (m, 1H), 1.94 - 1.80 (m, 1H), 1.74 (t, 3H), 1.64 - 1.56 (m, 2H), 1.36 - 1.24 (m, 1H), 1.20 (t, 3H), 1.15 (s, 6H), 1.11 - 1.04 (m, 3H), 1.03 - 0.97 (m, 1H).
[0606] The following examples were prepared similarly to Example 18, where the observed LC-MS m / z is [M+H] in the table below. + is shown as:
[0607] [Table 3-1]
[0608] [Table 3-2]
[0609] [Table 3-3]
[0610] [Table 3-4]
[0611] Example 31 (R)-N-(2-hydroxyethyl)-N-(2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-(tetrahydro-2H-pyran-4-yl)propenamide
[0612] [ka]
[0613] Step 1: (R)-N-(2-hydroxyethyl)-N-(2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-(tetrahydro-2H-pyran-4-yl)propenamide
[0614] [ka]
[0615] A solution of Preparation 40 (200 mg, 0.34 mmol) in THF (7 mL) was treated with iPrNEt (0.18 mL, 1.03 mmol), Preparation 21 (162 mg, 1.03 mmol), and CMPI (262 mg, 1.03 mmol). The reaction mixture was stirred at about 60° C. for about 16 hours. Water (15 mL) was added to the reaction mixture. The mixture was extracted into EtOAc (15 mL×2). The organic extracts were combined, dried, and concentrated. The resulting residue was purified by chromatography to give the title compound (120 mg, 48%). LC / MS m / z (M+H) + = 725.3.
[0616] Step 2: (R)-N-(2-hydroxyethyl)-N-(2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-(tetrahydro-2H-pyran-4-yl)propenamide
[0617] [ka]
[0618] A solution of Example 31, Step 1 (100 mg, 0.14 mmol) in DCM (5 mL) at approximately 0° C. was treated with TFA (1 mL), and the mixture was stirred at room temperature for approximately 2 hours. The reaction mixture was diluted with DCM (10 mL) and concentrated. The residue was taken up in methanol (5 mL) and treated with concentrated NHOH (1.5 mL), and the mixture was stirred at room temperature for approximately 2 hours. The reaction mixture was concentrated, and the residue was purified by preparative HPLC (Column: Boston Prime C18 150 × 30 mm, 5 μm; Mobile Phase A: Water (0.05% v / v concentrated NHOH); Mobile Phase B: MeCN; 30–53% B gradient, 10 min; Flow Rate: 25 mL / min) to give the title compound (10 mg, 15%). 1 H NMR (400 MHz, CD3OD) δ = 8.31 (br s, 1H), 7.97 (br s, 1H), 4.61 (s, 1H), 4.05 - 3.79 (m, 4H), 3.79 - 3.68 (m, 2H), 3.50 - 3.40 (m, 1H), 3.39 - 3.33 (m, 2H), 3.20 - 3.02 (m, 2H), 2.77 (d, 1H), 2.17 - 2.05 (m, 1H), 1.86 - 1.71 (m, 1H), 1.71 - 1.55 (m, 2H), 1.30 (s, 3H), 1.27 - 1.11 (m, 2H), 1.07 (d, 3H), 1.02 - 0.94 (m, 1H), 0.48 - 0.38 (m, 1H), 0.24 (t, 1H). LC / MS m / z (M+H) + = 465.3.
[0619] Example 32 (R)-N-(2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-N-methyl-2-(tetrahydro-2H-pyran-4-yl)propenamide
[0620] [ka]
[0621] Step 1: (R)—N-(2-(6,6-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-N-methyl-2-(tetrahydro-2H-pyran-4-yl)propanamide
[0622] [ka]
[0623] A solution of Preparation 35 (200 mg, 0.47 mmol) in THF (10 mL) was treated with Preparation 21 (0.0742 g, 0.469 mmol), CMPI (180 mg, 0.70 mmol), and iPrNEt (0.25 mL, 1.41 mmol) at about 30° C. The reaction mixture was stirred at about 60° C. for about 18 hours. Water was added, and the mixture was extracted into EtOAc (3×). The combined EtOAc extracts were dried (NaSO), filtered, and concentrated. The resulting residue was purified by chromatography to provide the title compound (100 mg, 38%). LC / MS m / z (M+H) + = 567.2.
[0624] Step 2: (R)—N-(2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-N-methyl-2-(tetrahydro-2H-pyran-4-yl)propenamide
[0625] [ka]
[0626] A solution of Example 32, Step 1 (100 mg, 0.18 mmol) in TFA (10 mL) was treated with triethylsilane (84 μL, 0.53 mmol) at approximately 30° C., and the mixture was stirred for approximately 2 hours. The solvent was removed under reduced pressure. The residue was treated with saturated aqueous NaHCO3, and the mixture was extracted with EtOAc (2×). The combined EtOAc extracts were dried (Na2SO4), filtered, and concentrated. The resulting residue was purified by preparative HPLC (Column: Boston Prime C18 150 × 30 mm, 5 μm; Mobile Phase A: Water (0.225% formic acid); Mobile Phase B: MeCN; Gradient: 7-50% B; Flow Rate: 25 mL / min) to give the title compound (34 mg, 44%). LC / MS m / z (M+H) + = 437.3.
[0627] Example 33 (S)—N-(2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1H-benzo[d]imidazol-5-yl)-2-morpholinopropanamide
[0628] [ka]
[0629] A solution of Preparation 49 (100 mg, 0.36 mmol) in pyridine (4 mL) was treated with Preparation 20 (113 mg, 0.71 mmol) and EDCI (272 mg, 1.42 mmol). The reaction mixture was stirred at room temperature for approximately 18 hours. The mixture was diluted with water and extracted with EtOAc (2×). The combined EtOAc extracts were washed with brine, dried (MgSO4), filtered, and concentrated. The residue was dissolved in a mixture of methanol and THF and treated with potassium carbonate (490 mg, 3.55 mmol), and the mixture was stirred at room temperature for approximately 4 hours. The reaction mixture was concentrated, and the residue was taken up in water and extracted with EtOAc. The EtOAc extracts were washed with brine, dried (MgSO4), filtered, and concentrated. The crude product was purified by preparative HPLC to give the title compound (66 mg, 44%). HPLC method: Column: Waters Atlantis C18 4.6 x 100 mm, 5 μm; Mobile phase A: 0.05% TFA (v / v) in water; Mobile phase B: 0.05% TFA (v / v) in MeCN. Gradient: 5% B to 95% B over 4 min, hold at 95% B for 1 min. Flow rate = 2 mL / min. Retention time = 1.7 min; LC / MS m / z (M+H) + = 424.5.
[0630] Example 34 (S)-N-Methyl-N-(5-methyl-2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-2-morpholinopropanamide
[0631] [ka]
[0632] A solution of Preparation 46 (23 mg, 75 μmol) and Preparation 20 (27 mg, 164 μmol) in pyridine (1 mL) was treated with EDCI (32 mg, 164 μmol). The reaction mixture was stirred at room temperature for approximately 80 hours. The reaction mixture was treated with Preparation 20 (27 mg, 164 μmol) and EDCI (32 mg, 164 μmol) in pyridine (1 mL). The reaction mixture was stirred at approximately 60° C. for approximately 18 hours. The reaction mixture was cooled to room temperature, treated with saturated aqueous NaHCO3, and washed with EtOAc (2×). The combined EtOAc extracts were dried (MgSO4), filtered, and concentrated. The residue was suspended in a mixture of DCM / heptane and concentrated. The residue was suspended in methanol and stirred with potassium carbonate at room temperature for approximately 45 minutes. The slurry was treated with water, and the methanol was evaporated under reduced pressure. The mixture was washed with EtOAc (2×). The combined EtOAc extracts were dried (MgSO4), filtered, and concentrated. The crude product was purified by preparative HPLC (Waters Atlantis C18 4.6 x 100 mm, 5 μm; Mobile phase A: 0.05% TFA (v / v) in water; Mobile phase B: 0.05% TFA (v / v) in MeCN. Gradient: linearly 95.0% water / 5.0% MeCN to 5.0% water / 95.0% MeCN in 4 min, hold at 5.0% water / 95.0% MeCN until 5 min; Flow rate: 2 mL / min) to give the title compound (2.4 mg, 7%). Retention time: 1.74 min; LC-MS m / z (M+H) + = 450.6.
[0633] Example 35 N-(5-Methoxy-2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-N-methyl-2-morpholinoacetamide
[0634] [ka]
[0635] Step 1: N-(5-methoxy-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-6-yl)-N-methyl-2-morpholinoacetate amide and N-(5-methoxy-2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-methyl-2-morpholinoacetamide
[0636] [ka]
[0637] A solution of 2-morpholinoacetic acid (31 mg, 0.21 mmol), BTFFH (68 mg, 0.21 mmol), and iPrNEt (68 μL, 0.38 mmol) was dissolved in DMF (0.2 mL), and the solution was stirred at room temperature for approximately 25 minutes. Preparation 42 (50 mg, 0.085 mmol) was added as a solution in DMF (0.7 mL), and the mixture was stirred at approximately 100° C. for approximately 18 hours. The reaction mixture was cooled to room temperature and diluted with water. The mixture was treated with sodium chloride and extracted with EtOAc (2×). The combined EtOAc extracts were dried (MgSO), filtered, and concentrated. The residue was suspended in a mixture of DCM and heptane and concentrated. The residue was purified by chromatography (silica, 20% to 100% EtOAc / heptane) to give the title compound (76 mg) as a mixture of regioisomers. LC-MS m / z (M+H) + = 713.8.
[0638] Step 2: N-(5-methoxy-2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-N-methyl-2-morpholinoacetamide
[0639] [ka]
[0640] A solution of the compound from Step 1 of Example 35 (61 mg, 0.09 mmol) in TFA (1 mL) was treated with triethylsilane (70 μL, 0.43 mmol), and the mixture was stirred at room temperature for approximately 45 minutes. The mixture was diluted with toluene and evaporated under a stream of nitrogen. The residue was taken up in 1:4 (v / v) concentrated NH4OH / ethanol and stirred at room temperature for approximately 1 hour. The reaction mixture was concentrated, diluted with water, and extracted with EtOAc (2×). The combined EtOAc extracts were dried (MgSO4), filtered, and concentrated. The residue was purified by preparative HPLC (Waters Atlantis C18 4.6 x 100 mm, 5 μm; Mobile phase A: 0.05% TFA (v / v) in water; Mobile phase B: 0.05% TFA (v / v) in MeCN. Gradient: 95.0% water / 5.0% MeCN linearly to 5.0% water / 95.0% MeCN in 4 min, hold at 5.0% water / 95.0% MeCN until 5 min; Flow rate: 2 mL / min) to give the title compound (11 mg, 28%). Retention time: 1.84 min; LC-MS m / z (M+H) + = 452.6.
[0641] The following examples were prepared similarly to Example 35, where the observed LC-MS m / z is [M+H] in the table below. + is shown as:
[0642] [Table 4-1]
[0643] [Table 4-2]
[0644] Examples 41 and 42 (2S)-2-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-N-methyl-N-(2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)propanamide and (2R)-2-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-N-methyl-N-(2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)propanamide
[0645] [ka]
[0646] Step 1: 2-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-N-methyl-N-(2-((4aS,5aR)-5a-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)propenamide
[0647] [ka]
[0648] A mixture of Preparation 41 (200 mg, 0.39 mmol), 6-oxa-3-azabicyclo[3.1.1]heptane tosylate (316 mg, 1.16 mmol), and iPrNEt (0.34 mL, 1.94 mmol) in DMF (1.5 mL) was stirred at room temperature for about 16 hours. The reaction mixture was then stirred at about 50° C. for about 16 hours. The reaction mixture was then stirred at about 80° C. for about 16 hours. The reaction mixture was cooled to room temperature, diluted with 3% aqueous LiCl, and extracted with EtOAc (2×). The organic layer was concentrated to give the title compound. Yield: 200 mg (89%). LC-MS m / z (M+H) + = 578.2.
[0649] Step 2: (2S)-2-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-N-methyl-N-(2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)propanamide and (2R)-2-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-N-methyl-N-(2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)propanamide
[0650] [ka]
[0651] A solution of the title compound from Step 1 above (180 mg, 0.31 mmol) in TFA (3 mL) at about 15 °C was treated with triethylsilane (0.25 mL, 0.31 mmol), and the mixture was stirred at about 15 °C for about 3 h. The reaction mixture was concentrated, and the residue was taken up in saturated aqueous NaHCO (10 mL) and extracted with EtOAc (2 × 10 mL). The EtOAc extracts were combined and concentrated. The residue was combined with that from an identical reaction using 20 mg of the title compound from Step 1 above and similar proportions of other reagents. The combined material was purified by preparative HPLC (Welch Xtimate C18 150 mm × 25 mm, 5 μm; mobile phase A: water (0.05% concentrated NHOH); mobile phase B: MeCN; 21–41% B gradient; 11 min, 25 mL / min) to provide the title compound as a mixture of enantiomers (40 mg). The mixture was separated by chiral SFC (Daicel Chiralcel OD 250 mm × 30 mm, 10 μm; mobile phase: 35% ethanol (0.1% concentrated NHOH) and 65% CO; flow rate 70 mL / min) to give the title compounds (absolute stereochemistry of individual examples not assigned). Example 41 19 mg (14%); 1H NMR (400 MHz, CDCl3) δ = 14.68 - 14.46 (m, 1H), 13.53 (br s, 1H), 8.34 (d, 1H), 8.04 (d, 1H), 4.52 (br s, 1H), 4.40 (br d, 1H), 3.69 (br d, 1H), 3.51 (q, 1H), 3.41 (s, 3H), 3.26 (td, 2H), 3.11 - 2.88 (m, 5H), 2.53 (dd, 1H), 2.29 (d, 1H), 1.36 (s, 3H), 1.28 (d, 3H), 1.26-1.19 (m, 1H), 0.48 (dd, 1H), 0.37 (t, 1H); LC-MS m / z (M+H)+ = 448.2. Example 42: 21 mg (15%); 1H NMR (400 MHz, CDCl3) δ = 14.64 - 14.43 (m, 1H), 13.64 - 13.42 (m, 1H), 8.35 (d, 1H), 8.04 (d, 1H), 4.52 (br s, 1H), 4.40 (br s, 1H), 3.68 (br d, 1H), 3.50 (q, 1H), 3.41 (s, 1H), 3.44 - 3.37 (m, 1H), 3.31 - 3.19 (m, 2H), 3.12 - 2.88 (m, 5H), 2.56 (dd, 1H), 2.29 (d, 1H), 1.36 (s, 3H), 1.28 (d, 3H), 1.26 - 1.20 (m, 1H), 0.48 (dd, 1H), 0.35 (t, 1H); LC-MS m / z (M+H)+ = 448.5.
[0652] Examples 43 and 44 were prepared similarly to Examples 41 and 42, with the observed LC-MS m / z being [M+H] in the table below. + is shown as:
[0653] [Table 5]
[0654] Examples 45 to 58 were prepared in parallel according to the following protocol:
[0655] [ka]
[0656] Each 2-dram vial was charged with the acid fragment (0.15 mmol) and Preparation 34 (0.5 mL of a 0.2 M solution in pyridine), followed by the addition of EDCI (0.5 mL of a 0.3 M solution in pyridine). The vials were heated to approximately 80° C. and shaken for approximately 16 hours. The solvent was removed under reduced pressure. The residue in each vial was suspended in 2:1 v / v DCM / TFA (2 mL) and treated with triethylsilane (0.2 mL), and the vials were shaken at approximately 80° C. for approximately 16 hours. The solvent was removed under reduced pressure. The residue in each vial was taken up in methanol (1.5 mL) and acidified to approximately pH 8 with concentrated NH4OH. The mixtures were purified by preparative HPLC to provide the title compounds, where the observed LC-MS m / z is [M+H] in the table below. + is shown as:
[0657] [Table 6-1]
[0658] [Table 6-2]
[0659] [Table 6-3]
[0660] [Table 6-4]
[0661] [Table 6-5]
[0662] Examples 59 to 70 were prepared in parallel according to the following protocol:
[0663] [ka]
[0664] Each 2-dram vial was charged with the acid fragment (0.15 mmol) and Preparation 34 (0.2 mL of a 0.5 M solution in THF), followed by the addition of pyridine (10 μL) and T3P (0.2 mL of a 50% w / w solution in EtOAc). The vials were heated to approximately 50°C and shaken for approximately 16 hours. The reaction mixture was treated with saturated aqueous NaHCO3 (1 mL) and extracted with EtOAc (3 × 2 mL). The combined EtOAc extracts were collected and concentrated into individual vials. The residue in each vial was suspended in 2:1 DCM / TFA (2 mL) and treated with triethylsilane (0.2 mL), and the vials were shaken at approximately 80°C for approximately 16 hours. The solvent was removed under reduced pressure. The residue in each vial was taken up in methanol (1.5 mL) and basified to approximately pH 8 with concentrated NH4OH. The mixture was purified by preparative HPLC to give the title compound, where the observed LC-MS m / z is [M+H] in the table below. + is shown as:
[0665] [Table 7-1]
[0666] [Table 7-2]
[0667] [Table 7-3]
[0668] [Table 7-4]
[0669] Examples 71 to 80 were prepared in parallel according to the following protocol:
[0670] [ka]
[0671] Each 2-dram vial was charged with the acid fragment (0.10 mmol) and Preparation 28 (0.15 mmol), followed by the addition of pyridine (1 mL) and EDCI (0.12 mmol). The vials were heated to approximately 30°C and shaken for approximately 16 hours. The solvent was removed under reduced pressure. The residue in each vial was treated with water (1 mL) and extracted with EtOAc (3x). The combined EtOAc extracts were dried (Na2SO4), filtered, and concentrated into vials. The residue in each vial was suspended in 5:1 DCM / TFA (1 mL), and the vials were shaken at approximately 30°C for approximately 16 hours. The solvent was removed under reduced pressure. The residue in each vial was taken up in 2:1 methanol / concentrated NH4OH (1 mL), and the vials were shaken at approximately 30°C for approximately 16 hours. The solvent was removed under reduced pressure. The crude product was purified by preparative HPLC to give the title compound, where the observed LC-MS m / z is [M+H] in the table below. + is shown as:
[0672] [Table 8-1]
[0673] [Table 8-2]
[0674] [Table 8-3]
[0675] Examples 81 to 89 were prepared in parallel according to the following protocol:
[0676] [ka]
[0677] Each 2-dram vial was charged with the acid fragment (0.10 mmol) and Preparation 28 (0.15 mmol), followed by pyridine (300 μL), THF (12 μL), and T3P (0.2 mL of a 50% w / w solution in EtOAc). The vials were heated to approximately 80° C. and shaken for approximately 16 hours. The solvent was removed under reduced pressure. The residue in each vial was treated with water (1 mL) and extracted with EtOAc (3×). The combined EtOAc extracts were dried (Na2SO4), filtered, and concentrated into vials. The residue in each vial was suspended in 5:1 DCM / TFA (1 mL), and the vials were shaken at approximately 30° C. for approximately 16 hours. The solvent was removed under reduced pressure. The residue in each vial was taken up in 2:1 methanol / concentrated NH4OH (1 mL), and the vials were shaken at approximately 30° C. for approximately 16 hours. The solvent was removed under reduced pressure. The crude product was purified by preparative HPLC to give the title compound, where the observed LC-MS m / z is [M+H] in the table below. + is shown as:
[0678] [Table 9-1]
[0679] [Table 9-2]
[0680] [Table 9-3]
[0681] Examples 90 to 114 were prepared in parallel according to the following protocol:
[0682] [ka]
[0683] Solution A: Preparation 35 (2.10 g) and methylimidazole (850 mg) in DCM (42 mL). Solution B: TCFH (2.1 g) in DCM (42 mL). To a 2-dram vial charged with the acid fragment (0.15 mmol), solution A (1 mL) and solution B (1 mL) were added, and the mixture was shaken at room temperature for about 16 hours. Water (2 mL) and DCM (2 mL) were added, and the DCM layer was concentrated. The residue was taken up in 1,2-dichloroethane (1 mL), treated with TFA (1 mL), and shaken at about 50° C. for about 16 hours. The solvent was removed under reduced pressure. The crude product was purified by preparative HPLC to give the title compound, where the observed LC-MS m / z is [M+H] in the table below. + is shown as:
[0684] [Table 10-1]
[0685] [Table 10-2]
[0686] [Table 10-3]
[0687] [Table 10-4]
[0688] [Table 10-5]
[0689] [Table 10-6]
[0690] [Table 10-7]
[0691] Examples 115 to 120 were prepared in parallel according to the following protocol:
[0692] [ka]
[0693] To a 2-dram vial charged with the amine fragment (0.3 mmol) was added Preparation 41 (103 mg, 0.2 mmol) as a solution in DMAC (1 mL) and iPrNEt (0.1 mL, 0.56 mmol). The mixture was shaken at about 100° C. for about 48 hours. The reaction mixture was cooled to room temperature and concentrated. The residue was taken up in TFA (1 mL) and treated with triethylsilane (0.1 mL). The reaction mixture was shaken at about 50° C. for about 16 hours. The solvent was removed under reduced pressure. The crude product was purified by preparative HPLC to give the title compound, where the observed LC-MS m / z is [M+H] in the table below. + is shown as:
[0694] [Table 11-1]
[0695] [Table 11-2]
[0696] Biological assays In vitro studies IL-2-induced T-cell kinase (ITK) activity, IC 50 (uM) ITK activity was determined by measuring the effect of test compounds in an ITK enzyme assay.
[0697] A solution of 1.0 M HEPES buffer pH 7.5 was prepared as follows: 238.3 g of HEPES free acid (Sigma) and 800 mL of water were combined and the mixture was stirred until completely dissolved. The pH was adjusted to 7.5 via titration with 5 N NaOH, and the volume was adjusted to 1000 mL. The solution was filtered and sterilized.
[0698] The ITK assay buffer was prepared as follows: 50 mL of HPLC-grade water was treated with 2 mL of 1.0 M HEPES buffer, 500 μL of 2% gelatin (Sigma), 1.0 mL of 1.0 M MgCl2 in water, and 1.0 mL of 0.5 M glutathione in water, and the solution was mixed. The solution was brought to 99 mL in a graduated cylinder with water and sterilized through a 0.2 μm filter. 0.1 mL of Brij-35™ Surfact-Amps™ detergent solution (10% w / v in water, ThermoFisher) and 1.0 mL of ATP (Teknova, 100 mM) were added, and the solution was mixed.
[0699] A 1.33x ITK enzyme solution was prepared as follows: 49.99 mL of ITK assay buffer was treated with 4.1 μL of ITK enzyme (ITK FL (N-flag and C-His tag, approximately 72 kDa) Lake Pharma, 0.25 mg / mL in a buffer containing 25 mM Tris, pH 7.8, 150 mM NaCl, 10% glycerol, and 2 mM TCEP), and the mixture was gently swirled. The resulting solution was stored on ice. 30 min before use, the enzyme solution was removed from the ice and equilibrated to RT by incubation in a RT water bath.
[0700] 4x ITK substrate solution was prepared as follows: 50 mL of ITK assay buffer was treated with 100 μL of BTK peptide (China Peptide Company, 2 mM stock solution in DMSO). The tube was capped and mixed by gentle inversion, then stored on ice. 30 min before use, the substrate solution was removed from the ice and allowed to equilibrate to RT by incubation in a RT water bath.
[0701] During the assay, 7.5 μL of 1.33× ITK enzyme solution was added to wells of a plate containing various concentrations of test compound in 0.1 μL of DMSO. The plate was incubated for 30 minutes at room temperature. Each well of the plate was treated with 2.5 μL of 4× ITK substrate solution, and the plate was sealed (TopSeal™, Perkin Elmer). The plate was centrifuged at 1000 rpm for 30 seconds and then incubated at room temperature for 60 minutes. The seal was removed, and each well was treated with 10 μL of stop / detection buffer (20 mM HEPES, pH 7.5, 0.01% gelatin, 1 nM LANCE PT66 (Perkin Elmer), 16.5 μg / ml Surelight APC (Perkin Elmer), 10 mM EDTA, 250 mM NaCl). The plate was re-covered and centrifuged at 1000 rpm for 30 seconds. Plates were incubated overnight at RT and in closed carriers to reduce dehydration. The seal was removed and fluorescence was read using a plate reader with an excitation wavelength of 665 nm and an emission wavelength of 615 nm. The concentrations of tested compounds and the resulting efficacy values were plotted and the 50% efficacy (IC 50 The concentration of compound required for ) was determined by a four-parameter logistic dose-response equation.
[0702] IC of the compounds of the present invention 50 (uM) values are presented in the table below. IL-2 inhibitory activity, IC 50 (uM)
[0703] IL-2 inhibitory activity in supernatants from activated CD4+ human T cells was determined by measuring the effect of test compounds on activity using cisbio HTRF™ technology.
[0704] Human CD4+ T cells were activated with CD3 / CD28 for 3 days and expanded for an additional 4–6 days (total 7–9 days). On day 0, frozen CD4+ T cells were thawed, treated with CD3 / CD28 Dynabeads, and incubated at 37°C / 5% CO2. On day 3, beads were removed and cells were cultured at 5 × 10 5 cells / cm 2 The cells were diluted to 1 × 10 in a G-Rex10 flask and incubated at 37°C / 5% CO. On days 7 to 9, the cells were removed from the G-Rex flask, counted, and plated at 1 × 10 in a standard tissue culture flask. 6 The cells were diluted back to 100 cells / ml.
[0705] Expanded CD4+ T cells were centrifuged at 300 × g for 10 minutes and resuspended at 500,000 cells / ml (30,000 cells / well). 60 μl of CD4+ T cells / well were added to a 384-well plate containing various concentrations of test compound in 0.1 μL of DMSO. The plate was incubated for 15 minutes at 37°C / 5% CO2. 20 μl of diluted ImmunoCult™ (STEMCELL Technologies, 1:12.5 in T cell assay medium) was added to all wells of the plate (final assay concentration of 1:50). The plate was further incubated for 20–24 hours at 37°C / 5% CO2. The plate was centrifuged at 300 × g for 10 minutes. 16 μL of the supernatant was removed and combined with 4 μl of IL-2 HTRF Abs (cisbio kit). Plates were incubated for 3 hours at RT and read at wavelengths of 665 nm and 615 nm using an EnVision plate reader. The concentrations of compounds tested and the resulting efficacy values were plotted and the 50% efficacy (IC 50 The concentration of compound required for ) was determined by a four-parameter logistic dose-response equation.
[0706] IC of the compounds of the present invention 50 (uM) values are presented in the table below.
[0707] Tropomyosin receptor kinase A (TRKA) activity, % inhibition Assays for determining TRKA activity are known in the art, see, for example, those described below. ·Skerratt SE et al., J.Med.Chem.(2016), 59(22):10084~10099 PMID:27766865. DOI:10.1021 / acs.jmedchem.6b00850 Bagal SK et al., J.Med.Chem.(2018), 61(15):6779~6800 PMID:29944371. DOI:10.1021 / acs.jmedchem.8b00633
[0708] TRKA, also known as neurotrophic tyrosine kinase receptor type 1 (NTKR1) activity, was determined by measuring the effect of test compounds on activity against the NTRK1 enzyme using the ThermoFisher Z'-LYTE assay fluorescence-based coupled enzyme format (www.thermofisher.com / selectscreen). Test compounds were screened at a fixed concentration of 1 μM, and % inhibition was determined and compared to a control with a fixed ATP concentration of 1 mM. The resulting effect value for the tested compound was compared to the assay control to determine % inhibition (%).
[0709] The % inhibition (%) values for compounds of the present invention are presented in the table below.
[0710] [Table 12-1]
[0711] [Table 12-2]
[0712] [Table 12-3]
[0713] Table 12-4
Claims
1. Formula (I) 【Chemistry 1】 (In the formula, R 0 is H, R 1 is methyl or R 0 , R 1 and the carbon atom to which they are attached form an optionally gem-difluoro substituted cyclopropyl; R 2 is H, (C 1 ~C 4 ) alkyl, hydroxy (C 1 ~C 4 ) alkyl or substituted by 1, 2 or 3 F; 1 ~C 4 ) alkyl; Each R 3 are independently H, F or (C 1 ~C 4 ) alkyl, or R 3 Both, together with the carbon atom to which they are attached, ・(C 4 ~C 7 ) cycloalkyl, - substituted by 1, 2 or 3 F (C 4 ~C 7 ) cycloalkyl, ・1 or 2 R 6 (C 4 ~C 7 ) cycloalkyl, ・(C 5 ~C 7 ) bicycloalkyl, - substituted by 1 or 2 F (C 5 ~C 7 ) bicycloalkyl, - a C-linked 6-membered saturated heterocycloalkyl containing one N or one O and optionally substituted by oxo, or - C-bonded 6-membered saturated heterobicycloalkyl containing one N or one O and optionally substituted by oxo Forming R 4 may be substituted by H, F, 1, 2 or 3 F (C 1 ~C 6 ) alkyl, -NR 7 R 8 , (C 4 ~C 7 ) cycloalkyl, C-linked 6-membered saturated heterocycloalkyl containing one N or one O and optionally substituted by oxo, N-linked 6-, 7- or 8-membered saturated heterocycloalkyl containing one N and optionally one O and optionally substituted by oxo, N-linked 6-, 7- or 8-membered saturated heterobicycloalkyl containing one N and optionally one O and optionally substituted by oxo, or N-linked 5- or 6-membered heteroaryl containing one or two N; R 5 is H, halogen, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, or (C 1 ~C 4 ) alkoxy substituted (C 1 ~C 6 ) alkoxy; Each R 6 are independent (C 1 ~C 3 ) alkyl; R 7 (C 1 ~C 6 ) alkyl; R 8 (C 1 ~C 6 ) alkyl or -C(O)(C 1 ~C 6 ) alkyl or a pharma- ceutically acceptable salt thereof.
2. Formula (Ia) or (Ib) 【Chemistry 2】 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof.
3. 3. The compound of claim 2 of formula (Ia) or a pharma- ceutically acceptable salt thereof.
4. R 2 4. The compound of claim 1, wherein is H, methyl, ethyl or hydroxyethyl, or a pharma- ceutically acceptable salt thereof.
5. R 2 5. The compound of claim 4, or a pharma- ceutically acceptable salt thereof, wherein is methyl.
6. R 3 are each independently H, F or (C 1 ~C 3 6. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein: R is 0 or 1; and R is 1 or 2.
7. R 3 and each is F; or a pharma- ceutically acceptable salt thereof.
8. On the other hand, R 3 is H, and the other R 3 7. The compound of claim 6, or a pharma- ceutically acceptable salt thereof, wherein is methyl.
9. Formula (Ic) 【Chemistry 3】 9. The compound of claim 8, or a pharma- ceutically acceptable salt thereof.
10. R 3 together with the carbon atom to which they are attached, ・(C 4 ~C 7 ) cycloalkyl, - substituted by 1, 2 or 3 F (C 4 ~C 7 ) cycloalkyl, 1 or 2 R 6 (C 4 ~C 7 ) cycloalkyl, ・(C 5 ~C 7 ) bicycloalkyl, - substituted by 1 or 2 F (C 5 ~C 7 ) bicycloalkyl, - a C-linked 6-membered saturated heterocycloalkyl containing one N or one O and optionally substituted by oxo, or - C-bonded 6-membered saturated heterobicycloalkyl containing one N or one O and optionally substituted by oxo 6. The compound of claim 1 , wherein the compound forms:
11. R 4 may be substituted by H, F, or 1 or 2 F (C 1 ~C 4 ) alkyl, or -NR 7 R 8 11. The compound of claim 1, wherein:
12. R 4 But (C 4 ~C 7 11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is a C-linked 6-membered saturated heterocycloalkyl containing one O, a N-linked 6-, 7- or 8-membered saturated heterocycloalkyl containing one N and optionally one O and optionally substituted by oxo, a N-linked 6-, 7- or 8-membered saturated heterobicycloalkyl containing one N and optionally one O, or a N-linked 5-membered heteroaryl containing two Ns.
13. R 4 13. The compound of claim 12, or a pharma- ceutically acceptable salt thereof, wherein is a C-linked 6-membered saturated heterocycloalkyl containing one O.
14. R 5 H, F, methyl, -OCH 3 Or -OC 2 H 5 OCH 3 14. The compound of any one of claims 1 to 13, wherein:
15. R 5 is H; or a pharma- ceutically acceptable salt thereof.
16. 16. A pharmaceutical composition comprising a compound according to any one of claims 1 to 15, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.
17. 17. The pharmaceutical composition of claim 16, comprising one or more additional therapeutic agents.
18. A pharmaceutical composition according to any one of claims 16 to 17 for the treatment of a disorder in which an ITK inhibitor is indicated.
19. The pharmaceutical composition of claim 18, wherein the disorder for which an ITK inhibitor is indicated is atopic dermatitis.
20. 20. Use of a compound according to any one of claims 1 to 15, or a pharma- ceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a disorder in which an ITK inhibitor is indicated.
